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A B S T R A C T
Background
Major depressive disorder (MDD) is highly debilitating, difficult to treat, has a high rate of recurrence, and negatively impacts the
individual and society as a whole. One emerging potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also
known as omega-3 oils, naturally found in fatty fish, some other seafood, and some nuts and seeds. Various lines of evidence suggest
a role for n-3PUFAs in MDD, but the evidence is far from conclusive. Reviews and meta-analyses clearly demonstrate heterogeneity
between studies. Investigations of heterogeneity suggest differential effects of n-3PUFAs, depending on severity of depressive symptoms,
where no effects of n-3PUFAs are found in studies of individuals with mild depressive symptomology, but possible benefit may be
suggested in studies of individuals with more severe depressive symptomology.
Objectives
To assess the effects of n-3 polyunsaturated fatty acids (also known as omega-3 fatty acids) versus a comparator (e.g. placebo, anti-
depressant treatment, standard care, no treatment, wait-list control) for major depressive disorder (MDD) in adults.
Search methods
We searched the Cochrane Depression, Anxiety and Neurosis Review Group’s Specialised Registers (CCDANCTR) and International
Trial Registries over all years to May 2015. We searched the database CINAHL over all years of records to September 2013.
Selection criteria
We included studies in the review if they: were a randomised controlled trial; provided n-3PUFAs as an intervention; used a comparator;
measured depressive symptomology as an outcome; and were conducted in adults with MDD. Primary outcomes were depressive
symptomology (continuous data collected using a validated rating scale) and adverse events. Secondary outcomes were depressive
symptomology (dichotomous data on remission and response), quality of life, and failure to complete studies.
Data collection and analysis
We used standard methodological procedures as expected by Cochrane.
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Main results
We found 26 relevant studies: 25 studies involving a total of 1438 participants investigated the impact of n-3PUFA supplementation
compared to placebo, and one study involving 40 participants investigated the impact of n-3PUFA supplementation compared to
antidepressant treatment.
For the placebo comparison, n-3PUFA supplementation results in a small to modest benefit for depressive symptomology, compared to
placebo: standardised mean difference (SMD) -0.32 (95% confidence interval (CI) -0.12 to -0.52; 25 studies, 1373 participants, very
low quality evidence), but this effect is unlikely to be clinically meaningful (an SMD of 0.32 represents a difference between groups
in scores on the HDRS (17-item) of approximately 2.2 points (95% CI 0.8 to 3.6)). The confidence intervals include both a possible
clinically important effect and a possible negligible effect, and there is considerable heterogeneity between the studies. Although the
numbers of individuals experiencing adverse events were similar in intervention and placebo groups (odds ratio (OR) 1.24, 95% CI
0.95 to 1.62; 19 studies, 1207 participants; very low-quality evidence), the confidence intervals include a significant increase in adverse
events with n-3PUFAs as well as a small possible decrease. Rates of remission and response, quality of life, and rates of failure to complete
studies were also similar between groups, but confidence intervals are again wide.
The evidence on which these results are based is very limited. All studies contributing to our analyses were of direct relevance to our
research question, but we rated the quality of the evidence for all outcomes as low to very low. The number of studies and number
of participants contributing to all analyses were low, and the majority of studies were small and judged to be at high risk of bias on
several measures. Our analyses were also likely to be highly influenced by three large trials. Although we judge these trials to be at low
risk of bias, they contribute 26.9% to 82% of data. Our effect size estimates are also imprecise. Funnel plot asymmetry and sensitivity
analyses (using fixed-effect models, and only studies judged to be at low risk of selection bias, performance bias or attrition bias) also
suggest a likely bias towards a positive finding for n-3PUFAs. There was substantial heterogeneity in analyses of our primary outcome
of depressive symptomology. This heterogeneity was not explained by the presence or absence of comorbidities or by the presence or
absence of adjunctive therapy.
Only one study was available for the antidepressant comparison, involving 40 participants. This study found no differences between
treatment with n-3PUFAs and treatment with antidepressants in depressive symptomology (mean difference (MD) -0.70 (95% CI -
5.88 to 4.48)), rates of response to treatment or failure to complete. Adverse events were not reported in a manner suitable for analysis,
and rates of depression remission and quality of life were not reported.
Authors’ conclusions
At present, we do not have sufficient high quality evidence to determine the effects of n-3PUFAs as a treatment for MDD. Our
primary analyses suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to
placebo; however the estimate is imprecise, and we judged the quality of the evidence on which this result is based to be low/very low.
Sensitivity analyses, funnel plot inspection and comparison of our results with those of large well-conducted trials also suggest that this
effect estimate is likely to be biased towards a positive finding for n-3PUFAs, and that the true effect is likely to be smaller. Our data,
however, also suggest similar rates of adverse events and numbers failing to complete trials in n-3PUFA and placebo groups, but again
our estimates are very imprecise. The one study that directly compares n-3PUFAs and antidepressants in our review finds comparable
benefit. More evidence, and more complete evidence, are required, particularly regarding both the potential positive and negative effects
of n-3PUFAs for MDD.
P L A I N L A N G U A G E S U M M A R Y
Omega-3 fatty acids for depression in adults
Why is this review important?
Major depressive disorder (MDD) is characterised by depressed mood and/or a markedly decreased pleasure or interest in all activities. It
has negative impacts on the individual and on society, often over the long term.One possible treatment forMDD is n-3 polyunsaturated
fatty acids (n-3PUFAs), also known as omega-3 oils, naturally found in fatty fish, some other seafood and some nuts and seeds. Various
lines of evidence suggests that n-3PUFAs may impact on depressive symptoms, but a lot of studies have different findings, making it
difficult to draw conclusions.
Who will be interested in this review?
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Health professionals, including general practitioners, mental health and psychiatric specialists; individuals with MDD, more mild or
additional depressive disorders; and the people around them.
What questions does this review aim to answer?
Do n-3PUFAs, compared to an alternative, have an effect on depressive symptoms, negative side effects, rates of recovery, quality of
life, and rates of dropout from studies, in individuals with a diagnosis of MDD?
Which studies were included in the review?
We searched scientific databases for all randomised controlled trials in adults with a diagnosis of MDD, where individuals received
either n-3PUFAs or an alternative, that were carried out up to May 2015.
We found 26 relevant studies: 25 studies involving 1438 people compared the impact of n-3PUFAs with that of placebo, and one study
involving 40 people compared the impact of n-3PUFAs with that of antidepressants. All studies were of direct relevance to our review,
but we considered the quality of the evidence to be low to very low.
What does the evidence from the review tell us?
At present, we do not have enough high quality evidence to determine the effects of n-3PUFAs as a treatment for MDD. We found a
small-to-modest positive effect of n-3PUFAs compared to placebo, but the size of this effect is unlikely to be meaningful to people with
depression, and we considered the evidence to be of low or very low quality, with many differences between studies. There was also
insufficient high quality evidence to determine the effects of n-3PUFAs on negative side effects or numbers failing to complete trials.
What should happen next?
We need more evidence, particularly to explain the differences between study findings, e.g. by looking at individuals who may and may
not benefit from n-3PUFAs. Future studies should also compare n-3PUFAs with usual antidepressant treatment, and investigate the
way these treatments may work.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
n-3PUFAs compared to placebo for depression in adults
Patient or population: adult patients with depression
Settings: Clinical and community settings
Intervention: n-3PUFAs
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo N-3PUFAs
Depressive symptomology
(continuous)
HDRS where possible; higher
scores indicate greater symp-
tomology
Follow-up: 4 - 16 weeks
The mean depressive symp-
tomology (continuous) in the
intervention groups was
0.32 standard deviations
lower
(0.52 to 0.12 lower). This rep-
resents a difference between
groups in scores on the HDRS
(17-item) of approximately 2.
2 points (95% CI 0.8 to 3.6)
1373
(25 studies)
⊕©©©
very low1,2,3,4,5
Adverse events
Study reports
Follow-up: 0 - 16 weeks
Study population OR 1.24
(0.95 to 1.62)
1207
(19 studies)
⊕©©©
very low3,4,5,6,7
482 per 1000 536 per 1000
(469 to 601)
Moderate
208 per 1000 246 per 1000
(200 to 298)
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Depressive symptomology
(dichotomous - remission)
Depressive symptomology
rating scale as used by au-
thors
Follow-up: 4 - 16 weeks
Study population OR 1.38
(0.87 to 2.2)
426
(6 studies)
⊕⊕©©
low3,4,6,7,8,9
238 per 1000 301 per 1000
(214 to 407)
Moderate
216 per 1000 275 per 1000
(193 to 377)
Depressive symptomology
(dichotomous - response)
Depressive symptomology
rating scale as used by au-
thors
Follow-up: 4 - 16 weeks
Study population OR 1.39
(0.95 to 2.04)
611
(15 studies)
⊕⊕©©
low3,4,6,7,8,9
328 per 1000 404 per 1000
(317 to 499)
Moderate
235 per 1000 299 per 1000
(226 to 385)
Quality of life
Validated scales as used by
authors, CGI where possible,
higher scores indicate poorer
quality of life
Follow-up: 4-16 weeks
The mean quality of life in the
intervention groups was
0.47 standard deviations
lower
(0.99 lower to 0.06 higher)
383
(9 studies)
⊕©©©
very low3,4,6,8,9,10
Failure to complete
Study reports
Follow-up: 0-16 weeks
Study population OR 0.84
(0.62 to 1.14)
1344
(21 studies)
⊕©©©
very low3,4,5,6,7
192 per 1000 166 per 1000
(128 to 213)
Moderate
200 per 1000 174 per 1000
(134 to 222)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Quality of the evidence downgraded by one level for study limitations. Judgements of high risk of bias in all studies, and different
effects when comparing analyses including only those studies with judgements of low risk of selection bias (allocation concealment),
performance bias (blinding of participants and personnel), or attrition bias (incomplete outcome data), and analyses including all
studies
2Quality of the evidence downgraded by one level for inconsistency. Evidence of high heterogeneity between studies. Heterogeneity not
well explained by the subgroup analyses
3No serious concerns regarding indirectness. All evidence is directly related to the research question
4Quality of the evidence downgraded by one level for imprecision. Moderate to wide confidence intervals
5Quality of the evidence downgraded by one level for publication bias. Strong suspicion of publication bias based on visual inspection of
the funnel plot
6Quality of the evidence downgraded by one level for study limitations. Judgements of high risk of bias in all studies included in this
analysis
7No serious concerns regarding inconsistency. Limited evidence of heterogeneity between studies
8Selected studies only were available to be included in this analysis
9Funnel plots were not created for this analysis, due to the low numbers of studies involved
10Quality of the evidence downgraded by one level for inconsistency. High heterogeneity between studies.
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B A C K G R O U N D
Description of the condition
Major depressive disorder (MDD) is characterised by: depressed
mood; markedly diminished pleasure or interest in all activities;
significant weight loss or weight gain, or decrease or increase in ap-
petite; insomnia or hypersomnia; psychomotor agitation or retar-
dation; fatigue or lethargy; feelings of worthlessness or inappropri-
ate guilt; disruptions to concentration and decision making; and
recurrent thoughts of death (APA 2013). Diagnosis is achieved by:
the presence of four or more symptoms (as above) plus depressed
mood or markedly diminished pleasure or interest in all activities,
for a consecutive period of two weeks; significant distress or im-
pairment in functioning as a result of symptoms; and an inability
to attribute symptoms to the physiological effects of a substance
or another medical condition (APA 2013). MDD is currently es-
timated to affect approximately 7% of western populations, with
resulting impact both at an individual and a societal level (APA
2013). MDD can be highly debilitating; can affect all areas of an
individual’s life; can be difficult to treat, with a high rate of re-
currence; and often exists in combination with other conditions
and disorders, such as cardiovascular disease and anxiety disorders
(APA 2013). Recent figures (2011) published by theWorldHealth
Organization estimate major depressive disorders to account for
3% of global ill health in terms of disability-adjusted life years
(WHO 2014), and projections for 2030 suggest an increase to
6% or 7% (WHO 2014). Given this increasing trend, there is an
urgent need for effective treatments and strategies for prevention.
Description of the intervention
One emerging potential treatment for MDD is n-3 polyunsatu-
rated fatty acids (n-3PUFAs), also known as omega-3 fatty acids.
n-3PUFAs are a family of polyunsaturated fatty acids, named as
such because of the positioning of the first double carbon bond on
the third atom from the methyl end of the acyl chain. All mem-
bers of the family are derived from parent fatty acid 18:3n-3 (Al-
pha-linolenic acid (ALA)), via desaturation and elongation. ALA,
however, can not be synthesised by humans, and thus must be
obtained from the diet (Haag 2003; Ruxton 2005). Longer-chain
n-3PUFAs can be formed in humans, but biological conversion
is slow and inefficient, making diet an important source for these
fatty acids as well (Ma 1995). Dietary sources of ALA include cer-
tain nuts and seeds, such as walnuts, flaxseed and rapeseed (canola)
oil. Dietary sources of the longer n-3PUFAs eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) include fatty fish, some
white fish, shellfish and other seafood such as seaweed, and certain
eggs and animal products, depending on the animal’s diet (BNF
1999; James 2000; Ruxton 2005; Simopolous 1999).
Links between n-3PUFAs and MDD were suggested following
recognition of a reduction in the dietary consumption of n-3PU-
FAs in recent decades and an increase in depressive conditions
(Simopolous 1999). Coupled with the reduction in n-3PUFA in-
takes, intakes of n-6 long chain polyunsaturated fatty acids (n-
6PUFAs) have also increased. Closely related to the n-3PUFAs, n-
6PUFAs (named from the positioning of the first double bond on
the sixth carbon atom from themethyl endof the acyl chain) are de-
rived from parent essential fatty acid 18:2n-6 (linoleic acid (LA)),
and for synthesis, share the same desaturases and elongases as n-
3PUFAs. n-3PUFAs and n-6PUFAs thus compete for synthesis
from their parent fatty acids. Dietary sources of LA and n-6PUFAs
include plant and vegetable seeds and oils, as found in margarines
and many processed foods (James 2000; Simopolous 1999). Our
traditional diet is thought to have contained approximately equal
amounts of energy from n-3PUFAs and n-6PUFAs (Simopolous
1999). By comparison, a current western diet is estimated to con-
tain approximately five to 20 times more energy from n-6PUFAs
than from n-3PUFAs (Gregory 2000; Simopolous 1999).
Early work investigating population consumption levels of n-
3PUFAs and n-3PUFA-rich foods, such as fish, suggested links
with population levels of MDD and various psychiatric condi-
tions (Hibbeln 1998; Noaghiul 2003; Peet 2004), and studies
since have found similar associations. Within countries, n-3PUFA
intakes have been negatively associated with depressive illness
(e.g. Silvers 2002; Tanskanen 2001). In clinical studies, low lev-
els of n-3PUFAs have been found in individuals diagnosed with
MDD (e.g. Edwards 1998; Peet 1998) and depressive disorders
(e.g. Garland 2007), and reporting high levels of depressed mood
(e.g. Mamalakis 2002; Mamalakis 2006), compared to controls.
Continuous relationships between n-3PUFA status and depres-
sive symptoms have also been found (e.g. Edwards 1998). In ran-
domised controlled trials (RCTs), beneficial effects of supplemen-
tation with n-3PUFAs compared to placebo have been reported
for MDD (e.g. Nemets 2002; Su 2003) and depressive disorders
(e.g. Frangou 2006; Stoll 1999).
How the intervention might work
The positive effects of n-3PUFAs on depressive illness are thought
to occur as a result of changes to cell membrane structure and func-
tion, impacting particularly on cell communication, inflamma-
tory processes and neurotransmitter activities (Haag 2003; James
2000; Ruxton 2005). Further details are available in Appendix 1.
Disrupted and abnormal cell signalling, inflammatory processes
and neurotransmitter system activities have all been implicated in
MDD (Parker 2006b; Stahl 2008).
Why it is important to do this review
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n-3PUFAs are known to be important in brain development and
function, and have been linked to depression in a variety of studies,
see Appendix 2. Not all studies, however, report beneficial effects
(see Appendix 2), and reviews and meta-analyses clearly demon-
strate variability between studies (e.g. Appleton 2006; Appleton
2008b; Appleton 2010; Lin 2007; Parker 2006b; Smith 2011;
Stahl 2008).Meta-analyses reveal some small benefit of n-3PUFAs
for depressive disorders (Appleton 2006; Lin 2007), but investi-
gations of the heterogeneity also suggest differential effects of n-
3PUFAs, depending primarily on severity of depressive symptoms
at baseline (Appleton 2010). Sensitivity analyses based on severity
of depressive symptoms at baseline suggest no benefits of n-3PU-
FAs for individuals with mild depressive symptoms or without a
diagnosis of depression, but provide some evidence of benefits in
individuals with severe depressive symptoms or with depressive
diagnoses (Appleton 2010). These findings suggest a possible ben-
efit of n-3PUFAs for MDD. This review investigates a role for n-
3PUFAs as a treatment for MDD.
Other reviews investigating a role for n-3PUFAs in depressive dis-
orders have recently been conducted (e.g. Bloch 2012; Grosso
2014; Martins 2011; Sublette 2011). These reviews typically use
a very broad definition of depression to include a variety of de-
pressive disorders and conditions, in a number of populations, in-
cluding children. This review considers solely major or unipolar
depressive disorder, and focuses on adults.
Various reviews of other treatments for MDD and other depres-
sive disorders are also available. A recent search of the Cochrane
Library revealed 407 completed reviews or reviews in progress fo-
cusing on treating or preventing depression. The majority of these
reviews investigate pharmacological (e.g. antidepressant) or psy-
chological (e.g. cognitive behavioural therapy) treatments for de-
pressive conditions, or focus on specific clinical populations, e.g.
people with stroke or people with diabetes mellitus. Only two of
these reviews include n-3PUFAs, both focusing on antenatal and
postnatal depression. One review investigates ’dietary supplements
for preventing postnatal depression’ (Miller 2013), and includes
one study of n-3PUFAs. This study found no preventive impact
of n-3PUFAs on the presence of postnatal depression. The other
review (Dennis 2013) includes two trials investigating the use of
n-3PUFAs for antenatal depression, and reports a beneficial effect
on depression in one trial and no benefit in the other. One fur-
ther review also focuses on a herbal treatment (St John’s Wort) for
depression (Linde 2008), but the active component of this plant-
based treatment is unrelated to n-3PUFAs or other fatty acids.
O B J E C T I V E S
To assess the effects of n-3 polyunsaturated fatty acids (n-3PU-
FAs) (also known as omega-3 fatty acids) versus a comparator (e.g.
placebo, antidepressant treatment, standard care, no treatment,
wait-list control) for major depressive disorder in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) were eligible, as the best
study design for assessing an intervention. We included all suitable
RCTs, regardless of quality, but we also recordedmeasures of risk of
bias. We also included cross-over and cluster-RCTs where suitable.
We excluded observational and case-control studies. Our aim was
to include as many relevant studies as possible to avoid limitations
and bias.
Types of participants
Participant characteristics
We included studies regardless of participant demographics (e.g.
gender, country of residence), although we considered only studies
involving adults (18 years and over).
Diagnosis
We only included studies that enrolled participants with a primary
diagnosis of major or unipolar depressive disorder, from a trained
professional or using a validated rating scale, or studies that in-
cluded a subgroup of these individuals. If a subgroup was used, we
included only the data from the subgroup in the review, and only
if the subgroup was defined and distinguished prior to randomisa-
tion. If data from diagnosed and non-diagnosed individuals were
mixed, we did not include these studies and data. We excluded
studies that enrolled participants without MDD, but with a pri-
mary diagnosis of an alternative depressive disorder, e.g. bipolar
disorder, postpartum depression (APA 2013), or any other psychi-
atric condition. We also excluded studies that describe a diagnosis
of MDD that was given only during or in relation to pregnancy. If
diagnoses were unclear, we did not include these studies or these
data. We included studies in the review only if we were certain
that all data relevant to our review were gained from participants
with MDD.
Comorbidities
We included studies regardless of the inclusion of participants with
other comorbid conditions (physical conditions, e.g. congestive
heart disease, or psychiatric conditions, e.g. anxiety). The inclu-
sion of studies involving participants with comorbid conditions
was due to the high likelihood of existing comorbidities in the
MDD population (APA 2013), and a desire to make the review as
generalisable as possible. We investigated any effects due to exist-
ing comorbidities in subgroup analyses.
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Adjunctive Therapy
We also included studies regardless of participant use of adjunc-
tive therapy. We included studies that recruited participants with
concomitant adjunctive therapy due to the high likelihood of ad-
junctive therapy use in the MDD population (APA 2013), and a
desire to make the review as generalisable as possible. We recorded
adjunctive therapies as part of the review, and also investigated
these in subgroup analyses.
Setting
We included studies regardless of setting, provided they used a
clinical diagnosis or equivalent depressive rating score.
Types of interventions
Experimental intervention
We included studies if they used an exposure of n-3PUFAs as the
sole or as an adjunctive therapy. We included studies regardless
of: the type and source of n-3PUFA provided (pure ALA, EPA,
DHAor any combinationof these, fish, flaxseed, rapeseed, etc); the
dose of n-3PUFA or duration of supplementation; and the mode
of provision (i.e. supplement capsules, supplemented foods). We
kept records of these differences, and used sensitivity analyses to
investigate effects based on n-3PUFA type. We included studies if
details of the type of n-3PUFA, dose, and ratio were not available,
as mechanisms for action remain unknown. We accepted studies
with a ’lead-in’ phase to allow for spontaneous remission or placebo
responding in participants, and recorded use of the ’lead-in’ phase.
Comparator intervention
We included studies regardless of the comparator used, but there
had to be a comparator.We counted waiting-list controls, no treat-
ment or standard care as possible comparators. We recorded all
comparators. We conducted separate analyses, depending on the
comparator used, to allow clear combination of like with like.
Types of outcome measures
We included studies that met the above criteria, regardless of
whether they reported on all of the following outcomes.
Primary outcomes
1. Depressive symptomology (continuous data): We assessed de-
pressive symptomology using any continuous validated measure.
The most commonly used validated rating scales are the Beck De-
pression Inventory (BDI) (Beck 1987), the Montgomery-Asberg
Depression Rating Scale (MADRS) (Montgomery 1979), and the
Hamilton Depression Rating Scale (HDRS) (Hamilton 1960),
but we also included studies using other scales.
2. Adverse events: We recorded measures of adverse events where
possible. We recorded the number and type (e.g. gastrointestinal,
psychiatric) of adverse events experienced, as reported in studies.
We used the number of individuals suffering, rather than the num-
ber of events, in analyses. Where adverse events were not reported,
we recorded this.
Secondary outcomes
3.Depressive symptomology (dichotomous data):We also assessed
depressive symptomology using remission or improvement as as-
sessed using clinical diagnoses by a trained professional or a vali-
dated rating scale, where provided.
4. Quality of life (continuous data): We assessed quality of life
using any continuous validated measure.
5. Failure to complete: We recorded the number of individuals
leaving each study early, and the reasons for early dropout.
Timing of outcome assessment
Where studies used multiple time points, we used only data from
the longest follow-up period for analyses. Previous work suggests
that effects are likely to increase over time (Calder 2003; Ruxton
2005).
Search methods for identification of studies
We identified suitable studies for inclusion by searching databases,
international trials registers and published review articles, and by
contacting authors of published trials.
Electronic searches
The Cochrane Depression, Anxiety and Neurosis Review
Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN)maintain two clinical trials registers at their editorial base in
Bristol, UK: a references register and a studies-based register. The
CCDANCTR-References Register contains over 39,000 reports
of RCTs in depression, anxiety and neurosis. Approximately 60%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-
Psi coding manual, using a controlled vocabulary (please contact
the CCDAN Trials Search Co-ordinator for further details). Re-
ports of trials for inclusion in the Group’s registers are collated
from routine (weekly), generic searches of MEDLINE (1950-),
EMBASE (1974-) and PsycINFO (1967-); quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL)
and review-specific searches of additional databases. Reports of
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trials are also sourced from international trials registers through
the World Health Organization’s trials portal (the International
Clinical Trials Registry Platform (ICTRP)), pharmaceutical com-
panies, the handsearching of key journals, conference proceedings
and other (non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN’s generic search strategies (used to identify
RCTs) can be found on the Group’s website.
1. We searched the CCDANCTR (Studies and References Reg-
isters) using the following terms:
(depress* or dysthymi* or “affective disorder*” or “affective symptom*”
or “mood disorder*” or “mental health”) AND (dha or docosahex* or
eicosapent* or epa or “fatty acid*” or *fish* or *linolenic* or *omega*
or n-3 or w-3 or *PUFA* or “cod liver oil”)
2. We also conducted complementary searches of the biblio-
graphic database Cumulative Index to Nursing & Allied Health
(CINAHL) (1982 to 19th Sept. 2013), using relevant subject
headings (controlled vocabularies) and search syntax; the search
strategy listed in Appendix 3. This database yielded no unique
studies to September 2013 (only secondary references were identi-
fied by CINAHL), and we therefore excluded it from subsequent
searches to May 2015.
3. We searched international trial registries via the World Health
Organization’s trials portal (ICTRP) and ClinicalTrials.gov to
identify unpublished or ongoing studies.
There were no restrictions on date, language or publication status
applied to the searches. We ran our most recent database searches
on 4th May 2015.
Searching other resources
We checked the reference lists of all included studies and relevant
reviews to identify additional studies missed from the original
electronic searches.
We also contacted authors of included studies for information on
unpublished or ongoing studies or to request additional trial data.
Data collection and analysis
We downloaded search results into Endnote. We downloaded se-
lected studies into Review Manager 5 (RevMan 2014). We detail
the number of search results at each stage of the search and selec-
tion process in the Results section.
Selection of studies
Two review authors (RP, HS) independently screened the titles
and abstracts of all studies identified by the search, and coded
them as ’retrieve’ (eligible or potentially eligible/unclear) or ’do
not retrieve’. We retrieved the potentially-relevant full-text study
reports/publications and two review authors (RP, HS) indepen-
dently screened the full text, identified studies for inclusion, and
recorded reasons for exclusion of the ineligible studies. We re-
solved disagreements through discussion or consultation with a
third author (KA). We identified and excluded duplicate records,
and we collated multiple reports that related to the same study,
so that each study rather than each report was the unit of interest
in the review. We included in the list and obtained titles or ab-
stracts which were potentially relevant, but where relevance was
not clear.We obtained and translated articles in foreign languages.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram and Characteristics of excluded studies
tables.
Data extraction and management
We used a data collection form to extract study characteristics and
outcome data. We developed the form specifically for this work,
and piloted it on two studies in the review, prior to use for all
studies. Two review authors (HS and KA or RP) extracted the
following study characteristics and outcome data from included
studies:
1. Methods: study design, total duration of study, details of
any ’lead-in’ period, use of several study centres, study location,
study setting, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, inclusion criteria, and exclusion
criteria, withdrawals.
3. Interventions: intervention, comparator, concomitant
therapies, and comorbidities.
4. Outcomes: primary and secondary outcomes, and time
points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Where multiple reports of the same study were available, we ab-
stracted data from all reports on separate data extraction forms
and subsequently combined them. We resolved discordances by
independent abstraction and then by discussion with a third au-
thor (RP or KA, respectively). We also contacted corresponding
authors directly for relevant information.
We have noted data that were not usable for analyses in the
Characteristics of included studies tables (Notes section). Two re-
view authors (HS, RP) transferred all data into the Review Man-
ager 5 (RevMan 2014) file, and double-checked that we had en-
tered data correctly by comparing the data presented in the review
with the study reports. A third review author (KA) also checked
study characteristics for accuracy against the trial reports.
Main comparisons
• n-3PUFAs versus comparator. Analyses are conducted by
comparator type.
Assessment of risk of bias in included studies
Three review authors (KA, HS, RP) independently assessed the
risk of bias for each study using the criteria outlined in theCochrane
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Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion. We assessed the risk of
bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We judged each potential source of bias as high, low or unclear
risk, using the criteria provided in Appendix 4, and have provided
a supporting quotation from the study report together with a jus-
tification for our judgement in each ’Risk of bias’ table. The review
authors (KA, HS, RP) agreed the criteria for judging risk of bias
following some experience of the literature, but prior to formal
data abstraction. We have summarised the risk of bias judgements
across different studies for each of the domains listed. Where in-
formation on risk of bias relates to unpublished data or correspon-
dence with a trialist, we have noted this in the ’Risk of bias’ table.
We have taken account when considering treatment effects of the
risk of bias for the studies that contribute to each outcome.
Measures of treatment effect
Continuous data
We recorded depressive symptomology and quality of life using all
scales as used in each study, after ensuring comparable direction.
We conducted analyses on data from only one scale per study. For
depressive symptomology, we used the scale most commonly used
in all studies (the HDRS: Hamilton 1960), where possible. For
quality of life, we used the scale most commonly used in all studies
reporting quality of life (the CGI: Guy 1976), where possible.
We collected continuous data in the formofN,mean, and standard
deviation per intervention group at baseline and at the end of
each intervention, as required for meta-analysis. If data were only
provided in other forms, e.g. as medians, change from baseline,
we contacted study authors and requested appropriate data.
We analysed continuous data as a standardised mean difference
(SMD) with a 95% confidence interval (CI).We undertook meta-
analyses only where this was meaningful, i.e. where treatments,
participants and the underlying clinical question were similar
enough for pooling to make sense. Where multiple trial arms were
reported in a single trial, we included only the relevant arms in
each analysis.
Dichotomous data
Data on adverse events were reported by the number of individ-
uals suffering, as opposed to the number of events. We collected
dichotomous data in the form of N per intervention group. We
analysed dichotomous data as Mantel-Haenszel odds ratios (ORs)
with 95% CIs. We also recorded reasons where possible.
We recorded depressive remission and response as provided.
Data on failure to complete were reported as the number of indi-
viduals failing to complete each trial, and reasons given for non-
completion.
Unit of analysis issues
Cross-over RCTs
No cross-over RCTs were included.
Cluster RCTs
No cluster RCTs were included.
Studies with multiple treatment groups
Where studies used multiple treatment groups, we treated each
group independently and included them in all appropriate analy-
ses. In these cases, we used the same comparator for all treatment
groups, and split the data from comparison groups across treat-
ment groups, as equally as possible for analysis. Where insufficient
numbers required numbers of individuals with events either to
be rounded up or rounded down, the number of individuals was
rounded to err on the side of no effect as opposed to an effect.
Assuming individuals took part in only one treatment/comparator
group, groups are independent. No studies involved individuals
in more than one treatment or comparison group.
Dealing with missing data
We contacted investigators in order to verify key study character-
istics and obtain missing numerical outcome data where possible.
We documented correspondence with trialists. We used intention-
to-treat (ITT) data where possible. We extracted data from per
protocol populations and included them if ITT data were not
available.
Where we could not obtain standard deviations from trial au-
thors, we imputed them by using standard deviation data from all
other trials using the same measure for depression in the review
(Furukawa 2006).
Assessment of heterogeneity
We undertook meta-analysis where treatments, participants and
the underlying clinical questionwere similar enough for pooling to
make sense, i.e. where n-3PUFAs were used as a treatment, where
participants had a diagnosis of major/unipolar depressive disorder
(or equivalent depressive rating score), and where n-3PUFAs were
implemented as a treatment for major/unipolar depressive disor-
der. Main analyses include all studies to allow sufficient numbers
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of studies for analyses to be meaningful, and were conducted using
a random-effects model and Hedges’ adjusted g, to allow consid-
eration of the likely heterogeneity between studies (Deeks 2001;
Egger 2001; Sterne 2001). We also applied a fixed-effect model
as sensitivity analyses to investigate bias as a result of systematic
differences between large and small studies that can be exacerbated
by the use of a random-effects model (Deeks 2001; Egger 2001;
Sterne 2001). Large differences between the results of our primary
analyses using random- and fixed-effect models would suggest us-
ing caution when interpreting results.
We investigated heterogeneity using the I² statistic (Higgins 2002;
Higgins 2003). We reported I² statistics and appropriate P values.
We grouped the I² statistic into four bands for interpretation, as
recommended in theCochrane Handbook (Higgins 2011). These
bands were 0% to 40%: might not be important; 30% to 60%:
may representmoderate heterogeneity; 50%to90%may represent
substantial heterogeneity; and 75% to 100%: considerable hetero-
geneity. We identified a priori possible sources of heterogeneity,
to include the comparator used, publication bias, the presence or
absence of comorbid conditions (physical and psychiatric), use of
n-3PUFAs as a sole or adjunctive therapy, and the risks of bias.
We investigated heterogeneity between studies based on the type
of participants involved using subgroup analyses, and based on
the risks of bias using sensitivity analyses. We also identified ad-
ditional potential sources of heterogeneity during the review pro-
cess. These included the use of EPA specifically as a treatment, the
inclusion of ALA in placebo capsules, the use of data from per pro-
tocol analyses, the use of imputed standard deviations from other
studies in analyses, and the consideration of multiple comparison
groups from the same trial as individual studies. We explored these
potential sources of heterogeneity using sensitivity analyses.
Assessment of reporting biases
We investigated publication bias using funnel plot asymmetry (
Sterne 2001). It should be noted that publication bias is one of
several possible causes of asymmetry in funnel plots.
Data synthesis
We combined trials reporting mean and standard deviation data
using meta-analysis (Sterne 2001).
For continuous data, we calculated the standardised mean effect
for all trials using Hedges’ adjusted g (Deeks 2001). Hedges’ ad-
justed g is a formulation of effect size used in the SMD method
that includes an adjustment to correct for small sample bias (Deeks
2001). Studies were weighted using the inverse-variance method.
We used random-effects models primarily to estimate the SMDs
for all analyses (Deeks 2001; Egger 2001; Sterne 2001). The ran-
dom-effects model assumes non-identical effects in different stud-
ies, and can be preferable to a fixed-effect model where hetero-
geneity between studies is high and unexplained. We also applied
a fixed-effect model as sensitivity analyses. Effect sizes are provided
as means and standard deviations, and are related to specific scales
to allow understanding by clinicians and practitioners.
For dichotomous data, we used theMantel-Haenszel method, and
calculated effect sizes as odds ratios.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses investigating effects of n-3PU-
FAs on MDD in:
1. Studies involving individuals with comorbid conditions,
studies involving individuals without comorbid conditions, and
studies involving a mix of individuals both with and without
comorbid conditions. This analysis demonstrates effects due to
participant characteristics which may affect treatment
recommendations and outcomes. We conducted analyses using
the same methods as for the main analyses, using: (i) studies in
which participants were clearly identified as having comorbid
conditions; (ii) studies in which participants were clearly
identified as being without comorbid conditions (based on
inclusion and exclusion criteria); and (iii) studies where
participants with and without comorbid conditions were mixed,
or where the presence or absence of comorbid conditions was not
clear.
2. Studies involving individuals receiving adjunctive therapies,
studies involving individuals not receiving adjunctive therapies,
and studies involving a mix of individuals both receiving and not
receiving adjunctive therapies. This analysis demonstrates effects
due to participant characteristics which may affect treatment
recommendations and outcomes. Analyses were conducted using
the same methods as for the main analyses, using (i) studies in
which participants were clearly identified as receiving adjunctive
therapies; (ii) studies in which participants were clearly identified
as not receiving adjunctive therapies (based on inclusion and
exclusion criteria); and (iii) studies where participants receiving
and not receiving adjunctive therapies were mixed, or where the
presence or absence of adjunctive therapy use was not clear. For
the purpose of these analyses, adjunctive therapy included
antidepressants, psychotherapy, and any other therapies that may
affect mood.
We conducted subgroup analyses only for the n-3PUFA versus
placebo comparison, and only for the primary outcomes.
Sensitivity analysis
We conducted sensitivity analyses to investigate the impact of:
1. Including all studies versus only studies that we judged to
be at low risk of bias. This analysis demonstrates the importance
of the use of only those trials at low risk of bias, and the levels of
confidence and caution that should be exercised in considering
the analyses of all studies. We conducted separate analyses using
the same methods as for the main analyses. We defined low risk
of bias as in the Cochrane Handbook (Higgins 2011), using (i)
selection bias, measured using allocation concealment; (ii)
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performance bias, using blinding of participants; (iii) attrition
bias, using incomplete outcome data. We conducted three
separate analyses, one for each risk of bias domain. We chose
these domains as the ones most likely to impact on RCTs
investigating subjective outcomes (depressive symptomology).
2. Using a fixed-effect model as opposed to a random-effects
model. The random-effects model was used for all main analyses.
We conducted fixed-effect analyses using the same data as for the
main analyses.
As a result of differences between studies identified during the
review process, we also conducted sensitivity analyses to investigate
the impact of:
1. Including all studies versus only those studies that used a
treatment that was solely or predominantly EPA. Recent reviews
of n-3PUFAs in depressive disorders have suggested a benefit
from supplementation solely with EPA or predominantly with
EPA (Grosso 2014; Martins 2011; Sublette 2011), although the
evidence is not conclusive (e.g. Ross 2007). We conducted
analyses using the same methods as for the main analyses.
2. Including all studies versus only those that do not use an oil
in placebo capsules that also contains n-3PUFAs. We found four
studies that used a placebo capsule containing ALA (parent n-
3PUFA of EPA and DHA) and were included in the review due
to low conversion rates of ALA to longer chain fatty acids in
humans (Ma 1995). We conducted analyses using the same
methods as for the main analyses.
3. Including all studies versus only those studies that provided
ITT data for analysis. We conducted analyses using the same
methods as for the main analyses.
4. Including all studies versus only those that did not involve
data imputation. Standard deviation data were unavailable for
five studies, and we imputed them to allow inclusion of these
studies in our main analyses. We conducted analyses using the
same methods as for the main analyses.
5. Including all studies as described versus the inclusion of all
trials that were split for analysis as complete trials. Several trials
used multiple treatments, and so were split for our primary
analyses (as described above) to allow accurate description of all
studies as required for subgroup analyses, and to allow
consistency between all studies. We combined trials that we had
split for the main analyses. We pooled data and conducted
analyses using the same methods as for the main analyses.
We conducted sensitivity analyses only for the n-3PUFA versus
placebo comparison. We applied the sensitivity analyses using a
fixed-effect model to all outcomes for completeness, but restricted
all other sensitivity analyses to test only our primary outcomes.
’Summary of findings’ table
We have provided a ’Summary of findings’ table, as recommended
in theCochraneHandbook (Higgins 2011). This ’Summary of find-
ings’ table is for the comparison of n-3PUFAs with placebo, and
includes all primary and secondary outcomes: depressive symp-
tomology (continuous), adverse events, depressive symptomology
(dichotomous remission and response), quality of life, and failure
to complete. We assessed the quality of evidence for all outcomes
using the GRADE system. This considers within-study risk of
bias (methodological quality), directness of evidence, heterogene-
ity, precision of effect estimates and risk of publication bias.
R E S U L T S
Description of studies
Results of the search
This review includes 20 trials with a total of 1458 participants.
The searches identified 677 records of potential relevance to our
review. Following the removal of duplicates, 575 remained. Initial
screening by title and abstract resulted in the removal of a further
422 records, to result in the retrieval of 153 full-text papers. Of
these, 85 records were found to relate to RCTs of relevance to our
review, while 68 records were excluded. Records were excluded at
this stage because they did not: refer to an RCT, involve individu-
als or a subgroup of individuals with MDD, involve adults, test n-
3PUFAs, involve a comparator, or they did not include depression
outcomes. We only included trials in the review if we were sure
that they met the eligibility criteria. Records that related to trials
that are currently ’ongoing’ and currently ’awaiting classification’
remained in the review at this stage, but may be excluded once
full details of these trials become available. We provide full details
of the search results in the PRISMA flow diagram (Figure 1). We
give the primary references to the trials they relate to as references
for each study. Of these, the trial by Lucas 2009 involves individ-
uals both with and without MDD (and participants were strati-
fied by diagnosis for randomisation), so we have included only the
subgroup of individuals with MDD in our review. The Coryell
trial includes tests of two doses of n-3PUFA (approximately 1
g/d, and approximately 2 g/d); the Da Silva 2005 trial involves
individuals who were randomised depending on antidepressant
status (antidepressants use/no antidepressant use) at trial entry;
the Jazayeri 2008 trial involves two separate comparator groups
(placebo/antidepressant); theMischoulon 2015 trial includes tests
of an enriched EPA treatment and an enriched DHA treatment;
and the Peet 2002 trial includes tests of three doses of n-3PUFA
(1 g/d, 2 g/d, 4 g/d). In these five trials, all groups were inde-
pendent, and we have considered each as a separate study. This
has resulted in the inclusion in analyses of 26 independent stud-
ies (Bot 2010; Carney 2009; Coryell (1g/d); Coryell (2g/d); Da
Silva (AD) 2005;Da Silva (nAD) 2005;Gertsik 2012;Gharekhani
2014; Gonzalez 2011; Grenyer 2007; Jazayeri (v placebo) 2008;
Jazayeri (v AD) 2008; Lespérance 2011; Lucas 2009; Marangell
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2003; Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon
(EPA) 2015; Nemets 2002; Park 2015; Peet (1g/d) 2002; Peet
(2g/d) 2002; Peet (4g/d) 2002; Rondanelli 2010; Silvers 2005; Su
2003).
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Figure 1. PRISMA Diagram
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Published datawere available for all 26 independent studies for our
primary outcomemeasure of depressive symptomology.We sought
additional data, additional details or clarification from all corre-
sponding authors. Of these, we were unable to contact Alfonso
Gonzalez (corresponding author for Gonzalez 2011), and Lauren
Marangell (corresponding author for Marangell 2003). The email
addresses provided for these individuals did not work, and subse-
quent web-based and telephone-based searches were not fruitful.
We received responses, however, from all other corresponding au-
thors. Where additional information was provided by authors, we
have detailed this in the Characteristics of included studies tables.
Included studies
Weprovide full characteristics of the 26 independent studies in the
Characteristics of included studies tables. We found considerable
differences between studies in all aspects of study methodology.
Full detail of the differences in each aspect of study methodology
are given below. We used data from all studies in all analyses where
possible. Data were missing from analyses due only to insufficient
detail, e.g. Da Silva (AD) 2005 and Da Silva (nAD) 2005 report
31 participants and two withdrawals, but fail to provide initial
group allocation for the two withdrawals, resulting in these data
being unavailable for use in analyses.
Design
All trials included in the review were RCTs involving parallel
groups randomised to receive either n-3PUFAs or a comparator.
Sample sizes
The studies included 1458 participants. Studies varied in sample
size, although the majority of studies were small. The number of
participants included in each studywere as follows: 11 (across both
Coryell (1g/d) and Coryell (2g/d)), 20 (Gonzalez 2011; Nemets
2002), 25 (Bot 2010), 28 (Su 2003), 29 (Lucas 2009), 31 (across
both Da Silva (AD) 2005 and Da Silva (nAD) 2005), 35 (Park
2015), 36 (Marangell 2003), 41 (Mischoulon 2009), 42 (Gertsik
2012), 46 (Rondanelli 2010), 54 (Gharekhani 2014), 60 (across
both Jazayeri (v placebo) 2008 and Jazayeri (v AD) 2008), 70
(across Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002),
77 (Silvers 2005), 83 (Grenyer 2007), 122 (Carney 2009), 196
(across Mischoulon (DHA) 2015; Mischoulon (EPA) 2015) and
432 (Lespérance 2011). In all trials, intervention and comparator
groups were composed of approximately equal numbers.
Setting
Participants were recruited from hospitals and clinics (Bot
2010; Carney 2009; Gharekhani 2014; Grenyer 2007; Jazayeri
(v placebo) 2008; Jazayeri (v AD) 2008; Mischoulon 2009;
Mischoulon (DHA) 2015; Mischoulon (EPA) 2015; Park 2015;
Su 2003); and community settings (Da Silva (AD) 2005; Da Silva
(nAD) 2005; Lucas 2009). Some studies used recruitment meth-
ods to capture individuals from both clinical and community set-
tings (Coryell (1g/d); Coryell (2g/d); Gertsik 2012; Lespérance
2011; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002;
Silvers 2005). One study was based in a residential nursing home
(Rondanelli 2010). Three studies did not report recruitment set-
ting (Gonzalez 2011, Marangell 2003, Nemets 2002).
Studies were undertaken in the United States (Carney 2009;
Coryell (1g/d); Coryell (2g/d); Gertsik 2012; Mischoulon 2009;
Mischoulon (DHA) 2015; Mischoulon (EPA) 2015), Canada
(Lespérance 2011; Lucas 2009), Iran (Gharekhani 2014; Jazayeri
(v placebo) 2008; Jazayeri (v AD) 2008), Australia (Grenyer
2007), Brazil (Da Silva (AD) 2005; Da Silva (nAD) 2005), Italy
(Rondanelli 2010), Korea (Park 2015), the Netherlands (Bot
2010), NewZealand (Silvers 2005), Taiwan (Su 2003), theUnited
Kingdom (Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002)
and Venezuela (Gonzalez 2011). Country of study was not re-
ported for the studies by Marangell 2003 or Nemets 2002. These
authors are based in the United States and Israel respectively.
Participants
This review relates only to MDD in adults, so all the included
studies involved adults. One study uses a local definition of adults
(16+ years), and has been included (Gharekhani 2014). Mean ages
ranged from a mean of 29 years (across Coryell (1g/d) and Coryell
(2g/d)) to a mean of 84 years (Rondanelli 2010). The majority of
participants in all studies were women, with the exception of two
(Carney 2009; Gharekhani 2014). Percentages of women ranged
from 52% (Bot 2010) to 85% (Nemets 2002). Two studies in-
volved only women (Lucas 2009; Rondanelli 2010), and in the
studies with a majority of men, the percentages of men were 56%
(Gharekhani 2014) and 66% (Carney 2009). Distribution of gen-
der was not reported in four studies (Gertsik 2012; Peet (1g/d)
2002; Peet (2g/d) 2002; Peet (4g/d) 2002).
Five studies included individuals from populations with specific
physical comorbidities: diabetes (Bot 2010), coronary heart dis-
ease (Carney 2009), end-stage renal disease (Gharekhani 2014),
and Parkinson’s disease (Da Silva (AD) 2005; Da Silva (nAD)
2005). The individuals in Da Silva (AD) 2005 and Da Silva
(nAD) 2005 may also have had psychiatric comorbidities. Three
studies included individuals with no comorbidities (based on ex-
clusion criteria) (Marangell 2003; Mischoulon 2009; Su 2003).
Seven studies included individuals with no physical comorbidities,
but some/possible psychiatric comorbidities (Jazayeri (v placebo)
2008; Jazayeri (v AD) 2008; Lucas 2009; Mischoulon (DHA)
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2015; Mischoulon (EPA) 2015; Nemets 2002; Park 2015), while
three studies included individuals with no psychiatric comor-
bidities, but some/possible physical comorbidities (Gertsik 2012;
Gonzalez 2011; Rondanelli 2010), and five studies included indi-
viduals with some/possible physical and psychiatric comorbidities
(Coryell (1g/d); Coryell (2g/d); Grenyer 2007; Lespérance 2011;
Silvers 2005). The trial by Peet 2002 (Peet (1g/d) 2002; Peet (2g/d)
2002; Peet (4g/d) 2002) reports no comorbidities, but also does
not report excluding individuals with physical or psychiatric co-
morbidities.
Studies included individuals who were all receiving adjunctive
therapy for depression at the time of the trial (Bot 2010; Carney
2009; Coryell (1g/d); Coryell (2g/d); Da Silva (AD) 2005; Gertsik
2012; Gonzalez 2011; Jazayeri (v placebo) 2008; Park 2015; Peet
(1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002), individuals
who were not receiving adjunctive therapy (Da Silva (nAD) 2005;
Gharekhani 2014; Jazayeri (v AD) 2008; Lucas 2009; Marangell
2003; Mischoulon (DHA) 2015; Mischoulon (EPA) 2015), and
a mix of individuals receiving and not receiving adjunctive ther-
apy (Grenyer 2007; Lespérance 2011; Mischoulon 2009; Nemets
2002; Rondanelli 2010; Silvers 2005; Su 2003). Adjunctive ther-
apy took the form of antidepressant medication in all studies, with
the exception of Mischoulon 2009, and included psychotherapy
(Lespérance 2011;Mischoulon 2009; Silvers 2005). In Rondanelli
2010, antidepressants were not taken, but participants were per-
mitted to take benzodiazepines, which may have impacted on de-
pressed mood.
Interventions
Studies used either a sole EPA intervention, at doses of 1 g/d (Bot
2010; Jazayeri (v placebo) 2008; Jazayeri (vAD)2008;Mischoulon
2009; Peet (1g/d) 2002), 2 g/d (Nemets 2002; Peet (2g/d) 2002),
3 g/d (Gonzalez 2011), and 4 g/d (Peet (4g/d) 2002); a sole DHA
intervention at a dose of 2 g/d (Marangell 2003); and EPA/DHA
combinations, at doses of 1.14 g/d (EPA:DHA - 740:400) (Coryell
(1g/d)), 1.2 g/d (EPA:DHA - 720:480) (Da Silva (AD) 2005; Da
Silva (nAD) 2005), 1.2 g/d (EPA:DHA -1050:150) (Lespérance
2011; Lucas 2009), 1.8 g/d (EPA:DHA - 1080:720) (Gharekhani
2014), 1.88 g/d (EPA:DHA - 930:750) (Carney 2009), 2.28 g/d
(EPA:DHA - 1480:800) (Coryell (2g/d)), 2.76 g/d (EPA:DHA -
0.56:2.2) (Grenyer 2007), 3 g/d (EPA:DHA - 600:2400) (Silvers
2005), 5.22 g/d (EPA:DHA - 3420:1800) (Park 2015) and 6.6
g/d (EPA:DHA - 4400:2200) (Su 2003). Four studies used an
intervention consisting of EPA, DHA and other n-3PUFAs, at
doses of 1.224 g/d (EPA:DHA:other - 180:900:144) (Mischoulon
(DHA) 2015), 1.436 g/d (EPA:DHA:other - 1060:274:102) (
Mischoulon (EPA) 2015), 2.4 g/d (EPA:DHA:other - 1800:400:
200) (Gertsik 2012) and 3.13 g/d (EPA:DHA:other - 1670:830:
630) (Rondanelli 2010).
All studies used a placebo comparator, with the exception of
Jazayeri (v AD) 2008, which compared n-3PUFAs with an-
tidepressants. Different placebos were used: oil (Coryell (1g/d);
Coryell (2g/d)), rapeseed oil (Jazayeri (v placebo) 2008), rapeseed
oil plus medium-chain triglycerides (Bot 2010), corn oil (Carney
2009), olive oil (Gertsik 2012; Grenyer 2007; Silvers 2005; Su
2003), mineral oil (Da Silva (AD) 2005; Da Silva (nAD) 2005),
paraffin oil (Gharekhani 2014; Mischoulon 2009; Peet (1g/d)
2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Rondanelli 2010), saf-
flower oil plus oleic acid (Park 2015), soybean oil (Mischoulon
(DHA) 2015; Mischoulon (EPA) 2015), sunflower oil plus 2%
fish oil (Lespérance 2011; Lucas 2009). We included studies using
rapeseed oil and soybean oil as a comparator, due to likely effects
as a result of longer n-3PUFAs (James 2000; Ruxton 2005) and
the reported low conversion rates of ALA to longer n-3PUFAs
(Ma 1995). The oil used in the Coryell studies also contained
some ALA (6%). Three studies did not report the placebo used
(Gonzalez 2011; Marangell 2003; Nemets 2002). In all cases, the
placebo was given in a similar dose to the intervention.
Treatment duration for each trial was as follows: four weeks
(Nemets 2002), six weeks (Coryell (1g/d); Coryell (2g/d);
Marangell 2003), eight weeks (Gertsik 2012; Gonzalez 2011;
Jazayeri (v placebo) 2008; Jazayeri (v AD) 2008; Lespérance
2011; Lucas 2009; Mischoulon 2009; Mischoulon (DHA) 2015;
Mischoulon (EPA) 2015; Rondanelli 2010; Su 2003), 10 weeks
(Carney 2009), 12 weeks (Bot 2010; Da Silva (AD) 2005; Da
Silva (nAD) 2005; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d)
2002; Park 2015; Silvers 2005), and 16 weeks (Gharekhani 2014;
Grenyer 2007).
In the trial where n-3PUFAs were compared with antidepressants
(Jazayeri (v AD) 2008), n-3PUFAs were given using EPA only, at
a dose of 1 g/d, and compared with 20 mg/d fluoxetine (antide-
pressant).
Outcomes
Primary Outcomes
Depressive symptomology (continuous data): Depressive symp-
tomology was reported using continuous data in all studies, at
both baseline and study end. Most studies used the Hamilton
Depression Rating Scale (HDRS) (Hamilton 1960) (including
the HDRS-short form (Reynolds 1995)), the Montgomery-As-
berg Depression Rating Scale (MADRS) (Montgomery 1979),
and/or the Beck Depression Inventory (BDI) (Beck 1987), but
the Inventory of Depressive Symptomology Self Report (IDS-SR)
(Trivedi 2004) (Lespérance 2011), the Hopkins SymptomCheck-
list Depression Scale (HSCL) (Williams 2004) (Lucas 2009), and
the Geriatric Depression Scale (GDS) (Yesvage 1983) (Rondanelli
2010) were also used. In almost all studies, depressive symptomol-
ogy scores were also collected at additional time points between
baseline and study end.
Adverse events:Number of individuals experiencing adverse events
were reported or provided for 22 studies (Bot 2010; Carney 2009;
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Coryell (1g/d); Coryell (2g/d); Da Silva (AD) 2005; Da Silva
(nAD) 2005; Gertsik 2012; Gharekhani 2014; Grenyer 2007;
Lespérance 2011; Lucas 2009; Mischoulon 2009; Mischoulon
(DHA) 2015;Mischoulon (EPA) 2015; Nemets 2002; Park 2015;
Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Rondanelli
2010; Silvers 2005; Su 2003). In some studies only the num-
ber of individuals experiencing serious adverse events (Bot 2010;
Coryell (1g/d); Coryell (2g/d); Gertsik 2012), clinically relevant
adverse events (Nemets 2002) or emerging or worsening adverse
events (Mischoulon (DHA) 2015; Mischoulon (EPA) 2015) were
reported, and three studies reported only the number of individ-
uals experiencing adverse events reported by at least 5% of partic-
ipants (Bot 2010; Gertsik 2012; Lespérance 2011). Three studies
reported the number of adverse events rather than the number of
individuals experiencing them (Jazayeri (v placebo) 2008; Jazayeri
(v AD) 2008; Marangell 2003). Six studies did not report adverse
events fully, clearly or in detail (Carney 2009; Da Silva (AD) 2005;
Da Silva (nAD) 2005; Gonzalez 2011; Grenyer 2007; Lespérance
2011). Many studies also reported types of adverse event expe-
rienced. The majority of adverse events were gastrointestinal, al-
though psychological and other physical events were also reported.
We included data on adverse events in analyses, provided the num-
ber of individuals reporting adverse events was reported in the n-
3PUFA and placebo group using the same definition of adverse
events (serious adverse events, etc.).
Secondary Outcomes
Depressive symptomology (dichotomous data): Depressive symp-
tomology in dichotomous terms was reported in 18 studies
(Carney 2009; Coryell (1g/d); Coryell (2g/d); Da Silva (AD)
2005; Da Silva (nAD) 2005; Gertsik 2012; Gonzalez 2011;
Jazayeri (v placebo) 2008; Jazayeri (v AD) 2008; Marangell 2003;
Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015; Nemets 2002; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet
(4g/d) 2002; Rondanelli 2010). These data were used to provide
rates of remission and/or response. As determined by original au-
thors, ’remission’ was defined as an end point score within the
no/low depression range on the scale utilised (score ≤ 7 on the
HDRS (Gertsik 2012; Mischoulon 2009; Mischoulon (DHA)
2015; Mischoulon (EPA) 2015), score ≤ 8 on the BDI (Carney
2009), score < 11 on the GDS (Rondanelli 2010)), and ’response’
was defined as a 50% improvement in depression scale score.
Quality of life: Quality of life was measured in 13 studies, us-
ing a range of validated scales: Clinical Global Impression (CGI)
(Guy 1976) (Da Silva (AD) 2005; Da Silva (nAD) 2005; Gertsik
2012; Lucas 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015; Park 2015), Patient Global Impression (PGI) (Guy 1976)
(Gertsik 2012), Global Assessment of Functioning Scale (GAF)
(Diguer 1993), (Grenyer 2007; Marangell 2003), Psychologi-
cal General Well-being Schedule (PGWB) (Dupuy 1984) (Lucas
2009), the Quality of Life Enjoyment and Satisfaction Question-
naire (QLESQ) (Endicott 1993) (Mischoulon 2009), the Short
Form (36)Health Survey (SF-36) (Ware 1993) (Gharekhani 2014;
Rondanelli 2010) and Likert scales (Grenyer 2007). We consid-
ered these scales to assess quality of life, although some of them
were used as secondary measures of depression in some studies.
For the CGI and PGI, higher scores denote poorer quality of life.
For the GAF, PGWB, QLESQ and SF-36, higher scores denote
better quality of life.
Failure to complete: All studies reported numbers of individuals
who failed to complete, with the exception of Rondanelli 2010,
where no details are provided but full data sets are available for
all participants, so we presume none failed to complete. For all
other studies, figures ranged from0% (Coryell (1g/d); Coryell (2g/
d)) to 55% (Gonzalez 2011). Some studies provided reasons for
withdrawal (Bot 2010; Carney 2009; Gharekhani 2014; Grenyer
2007; Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon
(EPA) 2015; Nemets 2002; Park 2015; Peet (1g/d) 2002; Peet
(2g/d) 2002; Peet (4g/d) 2002; Silvers 2005; Su 2003).
Excluded studies
Our searches identified only one trial registration that we have
classified as an excluded study (Characteristics of excluded studies).
This trial registration (Clayton 2009) details a trial that appears
to meet our inclusion criteria, but the study was withdrawn prior
to participant enrolment.
Ongoing studies
Sixteen RCTs investigating n-3PUFAs versus a comparator in
adults with MDD are currently ongoing. We provide details of
these in the tables of Characteristics of ongoing studies. Details
are based on trial registrations (we have had no correspondence
with authors of ongoing studies). We have included all potentially
relevant studies, to allow subsequent updates of the review to be
as inclusive as possible. Some of the studies that are currently in-
cluded as ongoing studies may be excluded from updates of the re-
view once study details become clearer following completion and
publication. Only subgroups of participants in some studies may
also be included in subsequent updates, depending on inclusion/
exclusion criteria and randomisation procedures. Some trials, for
example, focus on adolescents, but include individuals aged up to
25 years (Amminger 2013), and while the majority of respondents
in this trial may not be relevant to our review, it may be possible
to include a subset of individuals over 18 years, dependent on ran-
domisation procedures.
Studies awaiting classification
Nine trials are currently awaiting classification. Details of these
are provided in the tables of Characteristics of studies awaiting
classification. These search results comprise two conference ab-
stracts (Kwak 2013; Rees 2005), and seven trial registrations. We
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cannot yet include the conference abstracts, as we have not so far
been able to obtain enough information on these studies to be sure
that they are relevant to our review. Neither the first author nor
the last author on the abstracts have responded to email requests.
The seven trial registrations relate to trials that are now described
on trial register websites as ’completed’. We have emailed all con-
tact authors for further information to allow clarification. Corre-
sponding authors for Shinto 2005 and Su 2005 have responded,
stating that this trial will be published in due course, and that all
details will be available then. We have not received replies relating
to the trial registration from the correspondent for Naqvi 2008.
Emails for Murck 2004 and Lima 2006 have been returned unde-
livered and subsequent enquires of study sponsors have not been
fruitful. No contact details were available for two registrations
(EUCTR2006-004949-41-IT; NCT00816322). The abstract for
Rees 2005 has also been linked to a trial registration, but the status
of the trial is recorded as ’unknown’. We have again tried to make
contact, but have not received replies from study contacts.
Risk of bias in included studies
Details of the risk of bias judgements for each study are given in
the tables of Characteristics of included studies, and we present
a graphical representation of the overall risk of bias in included
studies in Figure 2 and Figure 3. We judged the risks of bias to be
very variable between studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We judged 21 studies to be at low risk of bias for random
sequence generation (Bot 2010; Carney 2009; Coryell (1g/d);
Coryell (2g/d); Da Silva (AD) 2005; Da Silva (nAD) 2005;
Gharekhani 2014; Grenyer 2007; Lespérance 2011; Lucas 2009;
Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015; Nemets 2002; Park 2015; Peet (1g/d) 2002; Peet (2g/d)
2002; Peet (4g/d) 2002; Rondanelli 2010; Silvers 2005; Su 2003).
In most of these studies, randomisation was undertaken using a
computer-generated random number generator, but drawing lots
(Da Silva (AD) 2005; Da Silva (nAD) 2005) and a random num-
ber table (Nemets 2002; Rondanelli 2010) were also used. For all
other studies (Gertsik 2012; Gonzalez 2011; Jazayeri (v placebo)
2008; Jazayeri (v AD) 2008; Marangell 2003), insufficient details
were provided, resulting in a judgement of unclear risk of bias.
Allocation concealment
We judged 15 studies to be at low risk of bias for allocation con-
cealment (Bot 2010;Grenyer 2007; Lespérance 2011; Lucas 2009;
Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015; Nemets 2002; Park 2015; Peet (1g/d) 2002; Peet (2g/d)
2002; Peet (4g/d) 2002; Rondanelli 2010; Silvers 2005; Su 2003).
In these studies, allocation concealment was ensured by individ-
uals outside the main research team conducting allocation, or by
using sequential numbering that had been prepared by individuals
outside the main research team. We judged two studies to be at
high risk of bias (Jazayeri (v placebo) 2008; Jazayeri (v AD) 2008),
following comments from the author that the randomisation se-
quence was not concealed from researchers. For all other studies
(Carney 2009;Coryell (1g/d);Coryell (2g/d);DaSilva (AD) 2005;
Da Silva (nAD) 2005; Gertsik 2012; Gharekhani 2014; Gonzalez
2011;Marangell 2003), insufficient details were provided, leading
to a judgement of unclear risk of bias.
Blinding
Blinding of participants and personnel
We judged six studies to be at low risk of bias for blinding of study
participants and personnel to treatment allocation (Bot 2010;
Lespérance 2011; Lucas 2009; Nemets 2002; Rondanelli 2010;
Silvers 2005). In these studies, blinding was undertaken by adding
a small amount of fish oil to the comparator treatment to control
for fishy aftertaste and/or adding flavours to both treatments to
mask a fishy aftertaste, and following investigation, blinding was
found to be successful. We judged 13 studies at high risk of bias
(Carney 2009; Da Silva (AD) 2005; Da Silva (nAD) 2005; Gertsik
2012; Gharekhani 2014; Grenyer 2007; Jazayeri (v placebo) 2008;
Jazayeri (v AD) 2008; Mischoulon 2009; Park 2015; Peet (1g/
d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002). In these studies,
there were no reports of attempting to mask the fishy taste of the
intervention, despite good descriptions of the placebo otherwise,
and no assessment to check successful concealment. In one study,
the majority of participants correctly guessed their allocation (
Grenyer 2007). We judged four studies to be at unclear risk of
bias (Coryell (1g/d); Coryell (2g/d); Gonzalez 2011; Marangell
2003) due to no report of attempts to mask a fishy taste, but
no clear description of other aspects of the placebo. We judged
a further three studies to be at unclear risk of bias (Mischoulon
(DHA) 2015; Mischoulon (EPA) 2015; Su 2003) because flavour
was added to the capsules to mask a fishy taste, but there was no
assessment to check the success of this precaution.
Blinding of Outcome assessment
We judged the blinding of outcome assessments depending on the
individuals making the assessment (participant, researcher, clini-
cian) and the blinding of those persons, as detailed in the blinding
of participants and personnel. Thus, we rated participant-rated
measures at a low risk of bias if we considered participants to be
successfully blinded to treatment allocation, at unclear risk of bias
if blinding was unclear, and at high risk of bias if we considered
participants not to be successfully blinded. We treated personnel-
rated measures in a similar fashion. In all cases, we used study re-
ports of the individuals making the assessment if possible, or used
standard assessments if details were not specified, e.g. in standard
practice, the BDI is a self-report instrument for completion by
patients. Where multiple outcome measures were used and these
were given different judgements of risk of bias, we took the key
risk of bias judgement to be the one applicable to the outcome
measure we used in our analyses.
Mood:
We judged 19 studies to be at low risk of bias, following ratings of
adequate blinding of those making the assessments or following
adequate blinding of those making the mood assessment used in
our analyses (Bot 2010; Carney 2009; Coryell (1g/d); Coryell
(2g/d); Da Silva (AD) 2005; Da Silva (nAD) 2005; Grenyer 2007;
Jazayeri (v placebo) 2008; Jazayeri (v AD) 2008; Lespérance 2011;
Lucas 2009; Mischoulon 2009; Nemets 2002; Park 2015; Peet
(1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002;Rondanelli 2010;
Silvers 2005). We rated six studies at unclear risk of bias, where
it was unclear who had made the assessment or whether those
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individuals were successfully blinded (Gertsik 2012; Gonzalez
2011; Marangell 2003; Mischoulon (DHA) 2015; Mischoulon
(EPA) 2015; Su 2003). We judged one study to be at high risk of
bias, where there was a high risk of bias in the blinding of those
making the mood assessment (Gharekhani 2014).
Adverse events:
We rated six studies at low risk of bias following judgements of
adequate blinding of those making the assessments (Bot 2010;
Lespérance 2011; Lucas 2009; Nemets 2002; Rondanelli 2010;
Silvers 2005). We judged nine studies to be at high risk of bias,
where assessments were made by those at high risk of performance
bias due to inadequate blinding (Gharekhani 2014;Grenyer 2007;
Jazayeri (v placebo) 2008; Jazayeri (vAD)2008;Mischoulon 2009;
Park 2015; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002).
We rated 11 studies at unclear risk of bias, where it was not appar-
ent who had made the assessment or if those individuals were suc-
cessfully blinded (Carney 2009; Coryell (1g/d); Coryell (2g/d);Da
Silva (AD) 2005; Da Silva (nAD) 2005; Gertsik 2012; Gonzalez
2011; Marangell 2003; Mischoulon (DHA) 2015; Mischoulon
(EPA) 2015; Su 2003).
Incomplete outcome data
Mood:
We rated outcome data for mood as complete if there were no
missing outcome data; or if: analyses were conducted using inten-
tion-to-treat (ITT) data, where ITT was defined as including all
those randomised; data were missing for less than 10% of the total
randomised population; reasons for missing outcome data were
unlikely to be related to true outcome; the difference in missing
data between intervention and comparator group was not more
than 10% of the total randomised population; and the missing
data were not unbalanced between intervention and comparator
groups in numbers and reasons.
We rated eight studies at low risk of bias for publication or provi-
sion of ITT data (as above) (Carney 2009; Coryell (1g/d); Coryell
(2g/d); Lucas 2009; Mischoulon 2009; Nemets 2002; Rondanelli
2010; Su 2003).We judged 18 studies to be at high risk of bias due
to the unavailability of ITT data (Bot 2010; Da Silva (AD) 2005;
Da Silva (nAD) 2005; Gertsik 2012; Gonzalez 2011; Marangell
2003; Mischoulon (DHA) 2015; Mischoulon (EPA) 2015; Park
2015; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Silvers
2005), or publication or provision of ITT data but a higher than
10% dropout rate (Gharekhani 2014; Grenyer 2007; Jazayeri (v
placebo) 2008; Jazayeri (v AD) 2008; Lespérance 2011).
Adverse events:
We judged outcome data for adverse events to be complete if
all adverse events were clearly reported, and incomplete if all ad-
verse events were clearly not reported. We rated 14 studies at low
risk of bias, due to clear complete reporting of all adverse events
(Gharekhani 2014; Jazayeri (v placebo) 2008; Jazayeri (v AD)
2008; Lucas 2009; Mischoulon 2009; Mischoulon (DHA) 2015;
Mischoulon (EPA) 2015; Park 2015; Peet (1g/d) 2002; Peet (2g/d)
2002; Peet (4g/d) 2002; Rondanelli 2010; Silvers 2005; Su 2003).
We judged six studies to be at high risk of bias due to clear in-
complete reporting of all adverse events (Bot 2010; Gertsik 2012;
Gonzalez 2011; Lespérance 2011;Marangell 2003;Nemets 2002).
We judged six studies at unclear risk of bias where adverse events
were not clearly reported (Carney 2009; Coryell (1g/d); Coryell
(2g/d);DaSilva (AD) 2005;Da Silva (nAD) 2005;Grenyer 2007).
Selective reporting
We judged16 studies to be at low risk of bias for selective reporting,
where reported outcomes have been checked against protocols (Bot
2010), or where authors have informed us that all planned out-
comes have been reported (Carney 2009; Da Silva (AD) 2005; Da
Silva (nAD) 2005; Gharekhani 2014; Grenyer 2007; Lespérance
2011; Lucas 2009; Nemets 2002; Park 2015; Peet (1g/d) 2002;
Peet (2g/d) 2002; Peet (4g/d) 2002;Rondanelli 2010; Silvers 2005;
Su 2003). Judgements of high risk of reporting bias were given
to six studies where all outcomes have not (yet) been reported
(Gertsik 2012; Jazayeri (v placebo) 2008; Jazayeri (v AD) 2008;
Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015), and to two unpublished studies (Coryell (1g/d); Coryell
(2g/d)). We judged two studies at unclear risk of bias where proto-
cols were not available and authors have not confirmed complete
reporting (Gonzalez 2011; Marangell 2003).
Other potential sources of bias
All studies appeared to be free from other sources of bias, with the
exception of Park 2015, where we found a significant imbalance
in all measures of mood and quality of life between intervention
and comparator groups at baseline.
Effects of interventions
See: Summary of findings for the main comparison n-3PUFAs
compared to placebo for depression in adults
Comparison 1: n-3PUFAs versus placebo
Twenty-five independent studies involving 1438 individuals con-
tribute to this comparison (Bot 2010; Carney 2009; Coryell
(1g/d); Coryell (1g/d); Da Silva (AD) 2005; Da Silva (nAD)
2005; Gertsik 2012; Gharekhani 2014; Gonzalez 2011; Grenyer
2007; Jazayeri (v placebo) 2008; Lespérance 2011; Lucas 2009;
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Marangell 2003; Mischoulon 2009; Mischoulon (DHA) 2015;
Mischoulon (EPA) 2015; Nemets 2002; Park 2015; Peet (1g/d)
2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Rondanelli 2010;
Silvers 2005; Su 2003); see also Summary of findings for the main
comparison.
Primary outcomes
1.1 Depressive Symptomology (continuous data)
All 25 studies provided continuous data on depressive sympto-
mology from 1373 individuals, and were included in analyses.
Analyses were based on HDRS scores for 17 studies (Carney
2009; Gertsik 2012; Gharekhani 2014; Gonzalez 2011; Grenyer
2007; Jazayeri (v placebo) 2008; Lucas 2009; Marangell 2003;
Mischoulon 2009; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015; Nemets 2002; Park 2015; Peet (1g/d) 2002; Peet (2g/d)
2002; Peet (4g/d) 2002; Silvers 2005; Su 2003), and also on
MADRS score for six studies (Bot 2010; Coryell (1g/d); Coryell
(2g/d); Da Silva (AD) 2005; Da Silva (nAD) 2005, Lespérance
2011), BDI score for one study (Gharekhani 2014), and GDS
score for one study (Rondanelli 2010).
n-3PUFAs were more effective than placebo: SMD = -0.32 (95%
CI -0.52 to -0.12) (see Analysis 1.1, Figure 4, Figure 5), but effect
sizes are small to modest, and there was substantial evidence of
heterogeneity between studies (I² = 58%). Confidence intervals
also range between a very small and a modest effect size, and
suggest a possible clinically important effect at their upper end.
Using GRADE criteria, we judged the quality of the evidence to
be very low. A standardised mean difference of 0.32 represents a
difference between groups in scores on the HDRS (17-item) of
approximately 2.2 points (95% CI 0.8 to 3.6).
Figure 4. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.1 Depressive symptomology
(continuous).
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Figure 5. Funnel plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.1 Depressive symptomology
(continuous).
1.2 Adverse Events
The number of individuals experiencing adverse events was similar
in n-3PUFA and placebo groups: OR = 1.24 (95% CI 0.95 to
1.62), 19 studies, 1207 participants (see Analysis 1.2, Figure 6,
Figure 7). Confidence intervals however are wide, and suggest that
effects could range from a reduction of 5% to an increase in adverse
events in n-3PUFA groups of 62%, compared with placebo. Using
GRADE criteria, we judged the quality of the evidence to be very
low. There was no evidence of heterogeneity between groups (I² =
0%).
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Figure 6. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.2 Adverse events.
Figure 7. Funnel plot of comparison: 1 n-3PUFAs vs Placebo, outcome: 1.2 Adverse events.
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Secondary outcomes
1.3 Depressive Symptomology (dichotomous data)
There was no evidence of a statistical difference in remission
rates following supplementation with n-3PUFAs compared with
placebo: OR = 1.38 (95% CI 0.87 to 2.20), 6 studies, 426 partici-
pants (see Analysis 1.3, Figure 8), but confidence intervals are very
wide. Confidence intervals suggest a possible effect ranging from a
13% reduction in remission rates with n-3PUFAs compared with
placebo, to a 220% increase in remission rates. Using GRADE
criteria, we judged the quality of the evidence to be low. There
was little evidence of heterogeneity between groups (I² = 7%).
Figure 8. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.3 Depressive symptomology
(dichotomous data): remission.
There was no strong evidence of a statistical difference in response
rates following supplementation with n-3PUFAs compared with
placebo: OR = 1.39 (95% CI 0.95 to 2.04), 15 studies, 611 par-
ticipants (see Analysis 1.4, Figure 9), but confidence intervals are
again verywide.Confidence intervals suggest a possible effect rang-
ing from a 5% reduction in remission rates with n-3PUFAs com-
pared with placebo, to a 204% increase in remission rates. Using
GRADE criteria, we judged the quality of the evidence to be low.
There was little evidence of heterogeneity between groups (I² =
6%).
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Figure 9. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.4 Depressive symptomology
(dichotomous data): response.
1.4 Quality of Life
Continuous data on quality of life were available in 383 par-
ticipants from nine studies (Da Silva (AD) 2005; Da Silva
(nAD) 2005; Gharekhani 2014; Lucas 2009; Marangell 2003;
Mischoulon (DHA) 2015; Mischoulon (EPA) 2015; Park 2015;
Rondanelli 2010). We conducted analyses on data from the
CGI (Da Silva (AD) 2005; Da Silva (nAD) 2005; Lucas 2009;
Mischoulon (DHA) 2015; Mischoulon (EPA) 2015; Park 2015),
the GAF (Marangell 2003) and the SF-36 (mental health sum-
mary scale) (Gharekhani 2014; Rondanelli 2010). We reversed
scores for the GAF and SF-36, so that in all scales a higher score
denotes poorer quality of life.
There was no strong evidence of a statistical difference in quality
of life between n-3PUFA and placebo groups: SMD = -0.47 (95%
CI -0.99 to 0.06). Confidence intervals range between a negligible
and a large effect size, suggesting both a possible absence of effect
at the lower end, and a possible important effect at the upper end.
Using GRADE criteria, we judged the quality of the evidence to
be very low, and there was considerable evidence of heterogeneity
between studies (I² = 82%) (see Analysis 1.5, Figure 10).
Figure 10. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.5 Quality of life.
1.5 Failure to Complete
Rates for failure to complete were similar in n-3PUFA and placebo
groups: OR = 0.84 (95% CI 0.62 to 1.14), 21 studies, 1344 par-
ticipants (see Analysis 1.6, Figure 11, Figure 12), but again confi-
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dence intervals are wide, and suggest that effects could range from
a reduction of 38% to an increase in study withdrawals of 14% in
n-3PUFA groups, compared to placebo. Using GRADE criteria,
we judged the quality of the evidence to be very low. There was
no evidence of heterogeneity between groups (I² = 0%).
Figure 11. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 1.6 Failure to complete.
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Figure 12. Funnel plot of comparison: 1 n-3PUFAs vs Placebo, outcome: 1.6 Failure to complete.
Comparison 2: n-3PUFAs versus antidepressants
Data were only available from one study for this comparison (
Jazayeri (v AD) 2008).
Primary outcomes
2.1 Depressive Symptomology (continuous data)
Depressive symptomology based on the HDRS was similar in the
n-3PUFA and antidepressant groups: MD (HDRS(24 item)) = -
0.70 (95%CI -5.88 to 4.48), 1 study, 40 participants (see Analysis
2.1). Confidence intervals however are very wide, and do not rule
out a modest benefit or detriment of n-3PUFAs, compared to
antidepressants.
2.2 Adverse Events
Adverse events were only reported in terms of the number of events
experienced, as opposed to the number of individuals experiencing
at least one event.
Secondary outcomes
2.3 Depressive Symptomology (dichotomous data)
Response rates were similar in n-3PUFA and antidepressant
groups: OR = 1.23 (95% CI 0.35 to 4.31), 1 study, 40 partici-
pants (see Analysis 2.2), but confidence intervals are very wide, and
do not rule out an important benefit or detriment of n-3PUFAs,
compared to antidepressants. Remission rates were not reported.
2.4 Quality of Life
Quality of life was not reported in this study.
2.5 Failure to complete
Rates for failure to complete were similar in n-3PUFA and antide-
pressant groups: OR = 1.00 (95% CI 0.21 to 4.71), 1 study, 40
participants (see Analysis 2.3). Confidence intervals however are
again very wide, and do not rule out important effects in either
direction.
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Subgroup analyses
We conducted subgroup analyses only for the n-3PUFA versus
placebo comparison, and only for the primary outcomes, but the
number of studies and the number of participants are low. There
were insufficient numbers of studies and participants for subgroup
analyses to be conducted for other outcomes or for the n-3PUFA
versus antidepressant comparison.
3. Analyses based on comorbidities
There was a suggestion of greater effect sizes (n-3PUFAs compared
to placebo) in depressive symptomology (continuous) in studies
including individuals with comorbid conditions: SMD = -0.65
(95%CI -1.28 to -0.02; 5 studies, 229 participants), and in studies
including individuals without comorbid conditions: SMD= -0.99
(95% CI -1.71 to -0.27; 3 studies, 104 participants), compared to
studies with a mix of individuals with comorbid and without co-
morbid conditions: SMD = -0.13 (95%CI -0.30 to 0.05; 17 stud-
ies, 1040 participants) (see Analysis 3.1, Figure 13). The number
of studies and the number of individuals in each subgroup how-
ever were small, particularly in the subgroup of studies including
individuals without comorbid conditions (3 studies, 104 partici-
pants), confidence intervals are very wide, suggesting that effects
could range frommuch stronger effects to those that are negligible,
and the evidence of heterogeneity within each subgroup was high
(I² = 28% to 74%). There was statistical evidence of a difference
between subgroups (P = 0.03), but the evidence of heterogeneity
between subgroups was high (I² = 72%).
Figure 13. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 3.1 Depressive symptomology
(continuous): Sub-groups based on presence / absence of comorbidities.
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Rates of adverse events were similar across the subgroups. Analysis
of studies including individuals with comorbid conditions (OR =
2.66 (95% CI 0.22 to 31.93); 3 studies, 201 participants), studies
including individuals without comorbid conditions (OR = 0.82
(95% CI 0.19 to 3.50) 2 studies, 69 participants), and studies
with a mix of individuals with and without comorbid conditions
(OR = 1.40 (95% CI 1.04 to 1.89) 14 studies, 937 participants)
indicated no statistical evidence of a difference between subgroups
(P = 0.68), and no evidence of heterogeneity between subgroups
(I² = 0%) (see Analysis 3.2). Heterogeneity was high in the sub-
group of studies including individuals with comorbid conditions
(I² = 71%), but low in the other two subgroups (I² = 0%), and
confidence intervals are again very wide, suggesting possible effects
that could range between a reduction in events with n-3PUFAs of
89% to an increase in events of 3193%.
4. Analyses based on adjunctive therapy
The effect of n-3PUFAs compared to placebo in depressive symp-
tomology (continuous) in studies with a mix of individuals re-
ceiving and not receiving adjunctive therapy was SMD = -0.43
(95% CI -0.82 to -0.04; 7 studies, 709 participants), in studies
with individuals not receiving adjunctive therapy was SMD = -
0.32 (95% CI -0.86 to 0.21; 6 studies, 308 participants), and
in studies only including individuals receiving adjunctive therapy
was SMD = -0.21 (95% CI -0.42 to 0.01; 12 studies, 356 partic-
ipants). There was no statistical evidence of a difference between
subgroups (P = 0.60) (see Analysis 4.1, Figure 14). However, the
number of studies and the number of individuals in each subgroup
were small, and confidence intervals are very wide, suggesting that
effects could range from a large beneficial effect of n-3PUFAs to
a small negative effect, compared with placebo. There was no ev-
idence of heterogeneity between subgroups (I² = 0%), and evi-
dence of heterogeneity was low in the subgroup of studies includ-
ing individuals receiving adjunctive therapy (I² = 0%). However,
heterogeneity was high in the other two subgroups (I² = 76% and
77% respectively).
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Figure 14. Forest plot of comparison: 1 n-3PUFAs vs placebo, outcome: 4.1 Depressive symptomology
(continuous): Sub-groups based on use / non-use of adjunctive therapies.
Rates of adverse events were similar across the subgroups. Analysis
of studies with a mix of individuals receiving and not receiving
adjunctive therapy: OR = 1.16 (95% CI 0.81 to 1.65; 6 stud-
ies, 644 participants), studies including individuals not receiving
adjunctive therapy: OR = 2.04 (95% CI 1.03 to 4.03; 4 stud-
ies, 259 participants), and studies including individuals receiving
adjunctive therapy: OR = 0.97 (95% CI 0.56 to 1.70; 9 studies,
304 participants) indicated that there was no statistical evidence
of a difference between subgroups (P = 0.23) and some evidence
of heterogeneity between subgroups (I² = 32%), see Analysis 4.2.
However, confidence intervals are very wide and suggest possible
effects ranging from a reduction in adverse events with n-3PUFAs
to a large increase in adverse events, compared with placebo. Evi-
dence of heterogeneity was low in all subgroups (I² = 0% to 16%).
Sensitivity analyses
We conducted sensitivity analyses only for the n-3PUFA versus
placebo comparison. The sensitivity analyses using a fixed-effect
model were for all outcomes, while all other sensitivity analyses
were conducted only for our primary outcome measures.
5. Low risk of bias
5.1 Selection bias
The results of analyses (random-effects model) using only the
studies that we judged to be at low risk of selection bias based
on allocation concealment assessment (Bot 2010; Grenyer 2007;
Lespérance 2011; Lucas 2009; Mischoulon 2009; Mischoulon
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(DHA) 2015;Mischoulon (EPA) 2015; Nemets 2002; Park 2015;
Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Rondanelli
2010; Silvers 2005; Su 2003) were:
Depressive symptomology (continuous data): SMD = -0.21 (95%
CI -0.45 to 0.03) (15 studies, 1033 participants), (I² = 59%).
Adverse events: OR = 1.31 (95% CI 0.98 to 1.75) (14 studies,
978 participants), (I² = 0%).
These analyses demonstrate no statistical differences between n-
3PUFA and placebo groups in depressive symptomology or ad-
verse events, but confidence intervals are wide and suggest both a
possible clinically important benefit of n-3PUFAs and a negligible
effect in depressive symptomology, and a range of effects in adverse
events from a possible reduction of 2% to a possible increase in
adverse events of 175%, with n-3PUFAs compared to placebo.
5.2 Performance bias
The results of all analyses using only the studies that we judged to
be at low risk of performance bias based on blinding of participants
and personnel assessment (Bot 2010; Lespérance 2011; Lucas
2009; Nemets 2002; Rondanelli 2010; Silvers 2005) were:
Depressive symptomology (continuous data): SMD = -0.14 (95%
CI -0.55 to 0.26) (6 studies, 610 participants), (I² = 69%).
Adverse events: OR = 1.22 (95% CI 0.85 to 1.74) (6 studies, 629
participants), (I² = 0%).
These analyses demonstrate no statistical differences between n-
3PUFA and placebo groups in depressive symptomology or ad-
verse events, but confidence intervals are wide and suggest both
a possible clinically important benefit of n3PUFAs and a small
detrimental effect of n-3PUFAs in depressive symptomology, and
a range of effects in adverse events from a possible reduction of
15% to a possible increase in adverse events of 174%, with n-
3PUFAs compared to placebo.
5.3 Attrition bias
The results of all analyses using only the studies that we judged to
be at low risk of attrition bias based on assessment of incomplete
outcome data (Carney 2009; Coryell (1g/d); Coryell (2g/d); Lucas
2009; Mischoulon 2009; Nemets 2002; Rondanelli 2010; Su
2003) were:
Depressive symptomology (continuous data): SMD = -0.39 (95%
CI -0.96 to 0.17) (8 studies, 297 participants), (I² = 76%).
Adverse events: OR = 0.82 (95% CI 0.46 to 1.45) (8 studies, 297
participants), (I² = 0%).
These analyses also demonstrate no statistical differences between
n-3PUFA and placebo groups in depressive symptomology or ad-
verse events, but confidence intervals are wide and suggest both a
possible clinically important benefit of n-3PUFAs and a negligible
effect in depressive symptomology, and a range of effects in adverse
events from a possible reduction of 54% to a possible increase in
adverse events of 145%, for n-3PUFAs compared with placebo.
6. Fixed-effect models
The results of all analyses using a fixed-effect model were:
Depressive symptomology (continuous data): SMD = -0.20 (95%
CI -0.31 to -0.09) (25 studies, 1373 participants).
Adverse events: OR = 1.29 (95% CI 0.99 to 1.67) (19 studies,
1207 participants).
Depressive symptomology (dichotomous data) - remission: OR =
1.38 (95% CI 0.89 to 2.13) (6 studies, 426 participants).
Depressive symptomology (dichotomous data) - response: OR =
1.42 (95% CI 1.00 to 2.01) (15 studies, 611 participants).
Quality of life: SMD = -0.35 (95% CI -0.56 to -0.13) (9 studies,
383 participants).
Failure to complete:OR = 0.85 (95%CI 0.64 to 1.14) (21 studies,
1344 participants).
Results are similar to those achieved using a random-effects model,
although effect sizes are noticeably smaller for measures of depres-
sive symptomology and quality of life. Effect sizes in depressive
symptomology are half the size using a fixed-effect model com-
pared to using a random-effects model. Differences between n-
3PUFA and placebo groups in quality of life are also statistically
significant.
Reporting Bias
The funnel plot for the main analysis of depressive symptomology
(continuous) is presented in Figure 5. This figure demonstrates
some asymmetry, suggesting possible publication bias in this out-
come.
Funnel plots for adverse events and failure to complete also demon-
strate some asymmetry, suggesting possible publication bias in
these outcomes also (Figure 7 and Figure 12 respectively).
Additional Sensitivity Analyses
7. Use of a treatment that was solely or predominantly
eicosapentaenoic acid (EPA)
7.1. Use of a treatment that was solely EPA
Eight studies used an intervention that was solely EPA (Bot 2010;
Gonzalez 2011; Jazayeri (v placebo) 2008; Mischoulon 2009;
Nemets 2002; Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d)
2002).
The results of analyses using only these studies were:
Depressive symptomology (continuous data): SMD = -0.45 (95%
CI -0.74 to -0.15) (8 studies, 203 participants), (I² = 0%).
Adverse events: OR = 0.99 (95% CI 0.39 to 2.45) (6 studies, 155
participants), (I² = 0%).
These analyses demonstrate a modest benefit for n-3PUFAs com-
pared to placebo for depressive symptomology and no differences
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between groups for adverse events, although confidence inter-
vals again suggest an effect size for depressive symptomology that
ranges from small to clinically important, and both a possible re-
duction and an increase in adverse events, for n-3PUFAs compared
to placebo. The overall effect size for depressive symptomology is
larger than that for all studies, and the evidence of heterogeneity
between studies is lower, but only a small number of studies are
included in this analysis.
7.2. Use of a treatment that was predominantly EPA
Thirteen studies used an intervention thatwas predominantly EPA
(Carney 2009; Coryell (1g/d); Coryell (2g/d); Da Silva (AD)
2005; Da Silva (nAD) 2005; Gertsik 2012; Gharekhani 2014;
Lespérance 2011; Lucas 2009; Mischoulon (EPA) 2015; Park
2015; Rondanelli 2010; Su 2003).
The results of analyses using only these studies were:
Depressive symptomology (continuous data): SMD = -0.40 (95%
CI -0.72 to -0.08) (13 studies, 906 participants), (I² = 71%).
Adverse events: OR = 1.26 (95% CI 0.88 to 1.80) (11 studies,
889 participants), (I² = 9%).
These analyses demonstrate a modest benefit for n-3PUFAs com-
pared to placebo for depressive symptomology and no differences
between groups for adverse events, although confidence inter-
vals again suggest an effect size for depressive symptomology that
ranges from small to clinically important, and both a possible re-
duction and an increase in adverse events, for n-3PUFAs compared
to placebo. The overall effect size for depressive symptomology is
larger than that for all studies, but the evidence of heterogeneity
between studies is greater.
8. Inclusion of ALA in placebo capsules
Six studies used a placebo containing ALA (an n-3PUFA) as a
comparison (Bot 2010; Coryell (1g/d); Coryell (2g/d); Jazayeri
(v placebo) 2008; Mischoulon (DHA) 2015; Mischoulon (EPA)
2015).
The results of analyses without these studies were:
Depressive symptomology (continuous data): SMD = -0.40 (95%
CI -0.65 to -0.15) (19 studies, 1121 participants), (I² = 66%).
Adverse events: OR = 1.14 (95% CI 0.85 to 1.54) (14 studies,
995 participants), (I² = 0%).
These analyses demonstrate a modest benefit for n-3PUFAs com-
pared to placebo for depressive symptomology and no differences
between groups for adverse events, although confidence inter-
vals again suggest an effect size for depressive symptomology that
ranges from small to clinically important, and both a possible re-
duction and an increase in adverse events, for n-3PUFAs compared
to placebo. The overall effect size for depressive symptomology is
larger than that for all studies, but the evidence of heterogeneity
between studies is also higher.
9. Use of data from per protocol analyses
We could not obtain ITT data (either from publications or from
authors) for 13 studies (Bot 2010; Da Silva (AD) 2005; Da
Silva (nAD) 2005; Gonzalez 2011; Marangell 2003; Mischoulon
(DHA) 2015; Mischoulon (EPA) 2015; Park 2015; Peet (1g/d)
2002; Peet (2g/d) 2002; Peet (4g/d) 2002; Silvers 2005).
The results of analyses without these studies were:
Depressive symptomology (continuous data): SMD = -0.36 (95%
CI -0.66 to -0.07) (13 studies, 946 participants), (I² = 70%).
Adverse events: OR = 1.17 (95% CI 0.74 to 1.85) (11 studies,
825 participants), (I² = 21%).
These results are very comparable to those conducted using all
studies, although confidence intervals are wider, suggesting less
precision in the overall effect sizes.
10. Use of imputed standard deviations from other studies in
analyses
We imputed standard deviations for five studies (Mischoulon
(DHA) 2015; Mischoulon (EPA) 2015; Peet (1g/d) 2002; Peet
(2g/d) 2002; Peet (4g/d) 2002).
The results of analyses without these studies were:
Depressive symptomology (continuous data): SMD = -0.22 (95%
CI -0.34 to -0.10) (20 studies, 1127 participants), (I² = 65%).
Adverse events: OR = 1.15 (95% CI 0.84 to 1.59) (14 studies,
1127 participants), (I² = 2%).
These analyses demonstrate smaller differences between n-3PUFA
and placebo groups for depressive symptomology and adverse
events than in our analyses of all studies. Confidence intervals are
also narrower, suggesting a greater precision compared to the over-
all effect sizes, although the evidence of heterogeneity between
studies remains high.
11. Consideration of multiple comparison groups from the
same study as individual studies
Four trials used multiple treatment groups that we considered
in our primary analyses as independent studies (Coryell (1g/d);
Coryell (2g/d); Da Silva (AD) 2005; Da Silva (nAD) 2005;
Mischoulon (DHA) 2015; Mischoulon (EPA) 2015; Peet (1g/d)
2002; Peet (2g/d) 2002; Peet (4g/d) 2002). Use of these studies
as independent groups may magnify between-study heterogeneity,
although data for all of these studies have been provided for each
group separately, so that combining groups results in standard de-
viations that are estimations based on pooling calculations.
The results of analyses using combined as opposed to split studies
were:
Depressive symptomology (continuous data): SMD = -0.34 (95%
CI -0.56 to -0.12) (20 studies, 1364 participants), (I² = 67%).
Adverse events: OR = 1.32 (95% CI 0.97 to 1.80) (16 studies,
1183 participants), (I² = 0%).
These results are very comparable to those conducted using all
studies as independent studies.
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D I S C U S S I O N
Summary of main results
We found trials comparing the impact of n-3PUFAs on major
depressive disorder (MDD) to two different comparators. Twenty-
five studies involving 1438 participants investigated the impact of
n-3PUFAs inMDDcompared toplacebo, and one study involving
40 participants investigated the impact of n-3PUFAs in MDD
compared to antidepressant treatment.
For the comparison with placebo, we provide a ’Summary of find-
ings’ table (Summary of findings for the main comparison).
Our primary outcomes were depressive symptomology assessed
using a continuous measure, and adverse events. Mean depressive
symptomology in n-3PUFA groups was 0.32 (95% CI 0.12 to
0.52) standard deviations lower than placebo following treatment.
This small-to-modest effect size represents a difference between
groups in scores on the HDRS (17-item) of approximately 2.2
(0.8 to 3.6 respectively). NICE guidelines (NICE 2004) have pre-
viously suggested a reduction in HDRS score of 3 or more to be
clinically meaningful, thus the clinical significance of our effect
size is small. The confidence intervals do not exclude a clinically
meaningful effect, but also include a negligible effect at the lower
end. Furthermore, the completeness and quality of the evidence
was very low (see below).
Numbers of individuals experiencing adverse events were similar
between intervention and placebo groups, although assessments
of adverse events were suitable for analysis in only 19 of the 25
studies, and our confidence intervals suggest that effects could
range from a small reduction to amodest increase in adverse events
in n-3PUFA groups compared with placebo. Furthermore, the
completeness and quality of the evidence providing these results
was also very low.
Rates of depression remission and response were also similar fol-
lowing n-3PUFA supplementation compared to placebo, but con-
fidence intervals again suggest a range of possible effects from a
small reduction in remission and response rates to a large increase.
Quality of life was similar in n-3PUFA compared with placebo
groups, although our confidence intervals again suggest both a
possible negligible effect and a possible clinically important ben-
efit of n-3PUFAs compared to placebo. Rates of failure to com-
plete were also similar between intervention and placebo groups,
although our confidence intervals again suggest possible effects
that could range from a small reduction to a modest increase in
study withdrawals in n-3PUFA groups compared with placebo.
There was only one study involving 40 participants for the com-
parison with antidepressants. This study found no differences be-
tween treatment with n-3PUFAs and treatment with antidepres-
sants in depressive symptomology (MD (HDRS(24 item))= -0.70
(95% CI: -5.88 to 4.48)), rates of response to treatment, or failure
to complete. Adverse events were not reported in a manner suit-
able for analysis, and rates of depression remission and quality of
life were not reported.
Overall completeness and applicability of
evidence
The evidence for both comparisons and for all outcomes is limited
and highly heterogeneous, resulting in findings that are imprecise
and potentially biased.
Firstly, for the comparison with placebo, the evidence comes from
25 studies, involving only 1438 participants and with only 1373
participants contributing to the analysis. While data are available
from all studies for the analyses on our primary outcome of depres-
sive symptomology, only small numbers of studies contributed to
some of our outcomes.
The studies available were highly heterogeneous. All studies were
directly relevant to our research question, but we found consider-
able differences in all aspects of study methodology. Studies dif-
fered in the type of participants involved, the interventions used,
the comparators used, the duration of supplementation, and the
range and measurement of outcomes assessed.
The majority of available studies were also small. Almost half of all
participants derive fromonly three trials: Carney 2009 (122partic-
ipants), Lespérance 2011 (432 participants), and the Mischoulon
2015 trial (196 participants). We judged these trials to be at low
risk of bias on most measures, but the contribution of these three
trials to our overall outcomes was high, even using a random-
effects model (depressive symptomology - 26.9%; adverse events
- 82%), and the outcomes of our meta-analyses reflect the out-
comes of these specific trials. All three trials found a negligible
mean difference between n-3PUFA and placebo groups following
supplementation. Biases or methodologically specific outcomes in
these trials may have contributed to our overall result. All three
trials, for example, include participants with comorbidities, use
an intervention composed of a combination of EPA and DHA,
and assess effects of supplementation after eight to ten weeks. All
of these factors may have affected study outcomes, which in turn
may have affected our overall outcome.
The funnel plot also suggests an absence of small studies showing
null findings. This asymmetry suggests probable publication bias,
and suggests that our analyses and overall effect size estimates may
be biased towards a positive finding for n-3PUFAs compared to
the true situation. Sensitivity analyses using a fixed-effect model
also demonstrated a smaller standardised mean difference between
n-3PUFA and placebo groups than that found using a random-
effects model, suggesting a positive influence from small positive
studies in our main analyses.
Sensitivity analyses using only the studies that we judged to be at
low risk of bias also suggest bias in our main analyses towards a
positive finding for n-3PUFAs. Many studies we judged to be at
high risk of bias in various domains. Analyses using only studies
that we judged to be at low risk of selection bias, performance bias
and attrition bias report smaller effect sizes than those found in
our main analyses, and confidence intervals include the possibility
of no differences between groups. This evidence, alongside that of
the funnel plot and the findings using a fixed-effects model suggest
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that the true effect of n-3PUFAs is likely to be smaller than that
reported in our main analyses.
Imprecise effect size estimates were found for all outcomes. In all
analyses, possible effects range from negligible (and in some anal-
yses from negative) effects to important clinical benefits. While
this imprecision does not rule out clinically relevant effects, con-
siderable caution must be used in interpreting all effect size esti-
mates. Further evidence, in the form of adequately-powered well-
designed trials, is clearly required before firm conclusions can be
drawn.
Findings in our primary outcome of depressive symptomology and
our secondary outcome of quality of life also demonstrate consid-
erable evidence of heterogeneity. Subgroup analyses investigated
possible sources, based on the inclusion of individuals with/with-
out comorbid conditions and the inclusion of individuals using/
not using adjunctive therapy, but we found little explanation for
this heterogeneity. There is some evidence of different effects de-
pending on the presence or absence of comorbid conditions, and
this has also been suggested in individual trials (e.g. Lespérance
2011), but effects are currently far from clear. Limited studies
contribute to each subgroup in our analyses, there is considerable
evidence of heterogeneity, and there is considerable overlap in ef-
fect size estimates for different subgroups. Limited explanation
was also gained from the analyses on adjunctive therapy, where
few differences between subgroups were found, although findings
again are far from conclusive.
Sensitivity analyses also investigated the impact of other aspects of
study methodology. Analyses investigating the effects of treatment
solely or predominantly with EPA revealed a stronger beneficial
effect of n-3PUFAs compared to placebo than we found in our
main analyses, although precision also decreases further, allowing
the possibility of negligible effects. Effects size estimates also in-
crease with the removal of studies that use placebos containing
ALA. This analysis suggests that ALA may confer some impacts
on depressive symptomology similar to those of the longer chain
n-3PUFAs EPA and DHA, but very few studies were available
for assessment. The possibility of different effects depending of n-
3PUFA type is interesting, and has been suggested elsewhere in
the literature (Martins 2011; Ross 2007; Sublette 2011), although
much of this speculation is based on post-hoc observation, and
only one current trial directly compares the impact of EPA and
DHA treatments (Mischoulon (DHA) 2015; Mischoulon (EPA)
2015), and found no differences. Mechanisms of action to ex-
plain different effects from different n-3PUFAs are hypothesised
(e.g. Ross 2007; Sublette 2011). Proposed mechanisms for action,
however, largely focus on the specific actions of EPA and DHA,
while offering little suggestion for a potential impact of ALA.
Sensitivity analyses investigating the methods used to conduct
analyses reveal few differences in findings from those in our main
analyses, although the removal of studies where we imputed stan-
dard deviations reduced effect sizes and improved precision.
Only one study was available for the comparison with antidepres-
sant treatment. This study was small, with 20 participants ran-
domised to each treatment arm, and 20% of participants in each
arm failed to complete the study. Adverse events were reported by
the number of events rather than the number of individuals suf-
fering, remission rates were not reported, but response rates and
failure to complete data were supplied.
Quality of the evidence
The quality of the evidence for both comparisons for all outcomes
is very low to low.Our judgements of quality according toGRADE
are given in the Summary of findings for the main comparison.
For the placebo comparison, for our primary outcome of depres-
sive symptomology, we considered the quality of evidence to be
very low. The body of evidence was composed of limited, pre-
dominantly small studies, within which there was substantial ev-
idence of heterogeneity that remains unexplained. Furthermore,
the majority of the contributing studies include judgements of
high risk of bias in at least one of the domains assessed, and sensi-
tivity analyses reveal different findings in analyses using all studies
and analyses using only studies judged to be at low risk of selec-
tion bias, performance bias or attrition bias. In all analyses using
only studies judged to be at low risk of bias, regardless of the mea-
sure of bias used, we found that n-3PUFAs did not impact on de-
pressive symptomology, compared to placebo. We found similar
results from the three large well-conducted trials mentioned ear-
lier (Carney 2009; Lespérance 2011; Mischoulon (DHA) 2015;
Mischoulon (EPA) 2015). As stated earlier, the consideration of
risk of bias suggests bias in our main analyses towards a positive
finding for n-3PUFAs, as a result of a high risk of bias in many of
the contributing studies. These findings suggest that the positive
effect of n-3PUFAs in our main analyses is a consequence pre-
dominantly of the inclusion of studies that may be at high risk of
bias. The true effect size estimate is thus likely to be smaller than
that provided by our main analyses.
For our second primary outcome of adverse events, the quality of
evidence was very low. There was limited evidence of heterogeneity
between studies in this analysis, but confidence intervals are wide,
suggesting a range of possible effects; data were only available from
selected studies, and visual inspection of the funnel plot suggests
probable publication bias. Analyses using only studies judged to
be at low risk of selection bias, low risk of performance bias, or
low risk of attrition bias suggest similar effects as those presented
in our main analyses.
For our secondary outcomes of depression remission and response
rates, the quality of the evidence was low. Heterogeneity between
studieswas low, but confidence intervals are verywide, suggesting a
broad range of possible effects, selected studies only were available
for these analyses, and we judged various elements of these studies
to be at high risk of bias.
For our secondary outcome of quality of life, the quality of the
evidence was very low. Selected studies only were available for these
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analyses, confidence intervals are very wide, suggesting a broad
range of possible effects, there was high heterogeneity, and we
judged various elements of these studies to be at high risk of bias.
For our secondary outcome of failure to complete, the quality of
the evidence was low. Most studies were available for this anal-
ysis, and heterogeneity between studies was low, but confidence
intervals are again wide, suggesting a range of possible effects, and
visual inspection of the funnel plot suggests a high probability of
publication bias.
For the antidepressant comparison, the quality of the evidence
was low. Evidence for this analysis came from only one study. We
judged this study to be at high risk of bias for allocation conceal-
ment, because the randomisation sequencewas not concealed from
researchers; for performance bias, because no steps were reported
to mask the fishy taste of the intervention or check concealment;
for attrition bias, due to a 20% dropout rate; and for reporting
bias, because some outcomes have not yet been published. We
judged data on depressive symptomology to be at low risk of bias
due to good blinding of study personnel, but we judged data on
adverse events to be at high risk of detection bias because these
were reported by participants, and adequate blinding was unclear.
We considered risk of attrition bias for adverse events to be low.
Inconsistency in trial reporting for both comparisons was obvious.
Depressive symptomology was frequently reported and analysed
using non-ITT data (assuming a definition of ITT based on num-
ber randomised). Adverse events were reported in a variety of ways:
by individual and event for all events, by individual for all events,
by individual for only serious, likely or frequent events, by event
type for all events, by event type for only serious, likely related or
frequent events, or a combination of these. Adverse events were
included for analysis (based on the number of individuals) in 19
of 25 of the studies. Our secondary outcomes of remission and
response in depressive symptomology and quality of life were not
well reported. Numbers of participants who failed to complete
each trial were well reported.
Potential biases in the review process
The findings of this review are likely to be biased, due to the ev-
idence available to contribute to analyses. Only a limited num-
ber of studies were available for assessing all outcomes for both
comparisons, only a few studies were available for assessing some
outcomes, and there was a high relative weighting in all analyses
for the placebo comparison from three large studies.
The review process also may have been biased. Our searches were
more likely to detect articles published in English and in main-
stream journals. We tried to minimise this bias by including trans-
lated articles, but translations were only undertaken for full arti-
cles that we selected for inclusion based on titles and abstracts.
We were also unable to contact authors of some articles that may
have been relevant. We excluded these articles, based on the in-
formation available to us, but increased information would have
reduced this bias. We made judgements of risk of bias according
to predefined rules, but the information required to make these
judgements was infrequently published, and our correspondence
with authors was again incomplete. Judgements of risk of bias,
however, were completed following all data collection, so did not
impact on the review process. Reliance on available data (even
from authors), also meant that only a few studies could contribute
to certain analyses. Remission and response rates were not assessed
in all studies, but could have been calculated had raw data been
available. Most studies did not assess quality of life. We relied
on authors of existing relevant studies or trial registrations for in-
formation on unpublished studies. Our searches covered relevant
conference-based publications, but we made no further attempts
to find or identify unpublished literature.
Agreements and disagreements with other
studies or reviews
Published reviews and meta-analyses are available investigating a
role for n-3PUFAs for depression compared to placebo. Many of
these have focused on randomised controlled trials, but most use
a broad definition of depression to consider studies of individuals
with a range of depressive diagnoses, including bipolar disorder
and postpartum depression, and studies of individuals with de-
pressive symptomology regardless of psychiatric condition. Early
reviews tended to use a broader working definition of depressive
symptomology, to allow inclusion of adequate studies for analyses,
but more recent reviews have used tighter inclusion criteria.
Of recent reviews, the review by Grosso 2014 reports two meta-
analyses, one of studies of individuals with a formal diagnosis,
and one of studies of individuals with high levels of depressive
symptomology but no formal diagnosis. The analysis of studies
of individuals with a formal MDD diagnosis includes nine of the
studies included in our analyses, but also includes two additional
reports of Rondanelli 2010, and includes both the placebo and
the antidepressant comparisons in Jazayeri (v placebo) 2008 and
Jazayeri (v AD) 2008), without taking account of the use of the
same placebo group. This analysis provides a combined effect size
estimate, representing a beneficial effect of n-3PUFAs, of SMD =
0.56 (95% CI 0.20 to 0.92). The analysis of studies of individuals
with high depressive symptomology but no formal diagnosis of
MDD includes four of the studies included in our analysis (al-
though individuals in the control group in Peet (1g/d) 2002; Peet
(2g/d) 2002; Peet (4g/d) 2002 are included repeatedly), but also
includes seven other studies that we discounted from our review
on the basis that individuals with low or moderate depression were
also included in intervention groups, and could confound find-
ings. This analysis produced a combined effect size estimate of
SMD= 0.22 (95%CI 0.01 to 0.43), and the two analyses together
result in a combined effect size estimate of SMD = 0.38 (95% CI
0.18 to 0.59) (I² = 55%). This combined estimate is very similar to
that achieved in our analyses, even though these additional stud-
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ies were included and six of those identified for inclusion in our
review did not contribute, including the large trial by Lespérance
2011.
The review by Bloch and Hannestad (Bloch 2012) is a review of
13 studies of individuals with MDD. This analysis includes nine
studies that we included in our review, but also includes one study
in mild-moderate depression (Rogers 2008), and three studies in
MDD associated with pregnancy. The use of the full study or
only the relevant subgroup in Lucas 2009 is also unclear. Ten of
the studies in our review, all published in 2008 or later, were not
included. The analysis reports no effects of n-3PUFAs compared
to placebo (SMD = 0.11, 95% CI -0.04 to 0.26, P = 0.14), but
has been criticised elsewhere (Lin 2012) for the inclusion of the
trials by Rogers 2008 and Lucas 2009, due to their inclusion of
individuals without a formal MDD diagnosis. Reanalysis of the
results of the remaining 11 studies demonstrates a small beneficial
effect of n-3PUFAs for MDD compared to placebo, of SMD =
0.29 (95% CI 0.10 to 0.48). This result is very similar to that
provided by our analyses.
The review by Martins 2011 includes 35 studies of depressive
symptomology, and includes a separate analysis of 14 studies of
individuals with MDD. Thirteen of these studies were also in-
cluded in our review, and their analyses provide a combined effect
size estimate, representing a benefit of n-3PUFAs: SMD = -0.45
(95% CI -0.75 to -0.15). This finding is larger than that found
in our analyses, but the confidence intervals are wide and include
the effect size estimates from our analyses.
The review by Sublette 2011 covers 19 trials, 13 of which are also
included in our review, while two trials were studies of individuals
with a primary diagnosis of bipolar disorder, three were studies of
individuals with postpartum depression, and one study included
individuals with mild-moderate as opposed to severe depression.
This review investigates specifically the percentage of EPA pro-
vided (≥ 60% vs < 60%) as a source of heterogeneity, and does
not report a combined effect size estimate for all studies.
Similar findings from several meta-analyses, despite the inclusion
and exclusion of different trials, may suggest a consistent effect of
n-3PUFAs versus placebo, but the consistency is more likely in the
limited evidence available for investigating these effects. All reviews
are based on the same very limited pool of studies, and report
wide confidence intervals and so a wide range of possible effects,
substantial heterogeneity between studies, and a high probability
of publication bias.
Our effect size estimate is also comparable to some degree with
that suggested by recent meta-analyses of the effects of antide-
pressants for MDD, compared to placebo. Kirsch 2008 reports a
weighted mean difference using the HDRS between antidepres-
sant and placebo groups in 35 US Food and Drug Administration
(FDA) registered studies of 1.8 HDRS scores, SMD = 0.32 (95%
CI 0.25 to 0.40). Turner 2008 reports a mean weighted effect size
of 0.37 (95% CI 0.33 to 0.41) from published and 0.15 (95%
CI 0.08 to 0.22) from unpublished US FDA-registered studies.
Fountoulakis 2013, in an analysis of recent meta-analyses, con-
firms a SMD of 0.32 (95% CI: 0.25 to 0.40), as the result from
the most appropriate analysis of the Kirsch 2008 data set. Some
evidence is available again suggesting greater effect sizes dependent
on depression severity, e.g. Fournier 2010 reports an effect size
of d = 0.17 (95% CI 0.04 to 0.30) in a patient-level analysis of
severe MDD cases, and of d = 0.47 (95% CI 0.34 to 0.59) in very
severe MDD cases, but limitations in the data available reduce
the value of these conclusions. Confidence intervals, however, are
much tighter for the analyses of antidepressants than was found
in our analyses, suggesting greater precision in these effect size
estimates. Analyses of antidepressants suggest effect size estimates
that range from small to modest, while our findings on n-3PU-
FAs also allow the inclusion of possible negligible effects. The ap-
parent comparability in effect size estimates between our findings
and those of reviews on antidepressants should not be taken as
evidence in support of n-3PUFAs. Furthermore, the small size of
the overall effect size estimate for both n-3PUFAs and antidepres-
sants should argue not for a favourable comparison of n-3PUFAs
with antidepressants, but for increased demand for more effective
treatments for depressive symptomology from elsewhere.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, we do not have sufficient high quality evidence to de-
termine the effects of n-3PUFAs as a treatment for MDD. Our
primary analyses suggest a small-to-modest, non-clinically bene-
ficial effect of n-3PUFAs on depressive symptomology compared
to placebo, although the effect size estimate is imprecise, and the
quality of the evidence on which this result is based is low to very
low. Sensitivity analyses, funnel plot inspection and comparison
of our results with those of large well-conducted trials also sug-
gest that this effect size estimate is likely to be biased towards a
positive finding for n-3PUFAs, and that the true effect is likely
to be smaller. The one study in our review that directly compares
n-3PUFAs and antidepressants finds comparable benefit, but the
quality of the evidence here is very low. Our data suggest similar
rates of adverse events and numbers failing to complete trials in n-
3PUFA and placebo groups. The data on adverse events and fail-
ure to complete are again of low quality, but given the high rates
of adverse events associated with some antidepressants, n-3PUFAs
may offer an alternative treatment of possible benefit and reduced
side effects. However, whether all possible negative side effects are
studied in trials is questionable, and high dropout rates as a result
of lack of improvement testify to the negative side effects of false
hope. Failure to seek or administer conventional treatment, as a
result of treatment with n-3PUFAs, may also represent an oppor-
tunity cost. We need more evidence, and particularly more com-
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plete evidence, regarding both the positive and negative effects of
n-3PUFAs for MDD.
Implications for research
More adequately-powered well-designed studies are required to
increase the evidence base, and explore particularly the hetero-
geneity found between studies investigating the impact of n-3PU-
FAs on depressive symptomology. Many studies are currently un-
derway, but studies that compare n-3PUFAs with usual antide-
pressant treatment, and studies to investigate differing effects de-
pending on individual characteristics and study methodology are
important. Our review suggests similar effects for n-3PUFAs and
antidepressant treatment for depressive symptomology, but bene-
fits of n-3PUFAs in terms of adverse events, compliance and pa-
tient acceptability are often provided by practitioners. Studies that
compare n-3PUFAs with antidepressant treatment on all possible
outcomes are required. Long-term benefits, long-term acceptabil-
ity and long-term compliance are rarely considered, and neither
is cost effectiveness. Studies comparing individuals and different
treatments are also needed. Studies do find positive effects, and
identification of those who are likely to benefit, or the particular
treatments of beneficial impact would be of value. Mechanistic
studies are also preferentially required. Hypotheses investigating
differential effects depending on participant type or studymethod-
ology should be based on proposed mechanisms to increase effi-
cacy, as opposed to post hoc comparisons of individual studies.
Future research should target the elucidation of mechanisms both
for the development and treatment of MDD, and should identify
the possible actions in these pathways for n-3PUFAs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bot 2010
Methods Randomised controlled parallel-arm trial, 12 weeks
Participants Participants: 25 participants had a mean age = 54 yrs (SD = 11), 13 women, 12 men,
recruited via VUUniversity Medical Centre diabetes outpatient clinic (Amsterdam, NL)
, advertisements on websites, newspapers and magazines. Participants were recruited
between April 2006 and May 2007, the trial was performed between June 2006 and July
2007
Comorbidities: Diabetes Type 1 and 2 in all participants, no other comorbidities
Adjunctive therapy: Yes for all participants (usual antidepressants)
Inclusion Criteria: aged 18 - 75 years, diagnosed with diabetes (Type 1 or 2, or use
of insulin or oral hypoglycaemic agents), on antidepressant medication for at least 2
months, met criteria for MDD using Composite International Diagnositic Interview
Exclusion criteria: serious co-morbid disease, using fish oil supplementation or con-
suming more than 3 servings of fish/week, alcohol or drug abuse, suicidal ideation, or
allergic to fish, fish products or rapeseed oil
Interventions Intervention: E-EPA (1 g/d, including mixed tocopherols), 2 x 500 mg capsules per day,
plus ongoing therapy
Comparator: Rapeseed oil + medium chain triglycerides (1 g/d, including mixed toco-
pherols), 2 x 500 mg capsules per day, plus ongoing therapy
Treatment received for 12 weeks
Outcomes Primary: MADRS measured at baseline, 1, 3, 5, 7, 9 and 12 weeks; Adverse Events
Secondary: Failure to complete
Notes Funded by Dutch Diabetes Research Foundation and Minami Nutrition, Belgium
Supplements provided by Minami Nutrition, Belgium
Conflicts of interest: CoI declared by one author
Compliance: EPA levels in red blood cell (RBC) phospholipids
Depressed mood (continuous): Analysis conducted on MADRS scores at 12 weeks, per
protocol data provided by authors
Adverse events: Adverse events reported in the analyses do not include side effects. 1
individual in the intervention group experienced an allergic reaction. Side effects were
not split according to group: no side effects in 8 individuals, prevalent side effects were
stomach ache (n = 10), belching (n = 7), nausea (n = 6), diarrhoea (n = 5). Values in the
analysis are for adverse events
Failure to complete: Intervention group = 2 (1 allergic reaction, 1 loss to follow-up),
Comparator group = 0
Risk of bias
Bias Authors’ judgement Support for judgement
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Bot 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation occurred with computer-
generated random number performed by
an employee of the pharmacy of VU
University Medical Centre (P.2, Mocking
2012)
Allocation concealment (selection bias) Low risk Randomisation performed by a pharmacy
employeewhowas not involved in data col-
lection or analysis (P.2, Mocking 2012)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and researchers were blinded
to treatment allocation until completion
of data collection. Identical packaging sent
out by the pharmacy. Participants in-
structed not to chew to avoid fishy taste.
(P.283 Bot 2010, P.2 Mocking 2012), but
no report of masking the fishy taste. “con-
cealment appeared to be successful.” - 33%
in both groups correctly guessed treatment
when questioned. (P.285, Bot 2010)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk MADRS: Research nurse and researchers
were blind to treatment allocation until
completion of data collection (P.283, Bot
2010, P.2, Mocking 2012)
Blinding of outcome assessment (Adverse
Events)
Low risk Adverse events were assessed by nurses
based on participant report. Participants
did not guess their treatment group (P.285,
Bot 2010)
Incomplete outcome data (attrition bias)
All outcomes
High risk MADRS: 1 person in intervention group
lost to follow-up, analysis not ITT (al-
though stated as ITT) (P.284, Bot 2010)
Incomplete outcome data (Adverse Events) High risk Adverse events: AEs reported but only the
prevalent side effects (P.285, Bot 2010)
Selective reporting (reporting bias) Low risk All depressionoutcomes reported (Protocol
included in Mocking 2012)
Other bias Low risk Study appeared to be free from other
sources of bias
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Carney 2009
Methods Randomised controlled parallel-arm trial, 10 weeks
Pre-randomisation: Paticipants were given a 2½ - 3½ week supply of sertraline (25 mg/
day) plus placebo for 2 weeks then reassessed for depression, compliance and tolerance
to medication
Participants Participants: 122 participants with a mean age = 58.3 years, 41 women, recruited from
cardiology practices in St Louis, Missouri, US and from cardiac diagnostic labs affiliated
withWashington University School of Medicine, USA. They were informed of the study
via physicians, study staff or pamphlets. Patients were recruited to the study between
May 2005 and December 2008
Comorbidities: CHD in all participants, no psychiatric comorbidities
Adjunctive therapy: Yes for all participants - antidepressant sertraline (50 mg/d)
Inclusion criteria: score≥ 16 BDI-II, DSM-IV criteria for current MDE (using SCID)
, CHD as documented by > 50% stenosis in at least 1 major coronary artery, a history of
revascularisation or hospitalisation for an acute coronary syndrome; continued to meet
DSM criteria, score ≥ 16 BDI-II, reported no serious adverse events, and took both
drugs ≥ 85% of days during pre-randomisation
Exclusion criteria: Cognitive impairment, comorbid psychiatric disorders, psychosis,
high risk of suicide or current substance abuse, an acute coronary syndrome within
the previous 2 months, a left ventricular ejection fraction of less than 30%, advanced
malignancy or physical inability to participate, use of antidepressants, anticonvulsants,
lithium, or n-3PUFA supplements, sensitivity to sertraline or n-3PUFA or physician/
patient refusal
Interventions Intervention: EPA/DHA combination (2 g/d ethyl esters, providing EPA 930mg,DHA
750 mg), 2 capsules per day, plus 50 mg/d sertraline
Comparator: Corn oil (2 g/d), 2 capsules per day, plus 50 mg/d sertraline
Treatment received for 10 weeks
Outcomes Primary:BDI-II (21-item),HDRS (17-item) both assessedweekly for 10weeks, Adverse
events
Secondary: Response, remission based on BDI, failure to complete
Notes Funded by National Heart Lung and Blood institute, US
Supplements provided by GlaxoSmithKline Inc, antidepressants provided by Pfizer Inc.
Conflicts of interest: CoIs declared by 2 authors
Compliance: RBCmembrane levels of EPA andDHAassessed before and after treatment.
Capsule counts at each study visit
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 10
weeks, using published ITT data
Adverse events: Adverse effects reported as a percentage rather than number of partici-
pants reporting 1 new symptom in the 10-week trial; Intervention group = 63% adverse
effects (19% symptoms previously associated with high doses of n-3PUFAs), Control
group = 73% adverse effects (22% symptoms previously associated with high doses of
n-3PUFAs). 14 adverse events, but details do not add up to 14. Values in the analysis
are for adverse effects
Failure to complete: Intervention = 3 (1 = health problems related to treatment, 1 =
withdrew consent, 1 = wanted other treatment); Comparator = 4 (2 = health problems
related to treatment, 1 = withdrew consent, 1 = wanted other treatment)
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Carney 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ASASpermuted-block randomisation allo-
cation programme (P.1652, Carney 2009)
Allocation concealment (selection bias) Unclear risk The group assignments were concealed in
sealed envelopes and opened at enrolment
(P.1652, Carney 2009), not clear if en-
velopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and nurses were blinded and
an identical placebo was used (P.1652,
Carney 2009). There was no attempt to
mask the fishy taste and no assessment to
check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk BDI (self-reported scale) - HIGH
HDRSprofessional rating scale - study psy-
chiatrists and nurses were blinded - LOW
Blinding of outcome assessment (Adverse
Events)
Unclear risk Adverse events - unclear whether these were
reported by clinicians or participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT on BDI and HDRS
Incomplete outcome data (Adverse Events) Unclear risk AEs were not clearly reported
Selective reporting (reporting bias) Low risk All major outcomes were reported (addi-
tional information from authors)
Other bias Low risk Study appeared to be free from other
sources of bias
Coryell (1g/d)
Methods Double-blind, randomised parallel-arm trial for 6 weeks, following 4-week open-label
trial of escitalopram (10 mg/d) to prospectively identify SSRI non-responders (< 50%
improvement) for augmentation
Participants Participants: 11 participants with a mean age of 28.8 (SD 9.3, range 18 - 48) years, 9
women and 2 men (split across Coryell (1g/d) and Coryell (2g/d)). Participants recruited
via clinician referrals and advertisements, in Iowa City, USA
Comorbidities: Possible physical and/or psychiatric comorbidities
Adjunctive therapy: Yes for all participants - escitalopram
Inclusion: Aged 18 - 55 years; current diagnosis of MDD; meets DSM-IV criteria
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Coryell (1g/d) (Continued)
Antidepressant for no more than 3 days within the past month or antidepressant for at
least the past month with no change in type or dose
Exclusion: More than 2 adequate antidepressant trials in the current episode; meets
DSM-IV criteria for substance dependence in the past year; substance abuse within the
past month; meets DSM-IV criteria for an eating disorder in the past year; allergy to fish;
bleeding disorder/taking warfarin; omega-3 supplements for 3 or more days in the past
4-month period; known to be pregnant; taking medications known to produce affective
symptoms; history of non-response to escitalopram/Lexapro
Interventions Intervention: EPA/DHA combination (740 mg EPA/d + 400 mg DHA/d), 2 capsules,
plus 2 placebo capsules
Comparator: 4 placebo capsules
All participants receive 4 capsules with either 0 or 2 capsules containing EPA
Treatment was received for 6 weeks
Outcomes Primary: MADRS scores, measurements at 6 weeks
Secondary: HDRS, adverse events, response based on 50% improvement based on
MADRS and HDRS
Notes Supplements provided by Ocean Nutrition Canada Ltd.
Conflicts of interest: None
Compliance: Capsule counts at each study visit
Depressed mood (continuous): Analysis conducted on MADRS scores at 6 weeks, using
unpublished ITTdata (missingdata forHDRS). Placebo group split across 2 intervention
groups (1 g/d = 2 participants, 2 g/d = 2 participants)
Adverse events: Data on serious and non-serious adverse events were collected.No serious
AEs were reported, but no data on non-serious adverse events were available. Values in
the analysis are for serious adverse events
Failure to complete: No withdrawals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, simple randomisa-
tion (email correspondence from trialist)
Allocation concealment (selection bias) Unclear risk Researcher was blind to allocation, research
nurse was not blind to allocation. Both
had contact with participants and unclear
who allocated participants (email corre-
spondence from trialist)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Researcher was blinded, research nurse was
not blinded, and both had contact with
participants. Participants were stated as
’blinded’, but nodetails of blinding of taste.
Possible attempts to check blinding, but no
data available (email correspondence from
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Coryell (1g/d) (Continued)
trialist)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessments made by researcher,
and researcher was blinded (email corre-
spondence from trialist)
Blinding of outcome assessment (Adverse
Events)
Unclear risk Outcome assessments made by partici-
pants, and unclear if they were blinded
(email correspondence from trialist)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete MADRS outcome data, and
ITT analysis (email correspondence from
trialist)
Incomplete outcome data (Adverse Events) Unclear risk No serious AEs were reported, but data on
non-serious adverse events are not available
(email correspondence from trialist)
Selective reporting (reporting bias) High risk Data not published (email correspondence
from trialist)
Other bias Low risk Study appeared to be free from other
sources of bias
Coryell (2g/d)
Methods Double-blind, randomised parallel-arm trial for 6 weeks, following 4-week open-label
trial of escitalopram (10 mg/d) to prospectively identify SSRI non-responders (< 50%
improvement) for augmentation
Participants Participants: 11 participants with a mean age of 28.8 (SD 9.3, range 18 - 48) years, 9
women and 2 men (split across Coryell (1g/d) and Coryell (2g/d)). Participants recruited
via clinician referrals and advertisements, in Iowa City, USA
Comorbidities: Possible physical and/or psychiatric comorbidities
Adjunctive therapy: Yes for all participants - escitalopram
Inclusion: Aged 18 - 55 years; current diagnosis of MDD; meets DSM-IV criteria
Antidepressant for no more than 3 days within the past month or antidepressant for at
least the past month with no change in type or dose
Exclusion: More than 2 adequate antidepressant trials in the current episode; meets
DSM-IV criteria for substance dependence in the past year; substance abuse within the
past month; meets DSM-IV criteria for an eating disorder in the past year; allergy to fish;
bleeding disorder/taking warfarin; omega-3 supplements for 3 or more days in the past
4-month period; known to be pregnant; taking medications known to produce affective
symptoms; history of non-response to escitalopram/Lexapro
Interventions Intervention: EPA/DHA combination (1480 mg EPA/d + 800 mg DHA/d), 4 capsules
Comparator: Placebo capsules, 4 capsules
All participants receive 4 capsules with either 0 or 4 capsules containing EPA
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Coryell (2g/d) (Continued)
Treatment was received for 6 weeks
Outcomes Primary: MADRS scores, measurements at 6 weeks
Secondary: HDRS, adverse events, response based on 50% improvement based on
MADRS and HDRS
Notes Supplements provided by Ocean Nutrition Canada Ltd.
Conflicts of interest: None
Compliance: Capsule counts at each study visit
Depressed mood (continuous): Analysis conducted on MADRS scores at 6 weeks, using
unpublished ITTdata (missingdata forHDRS). Placebo group split across 2 intervention
groups (1 g/d = 2 participants, 2 g/d = 2 participants)
Adverse events: Data on serious and non-serious adverse events were collected.No serious
AEs were reported, but no data on non-serious adverse events were available. Values in
the analysis are for serious adverse events
Failure to complete: No withdrawals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, simple randomisa-
tion (email correspondence from trialist)
Allocation concealment (selection bias) Unclear risk Researcher was blind to allocation, research
nurse was not blind to allocation. Both
had contact with participants and unclear
who allocated participants (email corre-
spondence from trialist)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Researcher was blinded, research nurse was
not blinded, and both had contact with
participants. Participants were stated as
’blinded’, but nodetails of blinding of taste.
Possible attempts to check blinding, but no
data available (email correspondence from
trialist)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessments made by researcher,
and researcher was blinded (email corre-
spondence from trialist)
Blinding of outcome assessment (Adverse
Events)
Unclear risk Outcome assessments made by partici-
pants, and unclear if they were blinded
(email correspondence from trialist)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete MADRS outcome data, and
ITT analysis (email correspondence from
trialist)
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Coryell (2g/d) (Continued)
Incomplete outcome data (Adverse Events) Unclear risk No serious AEs were reported, but data on
non-serious adverse events are not available
(email correspondence from trialist)
Selective reporting (reporting bias) High risk Data not published (email correspondence
from trialist)
Other bias Low risk Study appeared to be free from other
sources of bias
Da Silva (AD) 2005
Methods Pilot randomised controlled parallel-arm trial, 12 weeks
Participants split across Da Silva (AD) 2005 and Da Silva (nAD) 2005, depending on
antidepressant use, prior to randomisation
Participants Participants: 31 participants, with a mean age = 64.4 (range 49 - 78) years, 58% women
(split across Da Silva (AD) 2005 and Da Silva (nAD) 2005). Participants were selected
from Association of Patients with Parkinson’s disease of Paraná, Curitiba, Brazil
Comorbidities: Parkinson’s disease (PD), other possible comorbidities
Adjunctive therapy: Yes for all participants: antidepressants
Inclusion criteria: Parkinsons disease, DSM-IV criteria for MDD (MINI plus, and a
SCID), score < 2.5 Hoehn & Yahr scale for PD (Hoehn 1967), no signs of dementia
(MMSE) (Folstein 1975), UPDRS assessment (Taylor 2005), taking medication for
depression for at least 1 yr or refused to take medication
Exclusion criteria: initiated antidepressant use after diagnosis, cognitive and memory
declines, drug/alcohol dependent. Any participant who presented with an alteration of
PD (above 0.5 point on Hoehn and Yahr scale) after 3 months was also excluded
Interventions Intervention: EPA/DHA combination (720 mg/d EPA, 480 mg/d DHA, plus toco-
pherols), 4 capsules, plus ongoing therapy
Comparator:Mineral oil, 4 capsules/d, plus ongoing therapy
Treatment received for 3 months
Outcomes Primary: MADRS, BDI assessed at baseline and 12 weeks, Adverse events
Secondary: Response based onMADRS, CGI assessed at baseline and 12 weeks, Failure
to complete
Notes No funding reported.
Supplements provided by Herbarium Foundation for Health and Research
Conflicts of interest: None declared
Compliance: RBCmembrane levels of EPA andDHA assessed before and after treatment
Depressed mood (continuous): Analysis conducted on MADRS scores at 12 weeks, per
protocol data provided by authors
Adverse events: 2 individuals reported adverse events - 1 GI, 1 other physical (split across
Da Silva (AD) 2005 and Da Silva (nAD) 2005 - group not reported). Values could not
be included in analysis
Response (50% improvement inMADRS score) - Intervention group= 42%, comparator
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Da Silva (AD) 2005 (Continued)
group = 6% (split across Da Silva (AD) 2005 and Da Silva (nAD) 2005 - group not
reported). Values could not be included in analysis
Quality of Life: Analysis conducted on CGI
Failure to complete: 2 individuals withdrew (split across Da Silva (AD) 2005 and Da
Silva (nAD) 2005 - group not reported) (1 collateral effects, 1 worsening health status).
Values could not be included in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by drawing (ad-
ditional information from the author)
Allocation concealment (selection bias) Unclear risk Identification of the groups and separation
of the respective capsules were carried out
in the lab at University Federal do Parana
(P.353)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither researcher nor participants knew
which substance was given (identical
placebo). Not reported if the fishy taste was
disguised, and no assessment to check con-
cealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk MADRS and BDI (both evaluated by
trained psychologist blinded to allocation)
(P.353)
Blinding of outcome assessment (Adverse
Events)
Unclear risk Adverse events - unclear whether these were
reported by clinicians or participants
Incomplete outcome data (attrition bias)
All outcomes
High risk Data not ITT
Incomplete outcome data (Adverse Events) Unclear risk AEs were not clearly reported
Selective reporting (reporting bias) Low risk All depression data reported (additional in-
formation from author)
Other bias Low risk Study appeared to be free from other
sources of bias
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Da Silva (nAD) 2005
Methods Pilot randomised controlled parallel-arm trial, 12 weeks
Participants split across Da Silva (AD) 2005 and Da Silva (nAD) 2005, depending on
antidepressant use, prior to randomisation
Participants Participants: 31 participants, with a mean age = 64.4 (range 49 - 78) years, 58% women
(split across Da Silva (AD) 2005 and Da Silva (nAD) 2005). Participants were selected
from Association of Patients with Parkinson’s disease of Paraná, Curitiba, Brazil
Comorbidities: Parkinson’s disease (PD), other possible comorbidities
Adjunctive therapy: Yes for all participants: antidepressants
Inclusion criteria: Parkinsons disease, DSM-IV criteria for MDD (MINI plus, and a
SCID), score < 2.5 Hoehn & Yahr scale for PD (Hoehn 1967), no signs of dementia
(MMSE) (Folstein 1975), UPDRS assessment (Taylor 2005), taking medication for
depression for at least 1 yr or refused to take medication
Exclusion criteria: initiated antidepressant use after diagnosis, cognitive and memory
declines, drug/alcohol dependent. Any participant who presented with an alteration of
PD (above 0.5 point on Hoehn and Yahr scale) after 3 months was also excluded
Interventions Intervention: EPA/DHA combination (720 mg/d EPA, 480 mg/d DHA, plus toco-
pherols), 4 capsules, plus ongoing therapy
Comparator:Mineral oil, 4 capsules/d, plus ongoing therapy
Treatment received for 3 months
Outcomes Primary: MADRS, BDI assessed at baseline and 12 weeks, Adverse events
Secondary: Response based on MADRS, CGI assessed at baseline and 12 weeks, failure
to complete
Notes No funding reported.
Supplements provided by Herbarium Foundation for Health and Research
Conflicts of interest: None declared
Compliance: RBCmembrane levels of EPA andDHA assessed before and after treatment
Depressed mood (continuous): Analysis conducted on MADRS scores at 12 weeks, per
protocol data provided by authors
Adverse events: 2 individuals reported adverse events - 1 GI, 1 other physical (split across
Da Silva (AD) 2005 and Da Silva (nAD) 2005 - group not reported). Values could not
be included in analysis
Response (50% improvement inMADRS score) - Intervention group= 42%, comparator
group = 6% (split across Da Silva (AD) 2005 and Da Silva (nAD) 2005 - group not
reported). Values could not be included in analysis
Quality of Life: Analysis conducted on CGI
Failure to complete: 2 individuals withdrew (split across Da Silva (AD) 2005 and Da
Silva (nAD) 2005 - group not reported) Values could not be included in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by drawing (ad-
ditional information from the author)
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Da Silva (nAD) 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Identification of the groups and separation
of the respective capsules were carried out
in the lab at University Federal do Parana
(P.353)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither researcher or participants knew
which substance was given (identical
placebo). Not reported if the fishy taste was
disguised, and no assessment to check con-
cealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk MADRS and BDI (both evaluated by
trained psychologist blinded to allocation)
(P.353)
Blinding of outcome assessment (Adverse
Events)
Unclear risk Adverse events - unclear whether these were
reported by clinicians or participants
Incomplete outcome data (attrition bias)
All outcomes
High risk Data not ITT
Incomplete outcome data (Adverse Events) Unclear risk AEs were not clearly reported
Selective reporting (reporting bias) Low risk All depression data reported (additional in-
formation from author)
Other bias Low risk Study appeared to be free from other
sources of bias.
Gertsik 2012
Methods Randomised controlled parallel-arm trial, 8 weeks
Pre-randomisation 1 week placebo run-in phase
Participants Participants: 42 participants, mean age = 40.5 years (SD = 10.2). Distribution of gender
was not reported. Recruited via local advertisements or physician referral from theGreater
Los Angeles area with preliminary telephone screening
Comorbidities: No psychiatric comorbidities, possible physical comorbidities
Adjunctive therapy: Yes for all participants, citalopram (20 mg/d) with possible increase
in dose after 4 weeks
Inclusion criteria: aged 18 - 65 years; DSM IV criteria for MDD via the SCID, score >
17 onHDRS (21-item), contraception use in women of childbearing age; still qualifying
for inclusion after 1 week run-in
Exclusion criteria: psychiatric disorders including psychotic depression and bipolar
disorders, current drug/alcohol abuse/dependence or history of such in past 6 months,
unstable medical or neurological conditions likely to interfere with treatment, history
of allergy to citalopram or n-3PUFA, finfish or shellfish, history of failure to respond to
citalopram, history of seizure disorder, pregnancy, need for concomitant psychotropic
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Gertsik 2012 (Continued)
medication including other antidepressants, active suicidal ideation or safety concerns,
exposure to fluoxetine or MAOIs in previous 2 months, anticoagulant therapy, dietary
intake of > 3 g n-3PUFAs/day at baseline
Interventions Intervention: EPA/DHA combination (EPA = 1800 mg/d, DHA= 400 mg/d, other n-
3PUFAs = 200mg/d), 2 capsules, twice daily with meals, plus citalopram (20 mg/d)
Comparator: Olive oil (4 g/d), 2 capsules, twice daily with meals, plus citalopram (20
mg/d)
Treatment received for 8 weeks
Outcomes Primary: HDRS (21-item), BDI, MADRS - all assessed at baseline, randomisation, 2,
4, 6 and 8 weeks; Adverse events
Seconday: Remission and response based on HDRS; CGI, PGI; failure to complete
Notes Funded by NIH National Centre for Complementary and Alternative Medicine & National
Centre for Research Resources, USA
Supplements provided by Nordic Naturals
Conflicts of Interest: CoIs declared by 2 authors
Compliance: Capsule counts and assessment of citalopram blood levels
Depressed mood (continuous): Analysis conducted on HDRS (21-item) scores at 8
weeks, ITT data taken from published graph
Adverse events: Only reported for completers. No significant adverse events. Only fre-
quently-reported adverse effects were reported: Intervention group = 6 (all GI), com-
parator group = 4 (all GI). Less than 5% of participants in either group reported other
adverse events, e.g. headache, sedation or sexual dysfunction. Numbers reported in the
analysis relate to frequently-reported adverse effects
Quality of life: CGI, PGI, data not reported.
Failure to complete: Intervention group = 3 (2 undisclosed exclusion criteria, 1 lost to
follow-up), comparator group = 7 (2 lack of efficacy, 5 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block randomised by sex to receive
citalopram. Half of the subjects also re-
ceived omega-3 and the other half received
placebo” but method of sequence genera-
tion not reported (P.62)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was described as “masked” but
not clear who was blinded (P.61). It was
unclear if the fishy taste was disguised and
no assessment to check concealment
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Gertsik 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk HDRS, MADRS and BDI - all unclear -
The study was described as “masked” but
it was unclear who was blinded (P.61)
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs - measured by Treatment Emergent
Symptoms Scale (Guy 1976). The study
was described as “masked” but not clear
who was blinded (P.61)
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS, MADRS, BDI - Analysis not ITT
and > 10% missing data
Incomplete outcome data (Adverse Events) High risk AEs - only reported for completers
Selective reporting (reporting bias) High risk No protocol to check for additional out-
come measures. CGI, PGI not reported
Other bias Low risk Study appeared to be free from other
sources of bias
Gharekhani 2014
Methods Randomised controlled parallel-arm trial, 4 months
Participants Participants: 54 participants. Details reported only for completers - mean age by group
(Intervention = 56.8 (SD = 13.09) years; Comparator = 57.2 (SD = 15.19) years), 20
women, 25 mens. Participants recruited from haemodialysis (HD) units of 2 teaching
hospitals affiliated with Tehran University of Medical Sciences, Iran
Comorbidities: end-stage renal disease, no psychiatric comorbidities
Adjunctive treatment: no, for all participants
Inclusion criteria: Adult patients who had been treated with HD for at least 3 months
Exclusion criteria: BDI < 16, pregnancy, malabsorption syndrome, malignancy, inflam-
matory or infectious diseases, hypothyroidism, medical or surgical illness in recent 3
months, haemoglobinopathies, asthma, chronic obstructive pulmonary disease, coagu-
lopathies, known psychiatric disorders, lack of tolerance or hypersensitivity to fish prod-
ucts as well as those who were receiving corticosteroid, non-steroidal anti-inflammatory
drugs, omega-3 fatty acids in the previous 3 months, anticoagulants including warfarin,
immunomodulator or immunosuppressive were excluded
Interventions Intervention: EPA/DHA combination (1080 mg/d EPA: 720 mg/d DHA). 2 capsules,
3 x daily with meals for 4 months
Comparator: Placebo (paraffin oil), 2 capsules, 3 x daily with meals for 4 months
Outcomes Primary: BDI, Adverse events
Secondary: SF-36 (mental health component summary), failure to complete
BDI and SF-36 assessed at baseline and 4 months whilst undergoing haemodialysis
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Gharekhani 2014 (Continued)
Notes Funded: Tehran University of Medical Sciences (grant No: 17020)
Conflicts of Interest: None reported
Compliance: Pill counts
Depressed mood (continuous): Analysis conducted on BDI at 4 months, ITT data
provided by authors
Adverse events: All adverse events reported (side effects). Intervention group = 8 (all GI)
, comparator group = 0
Quality of life: SF-36 means and SDs, data provided by authors. Mental health summary
scale used in analyses
Failure to complete: Intervention group = 2 (1 non-compliance, 1 surgery), comparator
group = 7 (1 hospitalisation, 1 undergoing renal transplantation, 2 discomfort from
taking large capsule, 1 death due to CHD, 2 changing HD centre)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used a 9-block permuted ran-
domisation procedure to allocate partici-
pants randomly into 2 groups. Each block
contained an equal number of omega-3 and
control group selections, with the order of
the blocks permuted. Random numbers to
allocate blocks and randomise group selec-
tion were generated using Microsoft Office
Excel software, P.3
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No masking of fishy taste and no assess-
ment to check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk BDI (self report)
Blinding of outcome assessment (Adverse
Events)
High risk AEs (self report)
Incomplete outcome data (attrition bias)
All outcomes
High risk BDI - ITT data provided by authors, but >
10% dropout
Incomplete outcome data (Adverse Events) Low risk All AEs reported (correspondence from au-
thors)
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
from authors)
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Other bias Low risk Study appeared to be free from other
sources of bias
Gonzalez 2011
Methods Randomised controlled parallel-arm trial, 8 weeks
Participants Participants: 20 participants. 10 completing participants were a mean age = 38.77 years
(SD = 10.74, range 30 - 54), 8 women
Comorbidities: none reported, possible physical comorbidities
Adjunctive treatment: Yes for all participants, fluoxetine (20 mg/d)
Inclusion criteria: aged 18 - 60 years; diagnosis of MDD (assessed by SCID-ID), single
or recurrent episode according to DSM-IV-TR criteria
Exclusion criteria: not on antidepressants for at least 1month prior to first blood sample
collection, other psychiatric conditions; fish allergy; coagulopathies or taking aspirin
Interventions Intervention: EPA (3 g/d), 3 capsules, plus fluoxetine (20 mg/d)
Comparator: Placebo, 3 capsules, plus fluoxetine (20 mg/d)
Outcomes Primary: HDRS assessed at baseline, 2, 4, 6 and 8 weeks
Secondary: Response based on HDRS, failure to complete
Treatment for 8 weeks
Notes No funding reported.
Conflicts of Interest: not reported.
Compliance: not reported
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 8
weeks, calculated from published per protocol data
Adverse events: AEs not reported fully or clearly. Values could not be included in analyses
Failure to complete: 10peoplewithdrew (due to collateral effects, development ofmedical
diseases, and stopped attending the psychiatric clinic), but group allocation unclear. Data
is not reported for 1 additional individual
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised on a double-blind basis” but
method of sequence generation not re-
ported (abstract)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” (abstract) not reported
who is blind to treatment. It was unclear if
the fishy taste was disguised, and no assess-
ment to check concealment
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Gonzalez 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk HDRS - unclear whether outcome assessor
was blind to treatment
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs - unclearwhether outcome assessorwas
blind to treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS - not ITT, > 10% dropout (50%)
Incomplete outcome data (Adverse Events) High risk AEs - “10 did not continue the study for
several reasons. Among these, treatment
withdrawal was due to collateral effects, de-
velopment of medical diseases...” (transla-
tion) (P.74)
Selective reporting (reporting bias) Unclear risk No protocol available to check for addi-
tional outcome measures
Other bias Low risk Study appeared to be free from other
sources of bias
Grenyer 2007
Methods Randomised controlled parallel-arm trial, 16 weeks
Participants Participants: 83 outpatients from Northfields Clinics, University of Wollongong, Aus-
tralia, mean age 45.3 (range 18 - 70) years, 51 women
Comorbidities: Yes in some participants: anxiety (54%), personality disorder (57%)
Adjunctive therapy: Yes in some participants: 74% currently taking therapeutic doses
of antidepressants
Inclusion criteria: aged 18 - 75 years, SCID DSM-IV primary diagnosis of MDD,
HDRS > 16
Exclusion criteria: serious medical condition, non-consent for venipuncture, comorbid
substance abuse, psychotic, bipolar, OCD or eating disorder
Interventions Intervention: EPA/DHA combination (tuna fish oil providing 2.2 g/d DHA, 0.56 g/d
EPA, plus 80 mg vit E), 8 x 1 g capsules, plus ongoing therapy
Comparator: Olive oil, 8 g/d, 8 x 1 g capsules per day, plus ongoing therapy
Treatment received for 16 weeks
Outcomes Primary: HDRS, BDI - baseline, 3 week intervals until 16 weeks, Adverse events
Secondary: GAF, Likert scales of aches/pains, energy, fatigue, sleep, appetite; failure to
complete
Notes Funded by Clover Corporation Plc, Australia, University of Wollongong, Australia, and the
Australian Research Council
Supplements provided by Clover Corporation Plc, Australia
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Grenyer 2007 (Continued)
Conflict of Interest: Not reported
Compliance: Fortnightly capsule counts, EPA and DHA in RBC membranes, plasma
cholesterol and alpha-tocopherol at baseline, 6 weeks and 16 weeks
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 16
weeks, ITT data provided by authors
Adverse events: Only prespecified adverse events are reported. ~ of sample noticed
changes in stools due to capsules across both groups. Only significant differences between
groups also reported (belching, noticeable aftertaste in the mouth and breath), but no
values. Study could not be included in analyses
Quality of life: GAF measured, but no data available
Failure to complete: Interventon group = 8, comparator group = 15. Reasons - 8 time/
commitment, 4 moved away, 3 hospitalised, 2 time constraints, 6 lost to follow-up
(reasons not split by group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “urn” randomisation balanced by prognos-
tic factors of age, sex, therapy, HDRS score
(P.1394)
Randomisation was undertaken by a per-
son unconnected with the study in a dif-
ferent location, who used a computer ran-
domisation programme. Researchers gave
them the blocking variables and the allo-
cation was emailed back (correspondence
with author)
Allocation concealment (selection bias) Low risk Randomisation and capsule packing per-
formed externally (P.1394)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants, clinicians and researcherswere
blind to allocation. Identical placebo and
capsules odourless, however when checked
the majority (90% fish oil group, 64%
placebo group) of participants correctly
guessed their group (P.1395)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS - clinician-rated: physicians blinded
to allocation (LOW)
BDI - self report (HIGH)
Blinding of outcome assessment (Adverse
Events)
High risk AEs - participant-rated
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis conducted but 28% dropped
out
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Grenyer 2007 (Continued)
Incomplete outcome data (Adverse Events) Unclear risk AEs not clearly reported
Selective reporting (reporting bias) Low risk All relevant outcomes reported (correspon-
dence with author)
Other bias Low risk Study appeared to be free from other
sources of bias
Jazayeri (v AD) 2008
Methods Randomised controlled parallel 3-arm trial, 8 weeks
Participants Participants: 60 outpatients from the Roozbeh Psychiatry Hospital, Tehran, Iran (split
across Jazayeri (v placebo) 2008 and Jazayeri (v AD) 2008)). 48 participants completing
the study had a mean age = 34.8 years, 33 women
Comorbidities: No physical comorbidities, possible psychiatric comorbidities
Adjunctive therapy: No for all participants
Inclusion criteria: Aged 20 - 59 years, DSM-IV criteria forMDD (SCID), no psychotic
features, scoring > 15 HDRS (24-item), medication-free for at least 6 weeks
Exclusion criteria: comorbid psychiatric diagnosis (other than dysthymia and anxiety)
, significant medical illness established by medical history, physical examination or lab-
oratory tests, suicidal thoughts, substance abuse, history of hypomanic/manic/mixed
episode, pregnancy and lactation, consumption of n-3PUFAs in the previous year and
dietary intake of > 1 serving of fish per week, use of non-steroid anti-inflammatory drugs
and other drugs 2 weeks before or during the intervention
Interventions Intervention: E-EPA (1.1 g/d providing 1 g/d pure EPA, plus 11 mg vitamin E), 2 x
550 mg capsules, plus 20 mg/d fluoxetine placebo (starch and avicel) (EPA group)
Comparator: Rapeseed oil (1.1 g/d, plus 11 mg vitamin E), 2 x 550 mg capsules, plus
20 mg/d fluoxetine (Fluoxetine group)
Treatment received for 8 weeks
Outcomes Primary: HDRS (24-item) - baseline, 2, 4, 6, 8 weeks; Adverse events
Secondary: Response based on HDRS; Failure to complete
Notes Supported by Vice Chancellor for Research, Tehran University of Medical Sciences, Iran
Supplements provided by Minami Nutrition, Belgium
Conflicts of Interest: not reported
Compliance: Capsule counts
Depressed mood (continuous): Analysis conducted on HDRS (24-item) scores at 8
weeks, ITT data provided by authors
Adverse events: Number of events reported rather than number of participants expe-
riencing events. Intervention group = 5 adverse events (3 GI, 1 psychological, 1 other
physical), Comparator group = 28 adverse events (6 GI, 10 psychological, 12 other phys-
ical). Study could not be included in analyses
Failure to complete: Intervention group = 4 (1 developing suicidal ideation, 1 non-com-
pliance, 2 lost to follow-up), Comparator group = 4 (1 drowsiness, 1 non-compliance,
2 lost to follow-up)
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Jazayeri (v AD) 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Prearranged block randomisation” (P.193)
but unclear how sequence was generated
Permuted-block randomisation
(correspondence with authors)
Allocation concealment (selection bias) High risk The randomisation sequence was not con-
cealed from researchers (correspondence
with authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Double dummy” placebo technique used
to blind participants; however, no steps
taken to mask fish taste and no assessment
to check concealment (P.194 - 5)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS - physicians blind to treatment al-
location
Blinding of outcome assessment (Adverse
Events)
High risk AEs - participant-reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS - ITT data provided by authors, >
10% dropout from each group
Incomplete outcome data (Adverse Events) Low risk All AEs reported (Table 4, p.196)
Selective reporting (reporting bias) High risk Some outcomes not yet published (corre-
spondence with authors)
Other bias Low risk Study appeared to be free from other
sources of bias
Jazayeri (v placebo) 2008
Methods Randomised controlled parallel 3-arm trial, 8 weeks
Participants Participants: 60 outpatients from the Roozbeh Psychiatry Hospital, Tehran, Iran (split
across Jazayeri (v placebo) 2008 and Jazayeri (v AD) 2008)). 48 participants completing
the study had a mean age = 34.8 years, 33 women
Comorbidities: No physical comorbidities, possible psychiatric comorbidities
Adjunctive therapy: No for all participants
Inclusion criteria: Aged 20 - 59 years, DSM-IV criteria forMDD (SCID), no psychotic
features, scoring > 15 HDRS (24-item), medication-free for at least 6 weeks
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Jazayeri (v placebo) 2008 (Continued)
Exclusion criteria: comorbid psychiatric diagnosis (other than dysthymia and anxiety)
, significant medical illness established by medical history, physical examination or lab-
oratory tests, suicidal thoughts, substance abuse, history of hypomanic/manic/mixed
episode, pregnancy and lactation, consumption of n-3PUFAs in the previous year and
dietary intake of > 1 serving of fish per week, use of non-steroid anti-inflammatory drugs
and other drugs 2 weeks before or during the intervention
Interventions Intervention: E-EPA (1.1 g/d providing 1 g/d pure EPA, plus 11 mg vitamin E), 2 x
550 mg capsules, plus 20 mg/d fluoxetine (Fluoxetine + EPA combination group)
Comparator: Rapeseed oil (1.1 g/d, plus 11 mg vit E), 2 x 550 mg capsules, plus 20
mg/d fluoxetine (Fluoxetine group)
Treatment received for 8 weeks
Outcomes Primary: HDRS (24-item) - baseline, 2, 4, 6, 8 weeks; Adverse events
Secondary: Response based on HDRS; Failure to complete
Notes Supported by Vice Chancellor for Research, Tehran University of Medical Sciences, Iran
Supplements provided by Minami Nutrition, Belgium
Conflicts of Interest: not reported
Compliance: Capsule counts
Depressed mood (continuous): Analysis conducted on HDRS (24-item) scores at 8
weeks, ITT data provided by authors
Adverse events: Number of events reported rather than number of participants experi-
encing events. Intervention group = 20 adverse events (6 GI, 4 psychological, 10 other
physical), Comparator group = 28 adverse events (6 GI, 10 psychological, 12 other phys-
ical). Study could not be included in analyses
Failure to complete: Intervention group = 4 (1 steatorrhoea, 1 physical conditions, 1
non-compliance, 1 lost to follow-up), Comparator group = 4 (1 drowsiness, 1 non-
compliance, 2 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Prearranged block randomisation” (P.193)
but unclear how sequence was generated
Permuted-block randomisation
(correspondence with authors)
Allocation concealment (selection bias) High risk The randomisation sequence was not con-
cealed from researchers (correspondence
with authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Double dummy” placebo technique used
to blind participants, however no steps
taken to mask fish taste and no assessment
to check concealment (P.194 - 5)
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS - physicians blind to treatment al-
location
Blinding of outcome assessment (Adverse
Events)
High risk AEs - participant-reported
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS - ITT data provided by authors, >
10% dropout from each group
Incomplete outcome data (Adverse Events) Low risk All AEs reported (Table 4, p.196)
Selective reporting (reporting bias) High risk Some outcomes not yet published (corre-
spondence with authors)
Other bias Low risk Study appeared to be free from other
sources of bias
Lespérance 2011
Methods Randomised controlled parallel-arm trial, 8 weeks
Participants Participants: 432 outpatients with mean age = 46.0 (SD = 12.4) years, 68.5% women,
were recruited via adverts, physician referrals and caseloads of study investigators from 8
academic and psychiatric clinics in Canada. The study ran from Oct 2005 to Jan 2009
Comorbidities: Yes in some participants: anxiety disorders (52.8%), possible physical
comorbidities
Adjunctive therapy:Yes for some participants: 40.3% antidepressants at baseline, 14.8%
undergoingpsychotherapy, 27.1%regularly used at least 1 other psychotropicmedication
Inclusion criteria: aged 18 years and over, met diagnostic criteria for MDE (MINI
5), score ≥ 27 IDS-SR, clinically significant depressive symptoms for ≥ 4 weeks, if
taking antidepressants - to have been at maximum dosage for > 4 weeks, or if not on
antidepressants to have been intolerant for ≥ 2 previous antidepressants or refused to
take them despite medical advice
Exclusion criteria: known allergy or intolerance to fish/sunflower oil, taken > 14 g of n-
3PUFA supplements during past 4 weeks, diagnosis of alcohol/drug abuse/dependency
during past 12 months or bipolar disorder (MINI), significant suicidal risk based on
clinical judgement, history of MI, pancreatic insufficiency or coagulation diseases, regu-
larly taking drugs or herbs with antiplatelet or anticoagulant properties, non-menopausal
pregnant women or those not taking contraception
Interventions Intervention: EPA/DHA combination (EPA = 1050 mg/d, DHA = 150 mg/d), 3 x
capsules daily, plus ongoing therapy
Comparator: Sunflower oil + 2% fish oil (to help blind), 3 x capsules daily, plus ongoing
therapy
Treatment received for 8 weeks
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Outcomes Primary: IDS-SR, MADRS at baseline, 1, 2, 4 and 8 weeks, Adverse events
Secondary: Failure to complete
Notes Funded by Isodis Natura and Foundation Du Centre Hospitalier de l’Universite de Montreal
and the CRCHUM
Supplements provided by Isodis Natura
Conflicts of Interest: CoIs declared by 3 authors
Compliance: Reported in results, but method of assessment not reported
Depressed mood (continuous): Analysis conducted on MADRS scores at 8 weeks, un-
adjusted ITT data provided by authors
Adverse events: Adverse events only gained from completers, only includes events re-
ported by≥ 5% population. Serious adverse events reported by event not by individual.
Serious adverse events reported: Intervention group = 7 (3 physical, 4 psychological),
Comparator group = 4 (4 physical). Number of participants with non-serious adverse
events: Intervention group = 322 events in 161 participants (215 GI, 107 other), Com-
parator group = 294 events in 148 participants (181 GI, 113 other). Data in the analysis
are for non-serious adverse events
Failure to complete: Intervention = 30 (reasons not reported), Comparator = 27 (reasons
not reported)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, randomly permuted
blocks of 2 and 4, stratified by site and base-
line antidepressant use/non-use. (P.1056
and correspondence from author)
Allocation concealment (selection bias) Low risk Group assignment using sequentially-
numbered containers, generated by co-or-
dinating centre. Only technician prepar-
ing containers had access to randomisation
codes (P.1056)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study research personnel and participants
were blinded. 2% fish oil was added to
placebo to control for fishy aftertaste.
James’ blinding index used to check blind-
ing of treatment allocation (P. 1056)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk IDS-SR andMADRS both low - study psy-
chiatrists, personnel were blinded
Blinding of outcome assessment (Adverse
Events)
Low risk AEs - participant-assessed
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Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis and although similar dropouts
in each group, > 10% dropout
Incomplete outcome data (Adverse Events) High risk AEs - only reported AEs reported by > 5%
of participants
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
with author)
Other bias Low risk Study appeared to be free from other
sources of bias.
Lucas 2009
Methods Randomised controlled parallel-arm trial, 8 weeks. Subgroup analysis of 29 women with
MDD (randomisation stratified according to MDD diagnosis)
Participants Participants: 29 postmenopausal women with mean age = 49.6 years were recruited
from the general population inQuebec, Canada through newspaper, radio and television
advertisements, and flyers posted in clinics and by clinicians. Participants were recruited
from March 2005 to November 2006, study ran until February 2007
Comorbidities: No physical comorbidities, possible psychiatric comorbidities
Adjunctive therapy: No for all participants
Inclusion criteria: aged 40 - 55 years, postmenopausal, score ≤ 72 on the PGWB and
score < 26 on the HDRS (21-item)
Exclusion criteria: score ≥ 26 on the 21-item HDRS, physical conditions known to
affect mental health, substance abuse/dependence, high consumption of fish (> 3 serving
per week), fish allergies, past or current schizophrenia or bipolar disorder, risk of suicide or
homicide, postmenopausal for more than 5 years, use of St John’s Wort, antidepressants,
hormone replacement therapy or fish oil supplements in previous 3 months, use of
anticoagulants
Interventions Intervention: EPA/DHA combination (1.5 g/d ethyl esters, providing 1050 mg/d EPA,
150 mg/d DHA), 3 capsules daily
Comparator: Sunflower oil (1.5 g/d, plus 0.2% regular fish oil [18% EPA/12% DHA])
, 3 capsules daily
Treatment received for 8 weeks
Outcomes Primary: 21-item HDRS, 20-item HSCL (Williams 2004) measured at baseline, 4 and
8 weeks. Adverse events
Secondary: PGWB, CGI, Failure to complete
Notes Supported by Laval University, Canada
Supplements provided by Isodus Natura, Belgium
Conflicts of Interest: CoIs declared by one author
Compliance: Capsule counts, and RBC membrane analysis
Depressed mood (continuous): Analysis conducted on HDRS (21-item) scores at 8
weeks, ITT data provided by authors
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Adverse events: Adverse events reported by event, not by individuals. Only includes
events reported by≥ 5% population. Adverse events are not published separately for the
subgroup. Adverse events (number of individuals) in the analysis were provided by the
authors
Quality of life: CGI data used in the analysis
Failure to complete: Intervention group = 1 (lack of efficacy), comparator group = 2
(adverse events)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by history of major depres-
sive episode. Computer-generated strati-
fied randomisation lists prepared by a statis-
tician. (P.642)
Allocation concealment (selection bias) Low risk Researchers responsible for seeing partici-
pants allocated next available entry num-
ber. Statistician gave randomisation list to
pharmacy who packaged capsules. (P.642)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, investigators and staff were
blind to treatment assignment until the last
participants completed study (P.642)
Capsules were obtained directly from the
pharmacist
Matching placebo with added fish for af-
tertaste
There was no difference in the number of
people guessing their allocation correctly.
(P.645)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS/CGS/HSCL/PGWB - all low. Par-
ticipants, investigators and staff were blind
to treatment assignment until the last par-
ticipants completed study
Blinding of outcome assessment (Adverse
Events)
Low risk AEs - reported by participants who were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis - additional information from
authors
Incomplete outcome data (Adverse Events) Low risk All AEs reported - information provided by
the authors
Selective reporting (reporting bias) Low risk All outcomemeasures reported (correspon-
dence with author)
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Other bias Low risk Study appeared to be free from other
sources of bias
Marangell 2003
Methods Randomised controlled parallel-arm trial, 6 weeks
Participants Participants: 36 participants. 35 participants completing the study had a mean age =
47.3 years, 28 women
Comorbidities: No
Adjunctive therapy: No
Inclusion criteria: aged 18 - 65 years, metDSM-IV criteria forMDDwithout psychotic
features (assessed by SCID), score ≥ 12 on the MADRS and score ≥ 17 on the 28-item
HDRS, medication-free for≥ 2 weeks prior to enrolment, dietary intake of ≤ 1 serving
of fish per week
Exclusion criteria: physical conditions or psychiatric comorbidities, treatment resistance
Interventions Intervention: DHA (2 g/d)
Comparator: placebo (2 g/d)
Treatment received for 6 weeks
Outcomes Primary: MADRS, HDRS (28-item) measured at baseline, 2 and 6 weeks; Adverse
events
Secondary: Response based on MADRS; GAF; Failure to complete
Notes Funded by Martek Biosciences Corporation, USA
Conflicts of Interest: not reported
Compliance: RBC DHA levels
Depressed mood (continuous): Analysis conducted on HDRS (28-item) scores at 6
weeks, per protocol data as published
Adverse events: Number of events reported rather than number of participants with
at least 1 adverse event. Intervention group = 25 events (19 GI, 6 other physical),
comparator group = 5 (1 GI, 4 other physical)
Failure to complete: 1 participant withdrew (group allocation unclear) (reason not re-
ported). Study could not be included in analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported other than “double blind”
specified in title. It was unclear if the fishy
taste was disguised and no assessment to
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check concealment. It was unclear whether
or not the placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk MADRS/HDRS - unclear whether assessor
was blinded to treatment
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs - unclear whether assessor was blinded
to treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk MADRS/HDRS - not ITT analysis
Incomplete outcome data (Adverse Events) High risk Not all AEs reported - “AEs included ...” P.
997.
Selective reporting (reporting bias) Unclear risk No protocol available to check prespecified
outcome measures
Other bias Low risk Study appeared to be free from other
sources of bias
Mischoulon (DHA) 2015
Methods Multi-centre parallel design randomised controlled trial, 8 weeks
Participants Participants: 196 participants (split across Mischoulon (DHA) 2015 and Mischoulon
(EPA) 2015): 177 participants considered evaluable (provided 1 post-baseline assess-
ment); Mean age 45.8 (SD 12.5) years, 59.3% women (n = 105), 40.7% men (n =
72). Participants recruited at Massachusetts General Hospital and Cedars-Sinai Medical
Center through advertisements and referrals from outpatient programmes, from May
2006 to June 2011
Comorbidities: anxiety disorders/dysthymia in some participants, no serious/unstable
physical comorbidities
Adjunctive therapy: no, for all participants
Inclusion criteria: A diagnosis of MDD per the SCID-I/P), a CGI-S score ≥ 3, and a
baseline 17-item HDRS-17 score ≥ 15
Exclusion criteria: pregnancy or women of childbearing potential who were not using
a medically-accepted means of contraception; suicidality or homicidality; serious or
unstablemedical illness; current or past history of organicmental disorders, substance use
disorders, any psychotic disorders, and bipolar disorder; history of multiple adverse drug
reactions or allergy to the study compounds; concurrent use of psychotropicmedications,
systematic corticosteroid or steroid antagonists, anticoagulants, or immunosuppressant
agents; electroconvulsive therapy during the current episode; any trial of≥ 6 weeks with
citalopram 40 mg/d or equivalent antidepressant during the current episode (to select
a less refractory sample that would be more likely to respond to treatment); history of
use of 1 g/d of n-3 supplements; history of a bleeding disorder; psychotherapy; smoking
10 cigarettes per day; vitamin E supplementation > 400 IU; menstruating individuals
unable to have baseline and post-treatment blood drawn during the follicular phase; and
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individuals unable to refrain from nonsteroidal anti-inflammatory use for > 72 hours
prior to blood work. People with a CGI-I score of 1 or 2 (i.e. “much improved” or “very
much improved”) during the baseline visit (1 week after the screen visit) were excluded
from the study
Interventions Intervention: 1000 mg DHA enriched mix (consisting of 45 mg EPA / 225 mg DHA
[EPA:DHA 1:5], plus 10% docosapentaenoic acid [DPA, n-3], 2% heneicosapentaenoic
acid [HPA, n-3], 1% stearidonic acid [SDA, n-3], 1% eicosatetraenoic acid [ETA, n-
3], 0.4% α-linolenic acid [ALA, n-3], 1% arachidonic acid [AA, n-6], 0.5% linoleic
acid [LA, n-6], and 20% unspecified fatty acids) per soft-gel capsule. 4 DHA enriched
capsules (plus EPA arm placebo capsules) every morning for 8 weeks
Comparator: 980 mg soybean oil per capsule (formed of 53.6% LA, 7.1% ALA, 0.1%
myristic acid, 11% palmitic acid, 4% stearic acid, 0.2% palmitoleic acid, and 24% oleic
acid), 4 capsules every morning (plus EPA arm placebo capsules) for 8 weeks
Outcomes Primary: HDRS (17-item), QIDS-SR16, every 2 weeks for 8 weeks, Adverse events
(PRISE scale)
Secondary:Depression remission and response; CGI (Scale), CGI (Improvement),WBS
(Ryff 1995), QLESQ, every 2 weeks for 8 weeks Failure to complete
Notes Supported by NIH Grant
Supplements provided by Nordic Naturals
Conflicts of Interest: CoIs reported for several authors
Compliance: NR
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 8
weeks, published modified ITT (at least 1 post-baseline assessment) data used for anal-
yses, end outcome scores calculated from change data, SDs imputed from other studies
using the HDRS (17-item). Placebo group split across 2 intervention groups (DHA =
29 participants, EPA = 30 participants)
Adverse events: Adverse events reported by individuals, 20 - 30%of participants endorsed
some baseline PRISE physical or depressive symptoms. The following participants expe-
rienced emerging or worsening adverse events: Intervention = 40 of 56, Comparator =
33 of 60 (correspondence from author). Values included in the analysis are for emerging
or worsening AEs
Depression remission defined as final HDRS (17-item) score ≤ 7; Depression response
defined as improvement ≥ 50% in HDRS (17-item)
Quality of life: CGI scale data used in analyses
Failure to complete: Intervention group = 15 (2 insufficient time/energy, 5 lost to follow-
up, 3 violated protocol, 2 family emergency, 3 NR), comparator group = 12 (1 health
problems related to treatment, 1 scheduling issues, 3 lost to follow-up, 3 violated protocol,
4 NR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A fixed-block size of 30 participants
(MGH)or a randomly-permuted block size
between 6 and 15 participants (CSMC).
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P55
Allocation concealment (selection bias) Low risk Only blind treatment codes, co-ordinated
between both site pharmacies, were noted
on randomisation lists provided to study
staff. P55
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Flavours added to mask taste but no check
to assess blinding (correspondence fromau-
thors)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Self-reported for mood scales, P55
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs rated by participants, P55
Incomplete outcome data (attrition bias)
All outcomes
High risk Mood scales - not ITT and > 10% dropout
- P55, and correspondence from authors
Incomplete outcome data (Adverse Events) Low risk All reported (correspondence from au-
thors)
Selective reporting (reporting bias) High risk Well being scale and n-3PUFA blood levels
still to be reported (correspondence from
authors)
Other bias Low risk Study appeared to be free from other
sources of bias
Mischoulon (EPA) 2015
Methods Multi-centre parallel design randomised controlled trial, 8 weeks
Participants Participants: 196 participants (split across Mischoulon (DHA) 2015 and Mischoulon
(EPA) 2015): 177 participants considered evaluable (provided 1 post-baseline assess-
ment); Mean age 45.8 (SD 12.5) years, 59.3% women (n = 105), 40.7% men (n =
72). Participants recruited at Massachusetts General Hospital and Cedars-Sinai Medical
Center through advertisements and referrals from outpatient programmes, from May
2006 to June 2011
Comorbidities: anxiety disorders/dysthymia in some participants, no serious/unstable
physical comorbidities
Adjunctive therapy: no, for all participants
Inclusion criteria: A diagnosis of MDD per the SCID-I/P), a CGI-S score ≥ 3, and a
baseline 17-item HDRS-17 score ≥ 15
Exclusion criteria: pregnancy or women of childbearing potential who were not using
a medically-accepted means of contraception; suicidality or homicidality; serious or
unstablemedical illness; current or past history of organicmental disorders, substance use
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disorders, any psychotic disorders, and bipolar disorder; history of multiple adverse drug
reactions or allergy to the study compounds; concurrent use of psychotropicmedications,
systematic corticosteroid or steroid antagonists, anticoagulants, or immunosuppressant
agents; electroconvulsive therapy during the current episode; any trial of≥ 6 weeks with
citalopram 40 mg/d or equivalent antidepressant during the current episode (to select
a less refractory sample that would be more likely to respond to treatment); history of
use of 1 g/d of n-3 supplements; history of a bleeding disorder; psychotherapy; smoking
10 cigarettes per day; vitamin E supplementation > 400 IU; menstruating individuals
unable to have baseline and post-treatment blood drawn during the follicular phase; and
individuals unable to refrain from nonsteroidal anti-inflammatory use for > 72 hours
prior to blood work. People with a CGI-I score of 1 or 2 (i.e. “much improved” or “very
much improved”) during the baseline visit (1 week after the screen visit) were excluded
from the study
Interventions Intervention: 1000mgEPA enrichedmix (consisting of 530mgEPA / 137mgDHAper
soft gel [EPA:DHA 4:1], plus 7% stearidonic acid [SDA, n-3], 1% heneicosapentaenoic
acid [HPA, n-3], 1% docosapentaenoic acid [DPA, n-3], 1% eicosatetraenoic acid [ETA,
n-3], 0.2% α-linolenic acid [ALA, n-3], 3% arachidonic acid [AA, n-6], 0.2% linoleic
acid [LA, n-6], and 10% - 11% unspecified fatty acids) per soft-gel capsule. 2 EPA
enriched capsules (plus DHA arm placebo capsules) every morning for 8 weeks
Comparator: 980 mg soybean oil per capsule (formed of 53.6% LA, 7.1% ALA, 0.1%
myristic acid, 11% palmitic acid, 4% stearic acid, 0.2% palmitoleic acid, and 24% oleic
acid), 2 capsules every morning (plus DHA arm placebo capsules) for 8 weeks
Outcomes Primary: HDRS (17-item), QIDS-SR16, every 2 weeks for 8 weeks, Adverse events
(PRISE)
Secondary: Depression remission and response; CGI-S, CGI-I, WBS (Ryff 1995),
QLESQ, every 2 weeks for 8 weeks. Failure to complete
Notes Supported by NIH Grant
Supplements provided by Nordic Naturals
Conflicts of Interest: CoIs reported for several authors
Compliance: NR
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 8
weeks, published modified ITT (at least 1 post-baseline assessment) data used for anal-
yses, end outcome scores calculated from change data, SDs imputed from other studies
using the HDRS (17-item). Placebo group split across 2 intervention groups (DHA =
29 participants, EPA = 30 participants)
Adverse events: Adverse events reported by individuals, 20 - 30%of participants endorsed
some baseline PRISE physical or depressive symptoms. The following participants expe-
rienced emerging or worsening adverse events: Intervention = 40 of 56, Comparator =
33 of 60 (correspondence from author). Values included in the analysis are for emerging
or worsening AEs
Depression remission defined as final HDRS (17-item) score ≤ 7; Depression response
defined as improvement ≥ 50% in HDRS (17-item)
Quality of life: CGI scale data used in analyses
Failure to complete: Intervention group = 15 (2 insufficient time/energy, 5 lost to follow-
up, 3 violated protocol, 2 family emergency, 3 NR), comparator group = 12 (1 health
problems related to treatment, 1 scheduling issues, 3 lost to follow-up, 3 violated protocol,
77Omega-3 fatty acids for depression in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mischoulon (EPA) 2015 (Continued)
4 NR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A fixed-block size of 30 participants
(MGH)or a randomly-permuted block size
between 6 and 15 participants (CSMC).
P55
Allocation concealment (selection bias) Low risk Only blind treatment codes, co-ordinated
between both site pharmacies, were noted
on randomisation lists provided to study
staff. P55
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Flavours added to mask taste but no check
to assess blinding (author correspondence)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Self-reported for mood scales, P55
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs rated by participants, P55
Incomplete outcome data (attrition bias)
All outcomes
High risk Mood scales - not ITT and > 10% dropout
- P55, and correspondence from author
Incomplete outcome data (Adverse Events) Low risk All reported (correspondence from author)
Selective reporting (reporting bias) High risk Well being scale and n-3PUFA blood levels
still to be reported (correspondence from
author)
Other bias Low risk Study appeared to be free from other
sources of bias
Mischoulon 2009
Methods Randomised controlled parallel-arm trial, 8 weeks
Participants Participants: After 57 participants were randomised at a screening visit, 41 completed
a baseline visit and entered into the study; mean age 43 years (SD = 13), 63% women.
These participants were recruited via advertisements and referrals to the Massachussets
General Hospital Depression Clinical and Research Programme, from Jan 2003 to June
2006
Comorbidities: No
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Adjunctive therapy: Yes in some participants: concurrent psychotherapy if receiving
therapy prior to enrolment
Inclusion criteria: aged 18 - 80 years, DSM-IV diagnosis of MDD (using SCID-IP)
, score ≥ 18 on the 17-item HDRS and ≥ 3 on the CGI-SI scale, ability to provide
informed written consent, free from antidepressant, antipsychotic or mood-stabilisation
medication
Exclusion criteria: unstable medical conditions, psychiatric or psychotic comorbidities,
current serious suicide or homicidal risk, substance abuse, currently taking n-3PUFA
supplements, history of adverse drug reactions or allergy to study drugs, pregnancy or
no use of medically-approved contraception among women of child-bearing potential,
breastfeeding, failure to respond to ≥ 1 antidepressant trial, history of unstable seizure
disorder, history of electroconvulsive therapy in previous 6 months, anticoagulant use
Interventions Intervention: E-EPA (1 g/d, plus 0.2% alpha tocopherol), 2 x 500 mg capsules twice
daily or both at once
Comparator: Paraffin oil (1 g/d, plus 0.2% alpha tocopherol), 2 x 500 mg capsules twice
daily or both at once
Treatment received for 8 weeks
Outcomes Primary: HDRS (17-item) measured every 2 weeks for 8 weeks; Adverse events
Secondary: Remission and response based on HDRS; QLESQ; Failure to complete
Notes Funded by the National Center for Complementary and Alternative Medicine, NIH, USA
Supplements provided by Amarin Neuroscience Ltd, UK
Conflicts of Interest: CoIs declared from many authors.
Compliance: Capsule counts at each visit; Plasma n-3PUFA levels measured
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 8
weeks, ITT data provided by authors
Adverse events: Adverse events were reported in 7 individuals - Intervention group = 2
(2 GI), comparator group = 5 (5 GI)
Quality of life: QLESQ - data not reported.
Failure to complete: Intervention group = 6 (1 non-response, 1 commuting, 4 lost to
follow-up), comparator group = 11 (2 non-response, 1 feeling better, 8 lost to follow-
up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed by research
pharmacy using www.randomization.com
(P.1637)
Allocation concealment (selection bias) Low risk Assigned medications were coded and sent
to treatment team by research pharmacy (P.
1637)
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study clinicians and participants remained
blind to assignment for duration of study
(P.1637). It was unclear if the fishy taste
was disguised and no assessment to check
concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS - Study clinicians remained blind
to assignment for duration of study
Blinding of outcome assessment (Adverse
Events)
High risk AEs rated by participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk HDRS - ITT numbers obtained through
correspondence with author
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) High risk All primary outcome measures reported
(correspondence with author). QLESQ
was a planned outcome and measured but
not analysed or reported (correspondence
with author)
Other bias Low risk Study appeared to be free from other
sources of bias
Nemets 2002
Methods Randomised controlled parallel-arm trial, 4 weeks
Participants Participants: 20 participants with mean age = 53.4 (SD = 11.7, range 28 - 73) years, 17
women
Comorbidities: Yes in some participants: 1 participant had comorbid OCD
Adjunctive therapy: Yes in some participants: all with the exception of 1 participant
Inclusion criteria: recurrent MDD (according to DSM-IV criteria) from ≥ 2 clinical
interviews with ≥ 2 specialist psychiatrists spaced at least 1 week apart, aged 18 - 75
years, no unstable medical disease, no psychotic or psychiatric comorbidities other than
panic disorder, dysthymic disorder or OCD, no substance abuse
Interventions Intervention: E-EPA (2 g/d), 2 x 500 mg capsules, twice daily, plus ongoing therapy
Placebo: placebo, 2 x 500 mg capsules, twice daily, plus ongoing therapy
Treatment received for 4 weeks
Outcomes Primary:HDRS (24-item) measured at baseline and weekly for 4 weeks; Adverse events
Secondary: Response based on HDRS, Failure to complete
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Notes Funding: not reported
Supplements provided by Laxdale Ltd., UK.
Conflicts of Interest: not reported
Compliance: not reported
Depressed mood (continuous): Analysis conducted on HDRS (24-item) scores at 4
weeks, ITT data calculated from publication
Adverse events: Only clinically relevant adverse events were investigated, none found.
Values in the analysis are for clinically relevant AEs
Failure to complete: Intervention group = 0, comparator group = 1 (symptoms worsened)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised according to
a random-number table (correspondence
with author)
Allocation concealment (selection bias) Low risk Senior investigator generated random-
number table and was in a different build-
ing to senior clinician. Senior clinician was
not aware of the randomisation sequence.
(Correspondence with author)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Intervention and placebo
capsules were matching, although no at-
tempt to match taste. No participants re-
ported fishy sensations when asked specifi-
cally, and debriefing recorded a completely
random guess rate by participant and clin-
ician (P.477, 478)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS - assessors blind to treatment as-
signment
Blinding of outcome assessment (Adverse
Events)
Low risk AEs - participant-rated, participants blind
to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk HDRS - 1 participant dropped out, but
possible to conduct ITT analysis using
LOCF
Incomplete outcome data (Adverse Events) High risk Only clinically relevant AEs reported
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
with author)
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Other bias Low risk Study appeared to be free from other
sources of bias
Park 2015
Methods Randomised controlled parallel-arm trial, 12 weeks
Participants Participants: 35 participants, mean age only reported by group (Intervention = 43.5 (SD
= 3.72) years; comparator = 39.41 (SD = 3.58) years); 27 women, 8 men. Participants
recruited from Hanyang University Hospital, Korea, from 2010 to 2013
Comorbidities: None reported, possible psychiatric comorbidities
Adjunctive therapy: Yes, usual care and antidepressant medications in all participants
Inclusion criteria:CES-D-K (Cho 1998) score >24, confirmedby psychiatrist according
to DMS-IV
Exclusion criteria: pregnant, lactating, < 18 / > 65 years old, taking supplements con-
taining n-3PUFAs, medical comorbidity (CV disease, dementia), chronic depression
lasting > 2 years or treatment-resistant depression, other primary psychiatric disorders
(bipolar or schizophrenia)
Interventions Intervention: E-EPA/DHA combination (EPA = 3420 mg/d, DHA = 1800 mg/d), 3
capsules daily for 12 weeks
Comparator: safflower oil and oleic acid (3g), 3 capsules daily for 12 weeks
Outcomes Primary: HDRS (17-item), CES-D-K measured at baseline, 4, 8, 12 weeks; Adverse
events
Secondary: CGI, CGI-IS, dietary data, blood samples, failure to complete
Notes Funded by the Korean Research Foundation
Supplements provided by DSM Nutritional Products, Switzerland
Conflicts of Interest: None declared, however Dr Y Park is a founder of Omega Quant Asia
(a laboratory specialising in fatty acid analysis)
Compliance: Plasma n-3PUFA levels measured
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 12
weeks, data using modified ITT (at least 1 post-baseline visit) provided by authors
Adverse events: Adverse events were reported in 4 individuals: Intervention group = 3 (3
fishy eructation), comparator group = 1 (1 fishy eructation)
Quality of life: Analysis conducted on CGI (scale)
Failure to complete: Intervention group = 6 (1 rejected blood sampling, 5 participant
decision), comparator group = 5 (1 rejected blood sampling, 4 participant decision)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician, computer-gener-
ated randomisation scheme allowing for
randomisation blocks, P143
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Allocation concealment (selection bias) Low risk Sequentially-numbered containers with ei-
ther n-3PUFAs or placebo; randomly
assigned to participants. Identity codes
were concealed in sequentially-numbered
opaque envelopesmanaged by the study in-
vestigators, P143
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt tomask flavour or check blind-
ing, P142
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS scores were measured by psychia-
trist who was blinded to treatment groups
Blinding of outcome assessment (Adverse
Events)
High risk AEs - participant-rated (participants not
blinded effectively)
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS - > 10% missing in the overall sam-
ple and not ITT analysis
Incomplete outcome data (Adverse Events) Low risk All AEs reported, P144
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
from authors)
Other bias High risk Significant baseline imbalance for mood
disorders, P144
Peet (1g/d) 2002
Methods Randomised controlled multicentre parallel-arm trial, 12 weeks
Participants Participants: 70 participants with a mean age of 44.7 years were recruited by family
physicians in the UK who had an interest in depression and experience in conducting
clinical trials (split across Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002)
Comorbidities: none reported, but possible physical and/or psychiatric comorbidities
Adjunctive therapy: Yes in all participants: antidepressants
Inclusion criteria: aged 18 - 70 years, score≥ 15 on the 17-itemHDRS despite ongoing
treatment with a standard antidepressant at an adequate dose
Interventions Intervention: E-EPA (1 g/d + 3 g/d placebo), 4 x 500 mg capsules, twice daily
Comparator: liquid paraffin (4 g/d), 4 x 500 mg capsules, twice daily
Treatment received for 12 weeks
Outcomes Primary: HDRS (17-item), MADRS, BDI were all measured at baseline, 4, 8 and 12
weeks; Adverse events
Secondary: Response based on HDRS, MADRS and BDI; failure to complete
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Notes Funding: not reported
Conflicts of Interest: CoIs declared by one author. Other author works for Laxdale Ltd., UK.
Compliance: Capsule counts
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 12
weeks, published ITT data (although 1 participant from the placebo group is missing
from these data). Placebo group split across all 3 intervention groups (1 g/d = 5 par-
ticipants, 2 g/d = 6 participants, 4 g/d = 6 participants), SDs calculated from all other
studies also using the HDRS (17-item)
Adverse events: Intervention group: 18 events experienced by 9 participants (7 GI, 4
psychological, 7 other physical), comparator group: 23 events experienced by 10 partic-
ipants (4 GI, 2 psychological, 17 other physical)
Failure to complete: Intervention groups (2 per group, reasons not separated by group
1 g/d, 2g/d, 4 g/d) = 6 (3 withdrew consent, 1 lack of efficacy, 1 violated protocol, 1
adverse event), comparator group = 4 (1 withdrew consent, 1 violated protocol, 1 adverse
event, 1 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly allocated by PCI clinical ser-
vices computer” (P.914)
Allocation concealment (selection bias) Low risk Capsules were packed and coded by PCI
clinical services. Participants were ran-
domly allocated on entry to study, PCI
Clinical Services had no involvement with
the rest of the trial. (P.914)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants took the same number of cap-
sules, placebo and intervention capsules
were identical in appearance. Participants,
researchers and assessors blind to treatment
allocation. (P.914) It was unclear if they dis-
guised the fishy taste and no assessment to
check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS/MADRS - assessors blind to treat-
ment allocation (LOW)
BDI - participant-rated (HIGH)
Blinding of outcome assessment (Adverse
Events)
High risk AEs assessed by participants
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS/MADRS/BDI - Not ITT analysis
(only 17 participants used in the analysis of
placebo group)
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Peet (1g/d) 2002 (Continued)
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
from author)
Other bias Low risk Study appeared to be free from other
sources of bias
Peet (2g/d) 2002
Methods Randomised controlled multicentre parallel-arm trial, 12 weeks
Participants Participants: 70 participants with a mean age of 44.7 years were recruited by family
physicians in the UK who had an interest in depression and experience in conducting
clinical trials (split across Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002)
Comorbidities: none reported, but possible physical and/or psychiatric comorbidities
Adjunctive therapy: Yes in all participants: antidepressants
Inclusion criteria: aged 18 - 70 years, score≥ 15 on the 17-itemHDRS despite ongoing
treatment with a standard antidepressant at an adequate dose
Interventions Intervention: E-EPA (2 g/d + 2 g/d placebo), 4 x 500 mg capsules, twice daily
Comparator: liquid paraffin (4 g/d), 4 x 500 mg capsules, twice daily
Treatment received for 12 weeks
Outcomes Primary: HDRS (17-item), MADRS, BDI were all measured at baseline, 4, 8 and 12
weeks; Adverse events
Secondary: Response based on HDRS, MADRS and BDI; Failure to complete
Notes Funding: not reported
Conflicts of Interest: CoIs declared by one author. Other author works for Laxdale Ltd., UK.
Compliance: Capsule counts
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 12
weeks, published ITT data (although 1 participant from the placebo group is missing
from these data). Placebo group split across all 3 intervention groups (1 g/d = 5 par-
ticipants, 2 g/d = 6 participants, 4 g/d = 6 participants), SDs calculated from all other
studies also using the HDRS (17-item)
Adverse events: Intervention group: 18 events experienced by 9 participants (7 GI, 4
psychological, 7 other physical), comparator group: 23 events experienced by 10 partic-
ipants (4 GI, 2 psychological, 17 other physical)
Failure to complete: Intervention groups (2 per group, reasons not separated by group
1 g/d, 2g/d, 4 g/d) = 6 (3 withdrew consent, 1 lack of efficacy, 1 violated protocol, 1
adverse event), comparator group = 4 (1 withdrew consent, 1 violated protocol, 1 adverse
event, 1 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
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Peet (2g/d) 2002 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomly allocated by PCI clinical ser-
vices computer” (P.914)
Allocation concealment (selection bias) Low risk Capsules were packed and coded by PCI
clinical services. Participants were ran-
domly allocated on entry to study, PCI
Clinical Services had no involvement with
the rest of the trial. (P.914)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants took the same number of cap-
sules, placebo and intervention capsules
were identical in appearance. Participants,
researchers and assessors blind to treatment
allocation. (P.914) It was unclear if they dis-
guised the fishy taste and no assessment to
check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS/MADRS - assessors blind to treat-
ment allocation (LOW)
BDI - participant-rated (HIGH)
Blinding of outcome assessment (Adverse
Events)
High risk AEs assessed by participants
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS/MADRS/BDI - Not ITT analysis
(only 17 participants used in the analysis of
placebo group)
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
from author)
Other bias Low risk Study appeared to be free from other
sources of bias
Peet (4g/d) 2002
Methods Randomised controlled multicentre parallel-arm trial, 12 weeks
Participants Participants: 70 participants with a mean age of 44.7 years were recruited by family
physicians in the UK who had an interest in depression and experience in conducting
clinical trials (split across Peet (1g/d) 2002; Peet (2g/d) 2002; Peet (4g/d) 2002)
Comorbidities: none reported, but possible physical and/or psychiatric comorbidities
Adjunctive therapy: Yes in all participants: antidepressants
Inclusion criteria: aged 18 - 70 years, score≥ 15 on the 17-itemHDRS despite ongoing
treatment with a standard antidepressant at an adequate dose
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Peet (4g/d) 2002 (Continued)
Interventions Intervention: E-EPA (4 g/d), 4 x 500 mg capsules, twice daily
Comparator: liquid paraffin (4 g/d), 4 x 500 mg capsules, twice daily
Treatment received for 12 weeks
Outcomes Primary: HDRS (17-item), MADRS, BDI were all measured at baseline, 4, 8 and 12
weeks; Adverse events
Secondary: Response based on HDRS, MADRS and BDI; Failure to complete
Notes Funding: not reported
Conflicts of Interest: CoIs declared by one author. Other author works for Laxdale Ltd., UK.
Compliance: Capsule counts
Depressed mood (continuous): Analysis conducted on HDRS (17-item) scores at 12
weeks, published ITT data (although 1 participant from the placebo group is missing
from these data). Placebo group split across all 3 intervention groups (1 g/d = 5 par-
ticipants, 2 g/d = 6 participants, 4 g/d = 6 participants), SDs calculated from all other
studies also using the HDRS (17-item)
Adverse events: Intervention group: 18 events experienced by 9 participants (7 GI, 4
psychological, 7 other physical), comparator group: 23 events experienced by 10 partic-
ipants (4 GI, 2 psychological, 17 other physical)
Failure to complete: Intervention groups (2 per group, reasons not separated by group
1 g/d, 2g/d, 4 g/d) = 6 (3 withdrew consent, 1 lack of efficacy, 1 violated protocol, 1
adverse event), comparator group = 4 (1 withdrew consent, 1 violated protocol, 1 adverse
event, 1 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly allocated by PCI clinical ser-
vices computer” (P.914)
Allocation concealment (selection bias) Low risk Capsules were packed and coded by PCI
clinical services. Participants were ran-
domly allocated on entry to study, PCI
Clinical Services had no involvement with
the rest of the trial. (P.914)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants took the same number of cap-
sules, placebo and intervention capsules
were identical in appearance. Participants,
researchers and assessors blind to treatment
allocation. (P.914) It was unclear if they dis-
guised the fishy taste and no assessment to
check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS/MADRS - assessors blind to treat-
ment allocation (LOW)
BDI - participant-rated (HIGH)
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Peet (4g/d) 2002 (Continued)
Blinding of outcome assessment (Adverse
Events)
High risk AEs assessed by participants
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS/MADRS/BDI - Not ITT analysis
(only 17 participants used in the analysis of
placebo group)
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
from author)
Other bias Low risk Study appeared to be free from other
sources of bias
Rondanelli 2010
Methods Randomised controlled parallel-arm trial, 8 weeks
Participants Participants: 46 women with a mean age of 83.9 years, resident in a nursing home in
Pavia, Italy for ≥ 3 months. Data were gathered between January 2006 and December
2007
Comorbidities: No psychiatric comorbidities, arthritis in some individuals
Adjunctive therapy: No antidepressants, possible use of other therapies
Inclusion criteria: aged 65 - 95 years, BMI of 19 - 30 kg/m2, score > 10 on the GDS,
MMSE score > 24, met DSM-IV criteria for MDD or dysthymia, as assessed by senior
psychiatrist
Exclusion criteria: presence of clinically uncontrolled organic disease or clinically rel-
evant lab abnormalities, any psychotic or psychiatric comorbidities, including suicidal
ideation, current use of psychotropic drugs other than benzodiazepines
Ongoing pharmacological treatment for physical conditions, at the time of enrolment,
was maintained during the study
Interventions Intervention: EPA/DHA combination (3.13 g/d - EPA = 1.67 g/d, DHA = 0.83 g/d,
other n-3PUFAs = 0.63 g/d)
Comparator: Paraffin oil (2.5 g/d)
Treatment received for 8 weeks
Outcomes Primary: GDS was measured before and after treatment at week 0 and week 8. Adverse
events
Secondary: Remission and response based on GDS; SF-36 (mental health summary
score); Failure to complete
Notes Funded by Regione Lomdardia, Italy
Intervention provided by Also SpA Div. Also-Enervit, Zelbio (Co), Italy.
Conflicts of Interest: None declared.
Compliance: EPA and DHA levels in RBC membranes
Depressed mood (continuous): Analysis conducted on GDS scores at 8 weeks, published
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Rondanelli 2010 (Continued)
ITT data
Adverse events: No serious adverse events reported. Minor adverse events: Intervention
group = 6 (6 GI), comparator group = 6 (5 GI, 1 other physical). Values in the analysis
are for minor events
Failure to complete: Not mentioned, but full data sets provided for all participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Bottles for each treatment group were as-
signed a participant number according to a
coded (AB) block randomisation table pre-
pared by an independent statistician. (P.57)
Allocation concealment (selection bias) Low risk As participants were enrolled they were as-
signed a progressive participant number.
Investigators were blinded to the randomi-
sation table, the code assignments and the
procedure. (P.58)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators were blinded to the randomi-
sation table, the code assignments and the
procedure. Bottles of oily preparation were
identical for each treatment group and
lemon flavour was added to both oils. No
participants complained about a fish smell
or eructation or made any comment about
the contents of the supplement or percep-
tion of being in 1 of the 2 groups. (P.58,
60)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk GDS - Investigators and participants blind
to treatment
Blinding of outcome assessment (Adverse
Events)
Low risk AEs - investigators and participants blind
to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk GDS - ITT analysis
Incomplete outcome data (Adverse Events) Low risk All AEs are reported
Selective reporting (reporting bias) Low risk All outcomemeasures reported (correspon-
dence with author)
Other bias Low risk Study appeared to be free from other
sources of bias
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Silvers 2005
Methods Randomised controlled parallel-arm trial, 12 weeks
Participants Participants: 77 participants with a mean age = 38.8 years, 41 women, recruited through
a Community Mental Health Service, general practices and advertisements in commu-
nity newspapers in New Zealand. Participants were recruited between July 2000 and
September 2001
Comorbidities: possible physical and psychiatric comorbidities
Adjunctive therapy: Yes for some participants: 61 participants taking antidepressants,
21 participants receiving psychotherapy
Inclusion criteria: current depressive episode, aged 18 - 65 years, stable medication
for ≥ 2 months prior to enrolment, willing to provide blood samples and, if female,
premenopausal with a normal menstrual cycle, available for the length of the study
Exclusion criteria: any psychotic or psychiatric comorbidities other than anxiety disor-
ders, currently taking n-3PUFA supplements, allergy to seafood or objection to taking
fish-/olive oil-based products, blood clotting disorders or use of anticoagulants, any un-
stable medical conditions or conditions likely to affect gastrointestinal absorption
Interventions Intervention: EPA/DHA combination (8 g/d DHA enriched tuna oil providing 0.6 g/
d EPA, 2.4 g/d DHA, 80 mg vitamin E), 4 x 1 g capsules, twice daily, plus ongoing
therapy
Comparator: Olive oil (8 g/d) 4 x 1 g capsules, twice daily, plus ongoing therapy
Treatment received for 12 weeks
Outcomes Primary: HDRS Short Form (9-item) (score of > 10 represents severe depression) and
BDI-II were measured at baseline and weeks 2, 4, 8 and 12. Adverse events
Secondary: Failure to complete
Notes Funded by Foundation for Research, Science and Technology, New Zealand.
Supplements provided by Clover Corporation Plc, Australia
Conflicts of Interest: No CoIs declared.
Compliance: RBC membrane EPA and DHA levels measured, participants completing
exit interview asked about compliance
Depressed mood (continuous): Analysis conducted on HDRS (9-item) scores at 12
weeks, per protocol data obtained from authors
Adverse events: Intervention group - 20 events in 14 participants (11GI, 7 other physical,
2 not reported); comparator group - 16 events in 14 participants (8 GI, 2 psychological,
5 other physical, 1 not reported)
Failure to complete: Intervention group: 16 (2 withdrew before baseline, 9 discontinued
intervention, 1 head trauma, 1 physical disorder, 2 scored < 6 on HDRS at week 0,
1 not reported); comparator group 16 (2 withdrew before baseline, 5 discontinued
intervention, 1 head trauma, 3 personality disorders, 1 bipolar disorder, 4 scored < 6 on
HDRS at week 0)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation according to a prearranged
computer-generated code (P.212)
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Silvers 2005 (Continued)
Allocation concealment (selection bias) Low risk Randomisation sequence generated by
statistician not directly involved in the
study (P.212). Allocation sequence was
concealed from both participants and the
research psychologists (P.213)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules looked identical, fish smell and
taste were minimal. Participants were told
only that both oils were natural and after-
taste might be experienced. No evidence
that participants guessed their treatment al-
location (P = 0.804) (P.215)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HDRS/BDI - both researchers and partic-
ipants blind to treatment allocation
Blinding of outcome assessment (Adverse
Events)
Low risk AEs - participant-rated, participants blind
to treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk HDRS/BDI - analysis conducted on only
those providing 1 follow-up (not ITT), and
> 10% dropout
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) Low risk All relevant outcome measures reported
(correspondence with author)
Other bias Low risk Study appeared to be free from other
sources of bias
Su 2003
Methods Randomised controlled parallel-arm trial, 8 weeks
Pre-randomisation: all participants received single-blind placebo capsules for 1 week,
those with a ≥ 20% decrease in HDRS score (placebo responders) were excluded
Participants Participants: 28 outpatients referred by Taipei Medical University-Wan Fang Hospital.
22 participants completing the trial had a mean age = 38.4 years, 18 women
Comorbidities: No
Adjunctive therapy: Yes in some, if participants on stable medication at enrolment
Inclusion criteria: aged 18 - 60 years, diagnosis with DSM-IV MDD and no other
comorbid Axis I or Axis II psychiatric disorder, rated > 18 on the HDRS (21-item)
, stable medication or psychotherapy for 4 weeks before enrolment, physically healthy
under evaluations of medical history, physical examinations, and laboratory tests and
competent to understand the study and give written informed consent
Exclusion criteria: Participants receiving antipsychotics or mood stabilizers, ≥ 20%
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Su 2003 (Continued)
decrease in HDRS score (placebo responders) following pre-randomisation
Interventions Intervention: EPA/DHA combination (6.6 g/d - 4.4 g/d EPA and 2.2 g/d DHA, plus
tocopherols and tertiary-butylhydroquinone), 5 capsules, twice daily
Comparator: Olive oil ethyl esters (plus tocopherols and tertiary-butylhydroquinone),
5 capsules, twice daily
Treatment received for 8 weeks
Outcomes Primary: HDRS (21-item) measured at -1, 0, 2, 4, 6 and 8 weeks. Adverse events
Secondary: Failure to complete
Notes Funded by National Science Council, and China Chemical and Pharmaceutical Company,
Taiwan
Supplements provided by China Chemical and Pharmaceutical Company, Taiwan
Conflicts of Interest: not reported
Compliance: EPA and DHA levels from RBCs
Depressed mood (continuous): Analysis conducted on HDRS (21-item) scores at 8
weeks, ITT data provided by authors
Adverse events: Intervention group: 1 GI, 1 psychological; comparator group = 1 other
physical
Failure to complete: Intervention group = 2 (1 non-compliance, 1 lost to follow-up),
comparator group = 4 (1 non-compliance, 3 lost to follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number sheet generated in Excel
(correspondence with author)
Allocation concealment (selection bias) Low risk Packages were consecutively numbered ac-
cording to randomisation schedule by an
independent nutritionist (correspondence
with author)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Orange flavour was added to the capsules,
which were identical to blind the partici-
pants (P.268). However there was no assess-
ment to check concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk HDRS - unclear whether assessors were
blind to treatment allocation
Blinding of outcome assessment (Adverse
Events)
Unclear risk AEs - unclear whether participants were
blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk HDRS - ITT analysis obtained from au-
thor
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Su 2003 (Continued)
Incomplete outcome data (Adverse Events) Low risk All AEs reported
Selective reporting (reporting bias) Low risk All outcomes reported (correspondence
with author)
Other bias Low risk Study appeared to be free from other
sources of bias
BDI: Beck depression inventory
CES-D-K: Center for Epidemiological Studies depression scale Korean version
CGI: clinical global impression
CHD: coronary heart disease
DHA: docosahexaenoic acid
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition
EPA: eicosapentaenoic acid
GAF: global assessment of functioning
GDS: geriatric depression scale
GI: gastrointestinal
HSCL: Hopkins symptom checklist depression scale
ITT: intention-to-treat
HDRS: Hamilton depression rating scale
LOCF: last observation carried forward
MADRS: Montgomery-Asberg depression rating scale
MAOI: monoamine oxidase inhibitor
MDD: major depressive disorder
MDE: major depressive episode
MMSE: mini mental state examination
OCD: Obsessive-compulsive disorder
PGWB: psychological general well being
RBC: red blood cell
QLESQ: quality of life enjoyment and satisfaction questionnaire
SCID: structured clinical interview (depression)
SD: standard deviation
SSRI: selective serotonin reuptake inhibiting
UPDRS: Unified Parkinson disease rating scale
WBS: well-being scale
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Clayton 2009 Study record indicates study withdrawn prior to enrolment
Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2006-004949-41-IT
Methods Randomised, placebo-controlled, double-blind study
Participants Adults aged between 18 and 65, affected by MDD or recurrent depressive disorder according to DSM-IV-TR and
the HDRS
Interventions Intervention: fish oil 30 EPA/DHA plus SSRI
Comparator: placebo, plus SSRI
Outcomes Primary: Improvement in HDRS and CGI score
Notes
Kwak 2013
Methods 12-week, parallel-group, double-blind addition of choline alfoscerate or E-EPA to ongoing antidepressant therapy
Participants Adults aged over 60 years with depression
Interventions Intervention: E-EPA 2 g/d plus usual treatment
Comparator: Choline alfoscerate 800 mg/d plus usual treatment
Outcomes Executive function: Controlled OralWord Association Test; Korean Stroop Color-Word Test; Trail Making Test part
B
Depressive symptoms: Korean Geriatric depression scale (K-GDS); Quick Inventory of Depressive Symptomology-
Self Report (QIDSSR)
Notes Unsure if an RCT and unsure of MDD diagnosis - no correspondence from author
Lima 2006
Methods Randomised controlled trial
Participants Adults age 18 - 60 years with major depressive episode, according to DSM-IV criteria
Interventions Intervention: Fluoxetine (oral) 20 mg/day plus omega-3 (oral) 900 mg/day
Comparator: Fluoxetine (oral) 20 mg/day plus placebo
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Lima 2006 (Continued)
Outcomes Primary:
1. Response to differential treatment at 2, 4 and 6 weeks
2. Magnitude of the response at 2, 4 and 6 weeks
3. Biochemical analyses on blood samples at 0 and 6 weeks:
3.1. Neurotransmitters in plasma
3.2. Isolation of lymphocytes
3.3. Neurotransmitters in lymphocytes
3.4. Detection of tryptophan hydroxylase
3.5. Folate levels
3.6. Homocysteine levels
3.7. Vitamin B12 levels
4. In participants who took omega-3, brain-derived neurotrophic factor (BDNF) in serum and lymphocytes will be
determined
Secondary: Correlation between response to antidepressant and biochemical measurements
Notes
Murck 2004
Methods Multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
Participants Adults aged 18 - 75 with:
1. Score of ≥ 16 on the HDRS
2.Treatment for ≥ 8 weeks with 1 or more standard antidepressants, at stable dose for ≥ 3 weeks
3. Currently receiving at least the minimum therapeutic dose of 1 or more standard antidepressants, as defined in
the BNF
4. Diagnosis of major depressive disorder (DSM-IV)
Interventions Intervention: 1 g/d ethyl EPA
Comparator: Placebo
Outcomes Not reported
Notes
Naqvi 2008
Methods Allocation: Randomised
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adolescents between the ages of 13 and 21 currently under standard care treatment at the Child Division of the
Department of Psychiatry at Cedars-Sinai Medical Center
Diagnosed with MDD using the DSM-IV diagnostic criteria
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Naqvi 2008 (Continued)
Interventions Intervention: Cognitive behaviour therapy in combination with omega-3 fatty acid supplements
Comparator: Cognitive behaviour therapy in combination with placebo
Outcomes Primary: CDI, HDRS, both 8 times for an average of 8 weeks
Notes
NCT00816322
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy study
Intervention Model: Parallel Assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged between 18 and 65 years meeting DSM-IV criteria for MDD
Interventions Intervention: Omega-3 fatty acids
Comparator: placebo
Outcomes Primary: HDRS
Secondary: BDI; adverse effects; recurrence rate
Notes
Rees 2005
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy study
Intervention model: Parallel assignment
Masking: Double-blind
Primary Purpose: treatment
2 studies reported in abstract, depending on therapy at time of entry: Adjunctive study and monotherapy study
Participants Adults aged: 21 - 65 years
Inclusion Criteria:
• Must meet DSM-IV criteria for non-psychotic MDD lasting at least 6 weeks or dysthymia
• Must be under the care of a mental health practitioner
• Must be able to give informed consent
• Must be able to attend the Black Dog Institute
Adjunctive study: Participants with a first or new episode of MDD
Monotherapy Study: participants who have MDD but are not currently on an antidepressant
Interventions Adjunctive study: Intervention: 6 g/d fish oil plus standard treatment; comparator: placebo plus standard treatment;
treatment received for 4 weeks
Monotherapy study: Intervention: Fish oil; comparator: placebo; treatment received for 6 weeks
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Rees 2005 (Continued)
Outcomes Primary: Change from pretreatment score on Depression Rating Scale at 6 weeks
Secondary: Weekly measure of depressive symptoms; Weekly measure of anxiety symptoms; Weekly measure of
functional status; Blood levels of n-3PUFAs pre- and post-treatment
Notes
Shinto 2005
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy study
Intervention Model: Parallel assignment
Masking: Double-blind (participant, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged between 18 and 85 years with:
Diagnosis of relapsing-remitting MS
Diagnosis of depressive disorder
Score between 11 and 30 on the MADRS
Score of 25 or greater on the MMSE
Interventions Intervention: Fish oil concentrate (triglyceride form) at a dose of 6 g/d (1.95 g EPA and 1.45 g DHA)
Comparator: Placebo oil
Outcomes Primary: MADRS
Secondary: Quality of life (SF-36)
Notes
Su 2005
Methods Allocation: Randomised
Endpoint classification: Efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged 18 - 65 years meeting DSM-IV criteria for MDD
Interventions Intervention: DHA/EPA (1.6 ~ 2.8 g/d (5 capsules))
Comparator: placebo (5 g/d (5 capsules))
Outcomes Primary: HDRS
Secondary: BDI; Adverse events
Notes
BDI: Beck depression inventory
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BNF: British National Formulary
CDI: Children’s depression inventory
CGI: Clinical global impression
DHA: docosahexaenoic acid
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition
EPA: eicosapentaenoic acid
HDRS: Hamilton depression rating scale
MADRS: Montgomery-Asberg Depression Rating Scale
MDD: major depressive disorder
MMSE: Mini-Mental State Examination
SSRI: selective serotonin reuptake inhibiting
Characteristics of ongoing studies [ordered by study ID]
Amminger 2013
Trial name or title Youth Depression Alleviation: A randomised controlled trial of omega-3 fatty acids (fish oil) for major
depressive disorder in young people (YoDA-F)
Methods Randomised placebo-controlled trial
Participants Participants aged 15 - 25 years, seeking help for psychological distress
A score between 11 and 20 on the QIDS-A17-C at first contact with the service AND after 1 week (plus 1 -
5 days if the client is unable to attend earlier) at the second assessment, or at 2 subsequent (weekly) follow-
up assessments
A diagnosis of MDD using the SCID-I/P
Interventions Intervention: Cognitive behavioural case management plus 4 capsules of marine fish oil per day (providing
approximately 840 mg of EPA, approximately 560 mg of DHA, and approximately 5 mg of Vitamin E)
Comparator: Cognitive behavioural case management plus 4 capsules of placebo per day (approximately 700
mg paraffin oil)
Outcomes Primary: Change in depressive symptoms as assessed by QIDS-A17-C between baseline and 12 weeks
Secondary: Change in depressive symptoms as assessed by QIDS-A17-C between baseline and 26 weeks,
Remission rate at 12 and 26 week follow-up, Changes to symptomology and psychosocial functioning assessed
across a range of domains assessed at baseline and weeks 4, 8, 12, and 26
Starting date February 2014
Contact information G Paul Amminger, Orygen Youth Health Research Centre
Notes ACTRN12613001352796
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Carney 2013
Trial name or title Omega-3 for depression and other cardiac risk factors - 2
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy Study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Adults aged 30 - 75 years with:
Documented coronary heart disease
Diagnosis of MDD based on structured interview
Interventions Intervention: 2 g/d EPA, plus 50 mg/d sertraline for 10 weeks
Comparator: 2 g/d corn oil, plus 50 mg/d sertraline for 10 weeks
Outcomes Primary: BDI-II
Secondary: HDRS (17-item); heart rate variability; interleukin-6
Measurements taken at baseline and 10 weeks
Starting date April 2014
Contact information Patricia Herzing, Washington University School of Medcine
Notes
Gabbay 2006
Trial name or title The role Of omega-3 fatty acids in adolescent depression
Methods Allocation: randomised
Endpoint classification: Efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adolescents aged between 12 and 19 meeting DSM-IV-TR criteria for MDD
MDD duration of at least 8 weeks and a severity score of at least 40 on the CDRS-R
Age at first onset MDD of at least 12 years
Interventions Intervention: n-3PUFAs: the initial dose will be 1.2 g/d. This will be increased gradually by 0.6 g/d per 2
weeks to a possible maximum daily dose of 3.6 g/d
Comparator: Corn oil; the dosage will correspond to the titration schedule of the omega-3 fatty acid experi-
mental treatment
Outcomes Primary: CDRS-R
Secondary: CGI
Starting date December 2005
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Gabbay 2006 (Continued)
Contact information Vilma Gabbay, Mount Sinai School of Medicine
Notes
Howe 2008
Trial name or title Omega-3 fatty acid supplementation for symptoms of depression in patients with cardiovascular disease
Methods Randomised controlled trial, parallel, blinded
Participants Adults aged between 18 - 75 years with:
(a) angiographically-documented coronary artery disease, defined as > 50% stenosis in an epicardial coronary
artery on selective coronary angiography
(b) comorbid depression as determined by a score of ≥ 16 on the CES-D scale
Interventions Intervention: 4 x 1 g/d capsules of EPA-rich fish oil for 6 months (each capsule will contain 500 mg EPA and
25 mg DHA)
Comparator: 4 x 1 g/d capsules of soybean/corn oil for 6 months (each capsule will contain 500 mg soybean
oil and 500 mg corn oil)
Outcomes Primary: HDRS
Secondary: SF-36; SAQ; flow mediated dilatation in the brachial artery; Changes in cerebral blood flow
measured by transcranial Doppler ultrasound
Measurements taken at baseline, 3 months (HDRS, SF-36, SAQ) and 6 months
Starting date November 2008
Contact information Professor Peter Howe, Nutritional Physiology Research Centre, University of South Australia
Notes
Jiang 2014
Trial name or title Omega 3 for treatment of depression in patients with heart failure (OCEAN)
Methods Allocation: Randomized
Endpoint classification: Safety/efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged 21 years and over with:
Diagnosis of MDD determined by the DSM-IV-TR criteria with a HDRS score ≥ 18
New York Heart Association Class ≥ II
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Jiang 2014 (Continued)
Interventions Arm 1: 400/200 EPA/DHA fish oil 2 g/d
Arm 2: Almost pure EPA 2 g/d
Arm 3: Matched placebo corn oil capsules
Treatment given for 12 weeks
Outcomes Primary: Change in HDRS score; change in RBC/Plasma EPA
Starting date May 2014
Contact information Wei Jiang, Duke University
Notes
Kamath 2013
Trial name or title Omega 3 FA supplements as augmentation in the treatment of depression
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged 18 years and over with:
A diagnosis of depression
Cardiovascular disease, diabetes or cancer
Interventions Intervention: Desvenlafaxine (50 mg/d) and omega 3 FA supplement (range 2.4 g/d - 4.8 g/d) over a 12-
week period
Comparator: Desvenlafaxine (50 mg/day) and placebo (for omega 3 FA supplement) over a 12-week period
Outcomes Primary: HADS
Secondary: MADRS; SF-12; visual analogue scale for energy; visual analogue scale for pain; LSEQ
Starting date February 2013
Contact information Jayesh Kamath, University of Connecticut Health Center
Notes
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Khalili 2014
Trial name or title Comparing efficacy of omega-3 and placebo in reducing Beck Depression Score in HIV/AIDS patients
Methods Randomised, double-blind clinical trial
Participants HIV-positive patients aged between 18 - 65 years old, receiving antiretroviral therapy for at least 1 year, CD4
count ≥ 350 and Beck Depression Score ≥16
Interventions Intervention: Soft gelatin cap of omega-3 (Cap 1000 mg, Zahravi Pharmaceutical Company, Tabriz, Iran), 1
cap orally twice daily, for 8 weeks
Comparator: Soft gelatin cap of placebo (cap 1000 mg, Zahravi Pharmaceutical Company, Tabriz, Iran), 1
cap orally twice daily, for 8 weeks
Outcomes Primary: BDI at baseline, week 4 and 8
Starting date October 2014
Contact information Hossein Khalili, Tehran University of Medical Sciences
Notes
Lanctôt 2009
Trial name or title Treating depression in coronary artery disease with omega-3 fatty acids
Methods Allocation: Randomised
Endpoint classification: Efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged 45 - 80 years with:
DSM-IV criteria for MDE or minor depression as assessed by the SCID-I depression module
Stable coronary artery disease (based on no hospitalisation for cardiac events for at least 7 weeks prior)
Angiographic documentation of presence and extent of coronary artery disease
Interventions Intervention: 3 capsules (3 x 1 g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty
acids (1.2 g EPA, 0.6 g DHA, 0.1 g other omega-3 fatty acids)
Comparator: 3 capsules (3 x 1 g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3
fatty acids with negligible EPA and DHA
Outcomes Primary: HDRS
Secondary: SF-36; BDI-II
Measurements at baseline, 4, 8 and 12 weeks
Starting date June 2010
Contact information Abby Li, Sunnybrook Health Sciences Centre
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Lanctôt 2009 (Continued)
Notes
Mostafavi 2014
Trial name or title Evaluating effects of omega-3 supplementation on weight and depression among overweight or obese women
with depression compared to placebo
Methods Randomised, double-blind, 12-week, placebo-controlled study
Participants Females aged 18 to 50 years with:
BMI > 25
Mild (minor) depression based on semi-structured diagnostic interview by a psychiatrist
Interventions Intervention: 3 gm omega-3 (2 capsules with each meal) for 12 weeks
Comparator: 2 placebo capsules with each meal for 12 weeks
Outcomes Primary: weight, BMI and HDRS at baseline and weeks 2, 4, 8 and 12
Secondary: Central fat mass at baseline and weeks 2, 4, 8, and 12
Starting date June 2014
Contact information Seyed-Ali Mostafavi, Psychiatric Research Center, Roozbeh Hospital, South Kargar St., Tehran, Iran
Notes
Nakano 2014
Trial name or title Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind,
randomised controlled trial
Methods Randomised, double-blind, parallel-groups, controlled trial
Participants Adults aged between 20 - 65 years old with a MDE, where: the person did not receive any antidepressant
drugs for major depression, has a HDRS (17-item) score, the major depressive episode is the focus of the
treatment and the treating physician has judged escitalopram to be the appropriate first-line drug, and is a
native Japanese speaker
Interventions Intervention: Omega-3 polyunsaturated fatty acid
Comparator: placebo
Outcomes Primary: HDRS, at 12 weeks
Secondary: MADRS; BDI; QIDS-J; CGI-S; RS-14; Serum BDNF, proBDNF, MMP-9, fatty acid level;
Plasma IL-6
Starting date April 2014
Contact information Wakako Nakano, University of Occupational and Environmental Health Department of Psychiatry
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Nakano 2014 (Continued)
Notes
Parker 2006a
Trial name or title A study of omega-3 as an augmentor of antidepressant treatment for major depression
Methods Allocation: randomised
Endpoint classification: Safety/efficacy study
Intervention model: Parallel assignment
Masking: Double-blind
Primary purpose: treatment
Participants Adults aged between 18 and 65 years presenting with a first or new episode of DSM-IV non-psychotic MDD
warranting treatment with antidepressant mediation
Interventions Intervention: Omega-3 (fish oil)
Comparator: placebo (paraffin oil)
Outcomes Primary: Change from pretreatment score on Depression Rating scale at 4 weeks
Secondary: Daily mood rating; weekly measure of depression; weekly measure of anxiety; weekly measure of
functional status
Starting date February 2006
Contact information Catherine Owen, University of New South Wales
Notes
Parletta 2014
Trial name or title Effects of a Mediterranean-style diet and fish oil supplements on mood and health
Methods Randomised controlled trial (participants non-blinded)
Participants Adults aged 18 - 65 with:
Poor diet indicated by poor diet quality score
Self-reported depressive symptoms
Interventions Intervention: Fortnightly food hampers (containing extra virgin olive oil, seasonal fruit/vegetables - approx 2
fruits and 5 vegetables - and nuts)
2-hour fortnightly cooking workshops (using selected simple tasty affordable recipes based on Mediterranean
diet principles) for 3 months
Fish oil capsules (2/day containing a total of 1 g DHA+EPA) for 6 months, commencing at baseline
2-hour group nutrition education session following baseline assessments
Comparator: Fortnightly social groups for 3 months
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Parletta 2014 (Continued)
Outcomes Primary: DASS 21; Apolipoprotein B/A1 ratio in serum; AQoL-8d Quality of life questionnaire
Secondary: Sodium/potassium ratio in urine; blood pressure using an automatic sphygmomanometer, seated
after 5 minutes rest; 20-item PANAS; 14-item Mediterranean diet questionnaire; SDQ; 3-day food diaries to
measure dietary intake at food group level; erythrocyte fatty acid analysis in red blood cells; fasting glucose and
insulin in serum; carotenoids in plasma; inflammatory markers IL1b, IL6, IL8, IL10, TNF, IL18, MIC-1 and
oxidative stress markers reduced glutathione and oxidised glutathione - all in serum; anthropometric measures
(weight, height, waist and hip circumference) using ISAK protocols as per the International Standards for
Anthropometric Assesment protocols
All outcomes measured at baseline, 3 months, 6 months
Starting date April 2014
Contact information Natalie Parletta, School of Population Health, University of South Australia
Notes
Piperoglou 2014
Trial name or title Adjunctive natural lowdose docosahexaenoic acid (DHA) omega-3 in a 16week randomdouble-blind placebo
controlled (RDBPC) cross-over withdrawal study in a group of chronic, psychiatric out-patients with anxiety
and mood disorders
Methods Randomised controlled, double-blind, cross-over trial
Following the open-label phase (first 4 weeks of the study) there will be 2 double-blind cross-over phases,
each of 8 weeks duration, where the participant will first take DHA omega-3 then look-alike placebo capsule
containing safflower oil, or placebo then DHA omega-3. In the final 4 weeks phase all participants receive
DHA omega-3
Participants Adults aged 20 - 70 who are:
1. Outpatients with chronic anxiety and/or depressive symptoms
2. Patients currently taking DHA (NeuroSpark) capsules for at least 3 months prior to study entry
Interventions Intervention: Natural low-dose docosahexaenoic acid (DHA) omega-3 (NeuroSpark) 130 - 390 mg per day
in addition to standard psychiatric treatments
Comparator: safflower oil capsules
Treatment given for 16 weeks
Outcomes Primary: HAM-A, HDRS, LSEQ, Fatigue questionnaire
Secondary: Change from baseline in cognitive function; levels of metabolites of Arachidonic acid (AA);
cytokines (e.g. TNF-alpha and others), inflammatory markers (CRP), RBC membrane PUFA analyses to
measure PUFA levels
Measurements taken at weeks 0, 4, 12, 20 and 24 (various measures at each time point)
Starting date May 2014
Contact information Michael Piperoglou, University of Melbourne
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Piperoglou 2014 (Continued)
Notes
Smith 2010
Trial name or title An 8-week randomised, double-blind, placebo controlled trial investigating the role of adjunctive bioactive
lipids specifically; docosahexaenoic acid (DHA) versus eicosapentaenoic acid (EPA) in Major Depressive
Disorder - with a 6 week open label extension of DHA in patients aged 18-65 years
Methods 8 week randomised, double-blind, placebo-controlled trial
Participants Adults aged between 18 - 65 years diagnosed with a MDE
Interventions Arm 1: DHA (2 tablets (260 mg/day))
Arm 2: EPA (2 tablets or 360 mg/day)
Arm 3: Sunflower oil (2 tablets or 2000 mg/day)
In addition and where possible patient’s background antidepressant medication will remain as a fixed dose
for the 8 week study period
Outcomes Primary: HDRS, change from baseline at 8 weeks
Secondary: BDNF levels, change from baseline at 8 weeks
Starting date October 2010
Contact information Deirdre Smith, The Professorial Research Unit, University of Melbourne
Notes
Tayama 2014
Trial name or title Omega-3 polyunsaturated fatty acids and psychological interventions for workers with mild to moderate
depression: a randomised controlled trial
Methods Parallel, randomised, double-blind, placebo-controlled trial
Participants Japanese workers aged between 20 - 65 years
Interventions Intervention: Psychological interventions + n-3PUFAs
Comparator: Psychological interventions
Outcomes Primary: BDI-II
Secondary: Kessler K6, CES-D
Starting date September 2014
Contact information Jun Tayama, Nagasaki University
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Tayama 2014 (Continued)
Notes
Yao 2005
Trial name or title Decreasing risk of coronary artery disease in schizophrenia by omega-3 fatty acid supplementation (CAD)
Methods Allocation: Randomised
Endpoint classification: Efficacy study
Intervention model: Parallel assignment
Masking: Double-blind (participant, caregiver, investigator, outcomes assessor)
Primary Purpose: treatment
Participants Adults aged 18 or over meeting:
DSM-IV criteria for schizophrenia (or schizoaffective disorder), major depression, or bipolar (depressed phase)
disorder who are treated with antipsychotic, antidepressant or antimanic drugs and a lipid-lowering drug
(statin) for 2 months or longer
Interventions Intervention: EPA (2 g in 4 x 500 mg soft gels daily) + antipsychotic drug (doctor’s choice) treatment for
baseline, 1 month, 2 months and 4 months duration
Comparator: Placebo (soy bean oil, 2 g in 4 x 500 mg soft gels daily) + antipsychotic drug (doctor’s choice)
treatment for baseline, 1 month, 2 months and 4 months duration
Outcomes Primary: To assess whether EPA supplementation can lead to improvement in further reducing CAD risk
profile
Secondary: To test whether EPA supplementation can simultaneously improve the psychiatric status of patients
with schizophrenia
Starting date September 2005
Contact information Jeffrey Yao, University of Pittsburgh and VA Pittsburgh Healthcare System
Notes
BDI: Beck depression inventory
BDNF: Brain-derived neurotropic factor
CAD: coronary artery disease
CES-D: Center for Epidemiologic Studies - Depression
CGI: Clinical global impression
DASS: Depression anxiety stress scale
CDRS-R: children’s depression rating scale - revised
DHA: docosahexaenoic acid
DSM-IV: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition
EPA: eicosapentaenoic acid
HADS: Hospital anxiety and depression scale
HAM-A: Hamilton Anxiety Scale
HDRS: Hamilton depression rating scale
LSEQ: Leeds sleep evaluation questionnaire
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MDD: major depressive disorder
MDE: major depressive episode
PANAS: Positive And Negative Affect Scale
QIDS-A17-C: Quick inventory for depressive symptomatology - adolescent version
SAQ: Seattle Angina Questionnaire
SCID-IP: Structured Clinical Interview for DSM-IV Axis I Disorders, patient version
SDQ: Simple dietary questionnaire
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D A T A A N D A N A L Y S E S
Comparison 1. n-3PUFAs vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depressive symptomology
(continuous)
25 1373 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.52, -0.12]
2 Adverse events 19 1207 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.95, 1.62]
3 Depressive symptomology
(dichotomous - remission)
6 426 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.87, 2.20]
4 Depressive symptomology
(dichotomous - response)
15 611 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.95, 2.04]
5 Quality of life 9 383 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.99, 0.06]
6 Failure to complete 21 1344 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.62, 1.14]
Comparison 2. n-3PUFAs vs antidepressant
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depressive symptomology
(continuous)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Depressive symptomology
(dichotomous - response)
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3 Failure to complete 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 3. Subgroup analyses - n-3PUFAs vs placebo - analyses based on comorbidities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depressive symptomology
(continuous)
25 1373 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.52, -0.12]
1.1 Individuals with
comorbidites
5 229 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-1.28, -0.02]
1.2 Individuals with/without
comorbidities (mixed)
17 1040 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.30, 0.05]
1.3 Individuals without
comorbidities
3 104 Std. Mean Difference (IV, Random, 95% CI) -0.99 [-1.71, -0.27]
2 Adverse events 19 1207 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.98, 1.68]
2.1 Individuals with
comorbidities
3 201 Odds Ratio (M-H, Random, 95% CI) 2.66 [0.22, 31.93]
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2.2 Individuals with/without
comorbidities (mixed)
14 937 Odds Ratio (M-H, Random, 95% CI) 1.40 [1.04, 1.89]
2.3 Individuals without
comorbidities
2 69 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.19, 3.50]
Comparison 4. Subgroup analyses: n-3PUFAs vs placebo - analyses based on adjunctive therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depressive symptomology
(continuous)
25 1373 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.52, -0.12]
1.1 Individuals receiving
adjunctive therapy
12 356 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.42, 0.01]
1.2 Individuals receiving/not
receiving adjunctive therapy
(mixed)
7 709 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.82, -0.04]
1.3 Individuals not receiving
adjunctive therapy
6 308 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.86, 0.21]
2 Adverse events 19 1207 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.95, 1.62]
2.1 Individuals receiving
adjunctive therapy
9 304 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.56, 1.70]
2.2 Individuals receiving/not
receiving adjunctive therapy
6 644 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.81, 1.65]
2.3 Individuals not receiving
adjunctive therapy
4 259 Odds Ratio (M-H, Random, 95% CI) 2.04 [1.03, 4.03]
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Analysis 1.1. Comparison 1 n-3PUFAs vs placebo, Outcome 1 Depressive symptomology (continuous).
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 1 Depressive symptomology (continuous)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bot 2010 12 11.6 (9.1) 12 14 (6.9) 3.6 % -0.29 [ -1.09, 0.52 ]
Carney 2009 62 9.7 (6.5) 60 9.1 (6.7) 6.8 % 0.09 [ -0.26, 0.45 ]
Coryell (1g/d) 3 17 (8.7) 2 16 (8.3) 1.1 % 0.08 [ -1.71, 1.88 ]
Coryell (2g/d) 4 20 (8.5) 2 16 (8.3) 1.1 % 0.38 [ -1.36, 2.11 ]
Da Silva (AD) 2005 8 13.8 (2.7) 8 20.5 (6.8) 2.4 % -1.22 [ -2.32, -0.13 ]
Da Silva (nAD) 2005 6 12.5 (4.9) 7 20.9 (4.3) 1.7 % -1.71 [ -3.05, -0.36 ]
Gertsik 2012 18 10 (7.3) 22 15.3 (8.9) 4.5 % -0.63 [ -1.27, 0.01 ]
Gharekhani 2014 27 14.56 (6.8) 27 20.4 (6.69) 5.1 % -0.85 [ -1.41, -0.29 ]
Gonzalez 2011 4 6.8 (5.6) 5 8.6 (5.2) 1.8 % -0.30 [ -1.63, 1.03 ]
Grenyer 2007 40 10.9 (7.2) 43 10.6 (5.7) 6.1 % 0.05 [ -0.38, 0.48 ]
Jazayeri (v placebo) 2008 20 15.7 (8.6) 20 19.3 (8.2) 4.6 % -0.42 [ -1.05, 0.21 ]
Lesp rance 2011 218 17.9 (8.9) 214 18.8 (8.9) 8.0 % -0.10 [ -0.29, 0.09 ]
Lucas 2009 13 14.2 (5.6) 16 9.6 (5.2) 3.8 % 0.83 [ 0.06, 1.60 ]
Marangell 2003 18 15.4 (8.3) 17 22.7 (9.2) 4.2 % -0.82 [ -1.51, -0.12 ]
Mischoulon (DHA) 2015 58 10.54 (6.9) 29 9.71 (6.4) 6.0 % 0.12 [ -0.32, 0.57 ]
Mischoulon (EPA) 2015 60 8.96 (6.9) 30 9.71 (6.4) 6.1 % -0.11 [ -0.55, 0.33 ]
Mischoulon 2009 17 14.2 (8.7) 24 18.1 (6.8) 4.6 % -0.50 [ -1.13, 0.13 ]
Nemets 2002 10 11.6 (6.2) 10 21.4 (9.4) 2.8 % -1.18 [ -2.15, -0.21 ]
Park 2015 12 9.92 (5.43) 13 10.31 (7.18) 3.7 % -0.06 [ -0.84, 0.73 ]
Peet (1g/d) 2002 17 10 (6.9) 5 14.2 (6.4) 2.6 % -0.59 [ -1.61, 0.42 ]
Peet (2g/d) 2002 18 13.8 (6.9) 6 14.2 (6.4) 3.0 % -0.06 [ -0.98, 0.87 ]
Peet (4g/d) 2002 17 12.3 (6.9) 6 14.2 (6.4) 3.0 % -0.27 [ -1.20, 0.66 ]
Rondanelli 2010 22 12.6 (4.3) 24 15.9 (5.4) 4.9 % -0.66 [ -1.26, -0.07 ]
Silvers 2005 29 7 (5.7) 30 5.5 (6.2) 5.5 % 0.25 [ -0.26, 0.76 ]
Su 2003 14 9.1 (3.6) 14 15.4 (3) 3.1 % -1.85 [ -2.75, -0.94 ]
-4 -2 0 2 4
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(. . . Continued)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 727 646 100.0 % -0.32 [ -0.52, -0.12 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 56.79, df = 24 (P = 0.00018); I2 =58%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours n-3PUFAs Favours placebo
Analysis 1.2. Comparison 1 n-3PUFAs vs placebo, Outcome 2 Adverse events.
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 2 Adverse events
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bot 2010 1/13 0/12 0.7 % 3.00 [ 0.11, 80.95 ]
Carney 2009 39/62 44/60 12.0 % 0.62 [ 0.29, 1.33 ]
Coryell (1g/d) 0/3 0/2 Not estimable
Coryell (2g/d) 0/4 0/2 Not estimable
Gertsik 2012 6/20 4/22 3.4 % 1.93 [ 0.45, 8.18 ]
Gharekhani 2014 8/27 0/27 0.8 % 23.97 [ 1.31, 440.35 ]
Lesp rance 2011 161/218 148/214 40.7 % 1.26 [ 0.83, 1.91 ]
Lucas 2009 4/13 3/16 2.4 % 1.93 [ 0.34, 10.77 ]
Mischoulon (DHA) 2015 40/56 16/30 8.4 % 2.19 [ 0.87, 5.50 ]
Mischoulon (EPA) 2015 39/60 17/30 8.9 % 1.42 [ 0.58, 3.48 ]
Mischoulon 2009 2/17 5/24 2.3 % 0.51 [ 0.09, 2.99 ]
Nemets 2002 0/10 0/10 Not estimable
0.002 0.1 1 10 500
Favours n-3PUFAs Favours placebo
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Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Park 2015 3/18 1/17 1.3 % 3.20 [ 0.30, 34.24 ]
Peet (1g/d) 2002 9/17 3/5 1.7 % 0.75 [ 0.10, 5.69 ]
Peet (2g/d) 2002 13/18 4/6 1.8 % 1.30 [ 0.18, 9.47 ]
Peet (4g/d) 2002 10/17 3/6 2.0 % 1.43 [ 0.22, 9.26 ]
Rondanelli 2010 6/22 6/24 4.1 % 1.13 [ 0.30, 4.20 ]
Silvers 2005 14/40 14/37 8.3 % 0.88 [ 0.35, 2.24 ]
Su 2003 2/14 1/14 1.1 % 2.17 [ 0.17, 27.08 ]
Total (95% CI) 649 558 100.0 % 1.24 [ 0.95, 1.62 ]
Total events: 357 (n-3PUFAs), 269 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.22, df = 15 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours n-3PUFAs Favours placebo
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Analysis 1.3. Comparison 1 n-3PUFAs vs placebo, Outcome 3 Depressive symptomology (dichotomous -
remission).
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 3 Depressive symptomology (dichotomous - remission)
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carney 2009 17/62 15/60 28.6 % 1.13 [ 0.51, 2.54 ]
Gertsik 2012 8/18 4/22 10.1 % 3.60 [ 0.86, 15.01 ]
Mischoulon (DHA) 2015 16/58 9/29 20.5 % 0.85 [ 0.32, 2.24 ]
Mischoulon (EPA) 2015 20/60 10/30 22.3 % 1.00 [ 0.39, 2.53 ]
Mischoulon 2009 4/17 3/24 7.6 % 2.15 [ 0.41, 11.20 ]
Rondanelli 2010 9/22 4/24 10.9 % 3.46 [ 0.88, 13.61 ]
Total (95% CI) 237 189 100.0 % 1.38 [ 0.87, 2.20 ]
Total events: 74 (n-3PUFAs), 45 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.40, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours placebo Favours n-3PUFAs
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Analysis 1.4. Comparison 1 n-3PUFAs vs placebo, Outcome 4 Depressive symptomology (dichotomous -
response).
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 4 Depressive symptomology (dichotomous - response)
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carney 2009 28/62 27/60 23.0 % 1.01 [ 0.49, 2.05 ]
Coryell (1g/d) 1/3 0/2 1.1 % 3.00 [ 0.08, 115.34 ]
Coryell (2g/d) 0/4 0/2 Not estimable
Gertsik 2012 3/18 3/22 4.7 % 1.27 [ 0.22, 7.20 ]
Gonzalez 2011 4/5 4/5 1.5 % 1.00 [ 0.05, 22.18 ]
Jazayeri (v placebo) 2008 13/20 8/20 8.3 % 2.79 [ 0.77, 10.04 ]
Marangell 2003 5/18 4/17 6.0 % 1.25 [ 0.27, 5.73 ]
Mischoulon (DHA) 2015 26/58 14/29 15.9 % 0.87 [ 0.36, 2.13 ]
Mischoulon (EPA) 2015 26/60 14/30 16.3 % 0.87 [ 0.36, 2.11 ]
Mischoulon 2009 6/17 4/24 6.5 % 2.73 [ 0.63, 11.78 ]
Nemets 2002 6/10 1/10 2.5 % 13.50 [ 1.20, 152.21 ]
Peet (1g/d) 2002 9/17 2/5 3.5 % 1.69 [ 0.22, 12.81 ]
Peet (2g/d) 2002 2/18 1/6 2.1 % 0.63 [ 0.05, 8.43 ]
Peet (4g/d) 2002 6/17 2/6 3.7 % 1.09 [ 0.15, 7.80 ]
Rondanelli 2010 10/22 2/24 5.0 % 9.17 [ 1.72, 48.85 ]
Total (95% CI) 349 262 100.0 % 1.39 [ 0.95, 2.04 ]
Total events: 145 (n-3PUFAs), 86 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 13.86, df = 13 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 n-3PUFAs vs placebo, Outcome 5 Quality of life.
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 5 Quality of life
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Da Silva (AD) 2005 8 2.5 (1.2) 8 3.9 (1.5) 9.1 % -0.97 [ -2.03, 0.08 ]
Da Silva (nAD) 2005 6 2.2 (1.2) 7 3.7 (0.8) 7.9 % -1.39 [ -2.66, -0.13 ]
Gharekhani 2014 25 -66.48 (14.14) 20 -54.8 (15.55) 12.0 % -0.78 [ -1.39, -0.16 ]
Lucas 2009 13 3 (1.1) 16 2.1 (1.1) 11.0 % 0.80 [ 0.03, 1.56 ]
Marangell 2003 18 -64.3 (9.7) 17 -58.6 (10.1) 11.6 % -0.56 [ -1.24, 0.11 ]
Mischoulon (DHA) 2015 58 2.87 (1) 28 2.59 (1.1) 13.0 % 0.27 [ -0.18, 0.72 ]
Mischoulon (EPA) 2015 60 2.74 (1) 28 2.59 (1.1) 13.0 % 0.14 [ -0.31, 0.59 ]
Park 2015 12 2.42 (0.67) 13 2.77 (1.01) 10.8 % -0.39 [ -1.19, 0.40 ]
Rondanelli 2010 22 -69.8 (11) 24 -44.6 (15.6) 11.5 % -1.82 [ -2.52, -1.12 ]
Total (95% CI) 222 161 100.0 % -0.47 [ -0.99, 0.06 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 43.35, df = 8 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 n-3PUFAs vs placebo, Outcome 6 Failure to complete.
Review: Omega-3 fatty acids for depression in adults
Comparison: 1 n-3PUFAs vs placebo
Outcome: 6 Failure to complete
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bot 2010 2/13 0/12 0.9 % 5.43 [ 0.24, 125.59 ]
Carney 2009 3/62 4/60 3.8 % 0.71 [ 0.15, 3.32 ]
Coryell (1g/d) 0/3 0/2 Not estimable
Coryell (2g/d) 0/4 0/2 Not estimable
Gertsik 2012 3/20 7/22 3.9 % 0.38 [ 0.08, 1.73 ]
Gharekhani 2014 2/27 7/27 3.2 % 0.23 [ 0.04, 1.22 ]
Grenyer 2007 8/40 15/43 9.1 % 0.47 [ 0.17, 1.26 ]
Jazayeri (v placebo) 2008 4/20 4/20 3.8 % 1.00 [ 0.21, 4.71 ]
Lesp rance 2011 30/218 27/214 29.0 % 1.11 [ 0.63, 1.93 ]
Lucas 2009 1/13 2/16 1.4 % 0.58 [ 0.05, 7.26 ]
Mischoulon (DHA) 2015 15/65 6/29 7.9 % 1.15 [ 0.40, 3.35 ]
Mischoulon (EPA) 2015 15/66 6/30 8.0 % 1.18 [ 0.41, 3.41 ]
Mischoulon 2009 6/17 11/24 5.5 % 0.64 [ 0.18, 2.31 ]
Nemets 2002 0/10 1/10 0.8 % 0.30 [ 0.01, 8.33 ]
Park 2015 6/18 5/17 4.4 % 1.20 [ 0.29, 5.02 ]
Peet (1g/d) 2002 2/17 1/5 1.3 % 0.53 [ 0.04, 7.49 ]
Peet (2g/d) 2002 2/18 2/6 1.8 % 0.25 [ 0.03, 2.36 ]
Peet (4g/d) 2002 10/17 1/6 1.6 % 7.14 [ 0.68, 75.22 ]
Rondanelli 2010 0/22 0/24 Not estimable
Silvers 2005 16/40 16/37 11.0 % 0.88 [ 0.35, 2.17 ]
Su 2003 2/14 4/14 2.5 % 0.42 [ 0.06, 2.77 ]
Total (95% CI) 724 620 100.0 % 0.84 [ 0.62, 1.14 ]
Total events: 127 (n-3PUFAs), 119 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.60, df = 17 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours n-3PUFAs Favours placebo
117Omega-3 fatty acids for depression in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 n-3PUFAs vs antidepressant, Outcome 1 Depressive symptomology
(continuous).
Review: Omega-3 fatty acids for depression in adults
Comparison: 2 n-3PUFAs vs antidepressant
Outcome: 1 Depressive symptomology (continuous)
Study or subgroup n-3PUFAs antidepressants
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jazayeri (v AD) 2008 20 18.6 (8.5) 20 19.3 (8.2) -0.70 [ -5.88, 4.48 ]
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Analysis 2.2. Comparison 2 n-3PUFAs vs antidepressant, Outcome 2 Depressive symptomology
(dichotomous - response).
Review: Omega-3 fatty acids for depression in adults
Comparison: 2 n-3PUFAs vs antidepressant
Outcome: 2 Depressive symptomology (dichotomous - response)
Study or subgroup n-3PUFAs antidepressants Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jazayeri (v AD) 2008 9/20 8/20 1.23 [ 0.35, 4.31 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 9 (n-3PUFAs), 8 (antidepressants)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 n-3PUFAs vs antidepressant, Outcome 3 Failure to complete.
Review: Omega-3 fatty acids for depression in adults
Comparison: 2 n-3PUFAs vs antidepressant
Outcome: 3 Failure to complete
Study or subgroup n-3PUFAs antidepressants Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jazayeri (v AD) 2008 4/20 4/20 1.00 [ 0.21, 4.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (n-3PUFAs), 4 (antidepressants)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Subgroup analyses - n-3PUFAs vs placebo - analyses based on comorbidities,
Outcome 1 Depressive symptomology (continuous).
Review: Omega-3 fatty acids for depression in adults
Comparison: 3 Subgroup analyses - n-3PUFAs vs placebo - analyses based on comorbidities
Outcome: 1 Depressive symptomology (continuous)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Individuals with comorbidites
Bot 2010 12 11.6 (9.1) 12 14 (6.9) 3.6 % -0.29 [ -1.09, 0.52 ]
Carney 2009 62 9.7 (6.5) 60 9.1 (6.7) 6.8 % 0.09 [ -0.26, 0.45 ]
Da Silva (AD) 2005 8 13.8 (2.7) 8 20.5 (6.8) 2.4 % -1.22 [ -2.32, -0.13 ]
Da Silva (nAD) 2005 6 12.5 (4.9) 7 20.9 (4.3) 1.7 % -1.71 [ -3.05, -0.36 ]
Gharekhani 2014 27 14.56 (6.8) 27 20.4 (6.69) 5.1 % -0.85 [ -1.41, -0.29 ]
Subtotal (95% CI) 115 114 19.6 % -0.65 [ -1.28, -0.02 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 15.33, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 2.02 (P = 0.043)
2 Individuals with/without comorbidities (mixed)
Coryell (1g/d) 3 17 (8.7) 2 16 (8.3) 1.1 % 0.08 [ -1.71, 1.88 ]
Coryell (2g/d) 4 20 (8.5) 2 16 (8.3) 1.1 % 0.38 [ -1.36, 2.11 ]
Gertsik 2012 18 10 (7.3) 22 15.3 (8.9) 4.5 % -0.63 [ -1.27, 0.01 ]
Gonzalez 2011 4 6.8 (5.6) 5 8.6 (5.2) 1.8 % -0.30 [ -1.63, 1.03 ]
Grenyer 2007 40 10.9 (7.2) 43 10.6 (5.7) 6.1 % 0.05 [ -0.38, 0.48 ]
Jazayeri (v placebo) 2008 20 15.7 (8.6) 20 19.3 (8.2) 4.6 % -0.42 [ -1.05, 0.21 ]
Lesp rance 2011 218 17.9 (8.9) 214 18.8 (8.9) 8.0 % -0.10 [ -0.29, 0.09 ]
Lucas 2009 13 14.2 (5.6) 16 9.6 (5.2) 3.8 % 0.83 [ 0.06, 1.60 ]
Mischoulon (DHA) 2015 58 10.54 (6.9) 29 9.71 (6.4) 6.0 % 0.12 [ -0.32, 0.57 ]
Mischoulon (EPA) 2015 60 8.96 (6.9) 30 9.71 (6.4) 6.1 % -0.11 [ -0.55, 0.33 ]
Nemets 2002 10 11.6 (6.2) 10 21.4 (9.4) 2.8 % -1.18 [ -2.15, -0.21 ]
Park 2015 12 9.92 (5.43) 13 10.31 (7.18) 3.7 % -0.06 [ -0.84, 0.73 ]
Peet (1g/d) 2002 17 10 (7) 5 14.2 (6.4) 2.6 % -0.59 [ -1.60, 0.43 ]
Peet (2g/d) 2002 18 13.8 (7) 6 14.2 (6.4) 3.0 % -0.06 [ -0.98, 0.87 ]
Peet (4g/d) 2002 17 12.3 (7) 6 14.2 (6.4) 3.0 % -0.27 [ -1.20, 0.67 ]
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(. . . Continued)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rondanelli 2010 22 12.6 (4.3) 24 15.9 (5.4) 4.9 % -0.66 [ -1.26, -0.07 ]
Silvers 2005 29 7 (5.7) 30 5.5 (6.2) 5.5 % 0.25 [ -0.26, 0.76 ]
Subtotal (95% CI) 563 477 68.6 % -0.13 [ -0.30, 0.05 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 22.10, df = 16 (P = 0.14); I2 =28%
Test for overall effect: Z = 1.41 (P = 0.16)
3 Individuals without comorbidities
Marangell 2003 18 15.4 (8.3) 17 22.7 (9.2) 4.2 % -0.82 [ -1.51, -0.12 ]
Mischoulon 2009 17 14.2 (8.7) 24 18.1 (6.8) 4.6 % -0.50 [ -1.13, 0.13 ]
Su 2003 14 9.1 (3.6) 14 15.4 (3) 3.1 % -1.85 [ -2.75, -0.94 ]
Subtotal (95% CI) 49 55 11.9 % -0.99 [ -1.71, -0.27 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 5.78, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 2.69 (P = 0.0071)
Total (95% CI) 727 646 100.0 % -0.32 [ -0.52, -0.12 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 56.77, df = 24 (P = 0.00018); I2 =58%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 7.23, df = 2 (P = 0.03), I2 =72%
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Analysis 3.2. Comparison 3 Subgroup analyses - n-3PUFAs vs placebo - analyses based on comorbidities,
Outcome 2 Adverse events.
Review: Omega-3 fatty acids for depression in adults
Comparison: 3 Subgroup analyses - n-3PUFAs vs placebo - analyses based on comorbidities
Outcome: 2 Adverse events
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Individuals with comorbidities
Bot 2010 1/13 0/12 0.7 % 3.00 [ 0.11, 80.95 ]
Carney 2009 39/62 44/60 12.3 % 0.62 [ 0.29, 1.33 ]
Gharekhani 2014 8/27 0/27 0.9 % 23.97 [ 1.31, 440.35 ]
Subtotal (95% CI) 102 99 13.8 % 2.66 [ 0.22, 31.93 ]
Total events: 48 (n-3PUFAs), 44 (Placebo)
Heterogeneity: Tau2 = 3.39; Chi2 = 7.01, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Individuals with/without comorbidities (mixed)
Coryell (1g/d) 0/3 0/2 Not estimable
Coryell (2g/d) 0/4 0/2 Not estimable
Gertsik 2012 6/20 4/22 3.5 % 1.93 [ 0.45, 8.18 ]
Lesp rance 2011 161/218 148/214 41.4 % 1.26 [ 0.83, 1.91 ]
Lucas 2009 4/13 3/16 2.5 % 1.93 [ 0.34, 10.77 ]
Mischoulon (DHA) 2015 40/56 16/30 8.5 % 2.19 [ 0.87, 5.50 ]
Mischoulon (EPA) 2015 39/60 17/30 9.0 % 1.42 [ 0.58, 3.48 ]
Nemets 2002 0/10 0/10 Not estimable
Park 2015 3/18 1/17 1.3 % 3.20 [ 0.30, 34.24 ]
Peet (1g/d) 2002 9/17 3/5 1.8 % 0.75 [ 0.10, 5.69 ]
Peet (2g/d) 2002 13/18 4/6 1.8 % 1.30 [ 0.18, 9.47 ]
Peet (4g/d) 2002 10/17 3/6 2.1 % 1.43 [ 0.22, 9.26 ]
Rondanelli 2010 6/22 2/24 2.4 % 4.13 [ 0.73, 23.15 ]
Silvers 2005 14/40 14/37 8.4 % 0.88 [ 0.35, 2.24 ]
Subtotal (95% CI) 516 421 82.8 % 1.40 [ 1.04, 1.89 ]
Total events: 305 (n-3PUFAs), 215 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.75, df = 10 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.025)
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(. . . Continued)
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Individuals without comorbidities
Mischoulon 2009 2/17 5/24 2.3 % 0.51 [ 0.09, 2.99 ]
Su 2003 2/14 1/14 1.1 % 2.17 [ 0.17, 27.08 ]
Subtotal (95% CI) 31 38 3.4 % 0.82 [ 0.19, 3.50 ]
Total events: 4 (n-3PUFAs), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 649 558 100.0 % 1.28 [ 0.98, 1.68 ]
Total events: 357 (n-3PUFAs), 265 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.02, df = 15 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.071)
Test for subgroup differences: Chi2 = 0.77, df = 2 (P = 0.68), I2 =0.0%
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Analysis 4.1. Comparison 4 Subgroup analyses: n-3PUFAs vs placebo - analyses based on adjunctive therapy,
Outcome 1 Depressive symptomology (continuous).
Review: Omega-3 fatty acids for depression in adults
Comparison: 4 Subgroup analyses: n-3PUFAs vs placebo - analyses based on adjunctive therapy
Outcome: 1 Depressive symptomology (continuous)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Individuals receiving adjunctive therapy
Bot 2010 12 11.6 (9.1) 12 14 (6.9) 3.6 % -0.29 [ -1.09, 0.52 ]
Carney 2009 62 9.7 (6.5) 60 9.1 (6.7) 6.8 % 0.09 [ -0.26, 0.45 ]
Coryell (1g/d) 3 17 (8.7) 2 16 (8.3) 1.1 % 0.08 [ -1.71, 1.88 ]
Coryell (2g/d) 4 20 (8.5) 2 16 (8.3) 1.1 % 0.38 [ -1.36, 2.11 ]
Da Silva (AD) 2005 8 13.8 (2.7) 8 20.5 (6.8) 2.4 % -1.22 [ -2.32, -0.13 ]
Gertsik 2012 18 10 (7.3) 22 15.3 (8.9) 4.5 % -0.63 [ -1.27, 0.01 ]
Gonzalez 2011 4 6.8 (5.6) 5 8.6 (5.2) 1.8 % -0.30 [ -1.63, 1.03 ]
Jazayeri (v placebo) 2008 20 15.7 (8.6) 20 19.3 (8.2) 4.6 % -0.42 [ -1.05, 0.21 ]
Park 2015 12 9.92 (5.43) 13 10.31 (7.18) 3.7 % -0.06 [ -0.84, 0.73 ]
Peet (1g/d) 2002 17 10 (7) 5 14.2 (6.4) 2.6 % -0.59 [ -1.60, 0.43 ]
Peet (2g/d) 2002 18 13.8 (7) 6 14.2 (6.4) 3.0 % -0.06 [ -0.98, 0.87 ]
Peet (4g/d) 2002 17 12.3 (7) 6 14.2 (6.4) 3.0 % -0.27 [ -1.20, 0.67 ]
Subtotal (95% CI) 195 161 38.1 % -0.21 [ -0.42, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.53, df = 11 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Individuals receiving/not receiving adjunctive therapy (mixed)
Grenyer 2007 40 10.9 (7.2) 43 10.6 (5.7) 6.1 % 0.05 [ -0.38, 0.48 ]
Lesp rance 2011 218 17.9 (8.9) 214 18.8 (8.9) 8.0 % -0.10 [ -0.29, 0.09 ]
Mischoulon 2009 17 14.2 (8.7) 24 18.1 (6.8) 4.6 % -0.50 [ -1.13, 0.13 ]
Nemets 2002 10 11.6 (6.2) 10 21.4 (9.4) 2.8 % -1.18 [ -2.15, -0.21 ]
Rondanelli 2010 22 12.6 (4.3) 24 15.9 (5.4) 4.9 % -0.66 [ -1.26, -0.07 ]
Silvers 2005 29 7 (5.7) 30 5.5 (6.2) 5.5 % 0.25 [ -0.26, 0.76 ]
Su 2003 14 9.1 (3.6) 14 15.4 (3) 3.1 % -1.85 [ -2.75, -0.94 ]
Subtotal (95% CI) 350 359 35.0 % -0.43 [ -0.82, -0.04 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 25.00, df = 6 (P = 0.00034); I2 =76%
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(. . . Continued)
Study or subgroup n-3PUFAs Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.15 (P = 0.032)
3 Individuals not receiving adjunctive therapy
Da Silva (nAD) 2005 6 12.5 (4.9) 7 20.9 (4.3) 1.7 % -1.71 [ -3.05, -0.36 ]
Gharekhani 2014 27 14.56 (6.8) 27 20.4 (6.69) 5.1 % -0.85 [ -1.41, -0.29 ]
Lucas 2009 13 14.2 (5.6) 16 9.6 (5.2) 3.8 % 0.83 [ 0.06, 1.60 ]
Marangell 2003 18 15.4 (8.3) 17 22.7 (9.2) 4.2 % -0.82 [ -1.51, -0.12 ]
Mischoulon (DHA) 2015 58 10.54 (6.9) 29 9.71 (6.4) 6.0 % 0.12 [ -0.32, 0.57 ]
Mischoulon (EPA) 2015 60 8.96 (6.9) 30 9.71 (6.4) 6.1 % -0.11 [ -0.55, 0.33 ]
Subtotal (95% CI) 182 126 26.9 % -0.32 [ -0.86, 0.21 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 22.16, df = 5 (P = 0.00049); I2 =77%
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 727 646 100.0 % -0.32 [ -0.52, -0.12 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 56.77, df = 24 (P = 0.00018); I2 =58%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 1.01, df = 2 (P = 0.60), I2 =0.0%
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Analysis 4.2. Comparison 4 Subgroup analyses: n-3PUFAs vs placebo - analyses based on adjunctive therapy,
Outcome 2 Adverse events.
Review: Omega-3 fatty acids for depression in adults
Comparison: 4 Subgroup analyses: n-3PUFAs vs placebo - analyses based on adjunctive therapy
Outcome: 2 Adverse events
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Individuals receiving adjunctive therapy
Bot 2010 1/13 0/12 0.7 % 3.00 [ 0.11, 80.95 ]
Carney 2009 39/62 44/60 12.0 % 0.62 [ 0.29, 1.33 ]
Coryell (1g/d) 0/3 0/2 Not estimable
Coryell (2g/d) 0/4 0/2 Not estimable
Gertsik 2012 6/20 4/22 3.4 % 1.93 [ 0.45, 8.18 ]
Park 2015 3/18 1/17 1.3 % 3.20 [ 0.30, 34.24 ]
Peet (1g/d) 2002 9/17 3/5 1.7 % 0.75 [ 0.10, 5.69 ]
Peet (2g/d) 2002 13/18 4/6 1.8 % 1.30 [ 0.18, 9.47 ]
Peet (4g/d) 2002 10/17 3/6 2.0 % 1.43 [ 0.22, 9.26 ]
Subtotal (95% CI) 172 132 23.0 % 0.97 [ 0.56, 1.70 ]
Total events: 81 (n-3PUFAs), 59 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.94, df = 6 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Individuals receiving/not receiving adjunctive therapy
Lesp rance 2011 161/218 148/214 40.7 % 1.26 [ 0.83, 1.91 ]
Mischoulon 2009 2/17 5/24 2.3 % 0.51 [ 0.09, 2.99 ]
Nemets 2002 0/10 0/10 Not estimable
Rondanelli 2010 6/22 6/24 4.1 % 1.13 [ 0.30, 4.20 ]
Silvers 2005 14/40 14/37 8.3 % 0.88 [ 0.35, 2.24 ]
Su 2003 2/14 1/14 1.1 % 2.17 [ 0.17, 27.08 ]
Subtotal (95% CI) 321 323 56.5 % 1.16 [ 0.81, 1.65 ]
Total events: 185 (n-3PUFAs), 174 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.55, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
3 Individuals not receiving adjunctive therapy
Gharekhani 2014 8/27 0/27 0.8 % 23.97 [ 1.31, 440.35 ]
Lucas 2009 4/13 3/16 2.4 % 1.93 [ 0.34, 10.77 ]
0.01 0.1 1 10 100
Favours n-3PUFAs Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup n-3PUFAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mischoulon (DHA) 2015 40/56 16/30 8.4 % 2.19 [ 0.87, 5.50 ]
Mischoulon (EPA) 2015 39/60 17/30 8.9 % 1.42 [ 0.58, 3.48 ]
Subtotal (95% CI) 156 103 20.5 % 2.04 [ 1.03, 4.03 ]
Total events: 91 (n-3PUFAs), 36 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.59, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.05 (P = 0.040)
Total (95% CI) 649 558 100.0 % 1.24 [ 0.95, 1.62 ]
Total events: 357 (n-3PUFAs), 269 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.22, df = 15 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 2.92, df = 2 (P = 0.23), I2 =32%
0.01 0.1 1 10 100
Favours n-3PUFAs Favours placebo
A P P E N D I C E S
Appendix 1. How the intervention might work
The positive effects of n-3PUFAs on depressive illness are thought to occur as a result of integration into the cell membrane phospholipid
bilayer, resulting in changes in structure and function (Haag 2003; James 2000; Ruxton 2005). Incorporation into the cell membrane
can influence the physical state of the membrane, resulting in increased fluidity and permeability (Ehringer 1990; Hirashima 2004;
Tappia 1997), possibly aiding cross-cell membrane transport and communication (Haag 2003). Secondly, n-3PUFAs are also thought
to have effects on surrounding molecules and cell functions via enzyme activity which results in the release of fatty acids from the
phospholipid bilayer to form a number of anti-inflammatory eicosanoids, prostaglandins, and leukotrienes (Calder 2003; James 2000;
Ruxton 2005; Stahl 2008), and via enzyme activity of direct involvement in various neurotransmitter pathways (Haag 2003; James
2000; Ruxton 2005; Stahl 2008). Supplementation with n-3PUFAs has been found to result in: reduced production of inflammatory
cytokines - tumour necrosis factor alpha (TNFa), interleukin 1B, interleukin-6, C-reactive protein and serum amyloid A (Calder
2003; Caughey 1996; James 2000; Rallidis 2003); increased serotonergic and dopaminergic activity; and decreased concentrations of
noradrenalin (Chalon 2006; De la Presa Owens 1999; Hamazaki 2005; Sawazaki 1999; Yao 2004). Additionally, n-3PUFA-deficient
diets have been associated with reduced receptor density and disruptions to neurotransmitter activity in serotonergic (De la Presa
Owens 1999; Delion 1994; Delion 1996; McNamara 2006), dopaminergic (Chalon 2006; De la Presa Owens 1999; Delion 1994;
Delion 1996; McNamara 2006; Takeuchi 2002), and adrenergic systems (Takeuchi 2002) compared to controls. Disruptions to and
abnormal cell signalling, inflammatory processes and neurotransmitter system activities have been implicated in MDD (Parker 2006b;
Stahl 2008).
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Appendix 2. Why it is important to do this review
n-3PUFAs have been linked to depression in a variety of epidemiological studies (Hibbeln 1998; Noaghiul 2003; Peet 2004; Silvers
2002; Tanskanen 2001); clinical studies (Edwards 1998; Garland 2007; Mamalakis 2002; Mamalakis 2006; Peet 1998); and RCTs
(Frangou 2006; Nemets 2002; Stoll 1999; Su 2003).
However, several epidemiological studies have found no association between n-3PUFA intake and depressive illness (e.g. Appleton
2007; Frangou 2006; Hakkarainen 2004;Miyake 2006; Stoll 1999; Su 2003). Clinical studies have reported no differences in n-3PUFA
levels between individuals diagnosed with MDD and controls (e.g. Browne 2006;Mamalakis 2004) and no clear associations (Appleton
2008a). Several RCTs have also reported no effects of supplementation on MDD (e.g. Grenyer 2007; Silvers 2005), depressive illness
(e.g. Keck 2006) or depressed mood (e.g. Rogers 2008).
Reviews in this area clearly demonstrate considerable variability between studies (e.g. Appleton 2006; Appleton 2008b; Appleton 2010;
Lin 2007; Parker 2006b; Smith 2011; Stahl 2008). Meta-analyses also report considerable heterogeneity between studies ( Appleton
2006; Appleton 2010; Lin 2007). Meta-analyses reveal some small benefit of n-3PUFAs for depressive disorders (Appleton 2006; Lin
2007), but investigations of the considerable heterogeneity also suggest differential effects of n-3PUFAs dependent primarily on severity
of depressive symptoms at baseline (Appleton 2010). Sensitivity analyses based on severity of depressive symptoms at baseline suggest
no benefits of n-3PUFAs for individuals with mild depressive symptoms or without diagnosis of depression, but also provide some
evidence of benefits in individuals with severe depressive symptoms or with depressive diagnoses (Appleton 2010). These findings
suggest a possible benefit of n-3PUFAs for MDD.
Appendix 3. CINAHL search strategy
[Diagnosis]
S1 (MH “Depression”)
S2 (MH “Depression, Reactive”)
S3 (MH “Dysthymic Disorder”)
S4 (MH “Affective Disorders”)
S5 (MH “Affective Symptoms”)
S6 (depress* or dysthymi* or “adjustment disorder*” or “affective disorder*” or “affective symptom*” or “mood disorder*”)
S7 (S1 or S2 or S3 or S4 or S5 or S6 or S7)
[Intervention]
S8 (MH “FISH OILS”)
S9 (MH “FATTY ACIDS, OMEGA-3”)
S10 (MH “DOCOSAHEXAENOIC ACIDS”)
S11 (MH “EICOSAPENTAENOIC ACID”)
S12 (AB ( (DHA or Docosahex* or Eicosapent* or EPA or “fatty acid*” or fish* or linolenic or omega-3 or n-3 or w-3 or PUFA* or
“cod liver oil” or “cod-liver oil”) ) OR TI ( (DHA or Docosahex* or Eicosapent* or EPA or “fatty acid*” or fish* or linolenic or omega-
3 or n-3 or w-3 or PUFA* or “cod liver oil” or “cod-liver oil”)))
S13 (S8 or S9 or S10 or S11 or s12)
[RCT Filter]
S14 (MH “Clinical Trials+”)
S15 (PT Clinical trial)
S16 (TX clini* n-3 (trial* or study or studies))
S17 (TX ((singl* N1 blind*) or (singl* N1 mask*)) or TX ((doubl* N1 blind*) or (doubl* N1 mask*))
or TX ((tripl* N1 blind*) or (tripl* N1 mask*)))
S18 (TX random* n-3 control*)
S19 (MH “Random Assignment”)
S20 (TX random and (allocat* or assign*))
S21 (TX placebo*)
S22 (TX (waitlist* or (wait* and list*)) and (control* or group))
S23 (TX “treatment as usual” or TI TAU or AB TAU)
S24 (TX (control* n-3 (trial* or study or studies or group*)))
S25 (MH “Quantitative Studies”)
S26 (S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25)
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S27 (S7 and S13 and s26)
Appendix 4. Risk of Bias Assessment Tool
n-3PUFAs and MDD. Risk of Bias Assessment Tool
SEQUENCE GENERATION
LOW RISK
The investigators describe a random component in the sequence generation process such as:
· Referring to a random number table; Using a computer random number generator; Coin tossing; Shuffling cards or envelopes;
Throwing dice; Drawing of lots/slips; Minimization*
*Minimization may be implemented without a random element, and this is considered to be equivalent to being random
HIGH RISK
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example:
· Sequence generated by odd or even date of birth
· Sequence generated by some rule based on date (or day) of admission
· Sequence generated by some rule based on hospital or clinic record number
Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious.
They usually involve judgement or some method of non-random categorization of participants, for example:
· Allocation by judgement of the clinician
· Allocation by preference of the participant
· Allocation based on the results of a laboratory test or a series of tests
· Allocation by availability of the intervention.
UNCLEAR RISK
Insufficient information about the sequence generation process to permit judgement of ‘Yes’ or ‘No’
ALLOCATION CONCEALMENT
LOW RISK
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation:
· Central allocation (including telephone, web-based, and pharmacy-controlled, randomization)
· Sequentially numbered drug containers of identical appearance
· Sequentially numbered, opaque, sealed envelopes - all 3 features of the envelopes must be described
HIGH RISK
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as
allocation based on:
· Using an open random allocation schedule (e.g. a list of random numbers)
· Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially
numbered)
· Alternation or rotation
· Date of birth
· Case record number
· Any other explicitly unconcealed procedure.
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(Continued)
UNCLEAR RISK
Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is usually the case if the method of concealment is not described
or not described in sufficient detail to allow a definite judgement - for example if the use of assignment envelopes is described, but it
remains unclear whether envelopes were sequentially numbered, opaque and sealed.
BLINDING OF PARTICIPANTS AND PERSONNEL
LOW RISK
· Some assessment of blinding at follow-up, and blinding found to be successful
· Flavours of both intervention and control treatments masked by flavour
· Small amount of fish oil added to placebo
HIGH RISK
· Either participants or study personnel were not blinded.
· Participants guessed allocation
· No attempts to mask / counter fish oil taste / smell, despite clear description of other aspects of intervention and placebo
UNCLEAR RISK
Insufficient information to permit judgement of ‘Low’ or ‘High Risk’
BLINDING OF OUTCOME ASSESSORS
LOW RISK
·Methods of blinding of outcome assessors described sufficiently and deemed adequate
HIGH RISK
Any one of the following:
·Methods of blinding of outcome assessors described sufficiently but deemed inadequate
· No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding
UNCLEAR RISK
· Insufficient information to permit judgement of ‘Low’ or ‘High Risk’
Where more than one outcome measure is used, overall score will be based on the one used in our analyses.
INCOMPLETE OUTCOME DATA= only relevant to data after randomisation
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LOW RISK
Any one of the following:
· No missing outcome data
· ITT analysis (includes all those randomized)
·Missing outcome data less than 10% of the total randomised population
·Missing outcome data for mood less than 5% of the total randomised population
· Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias)
·Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups
· Difference in missing data between the groups not greater than 10%
· i.e. intervention group of 120 has 6 drop out (5% of trial arm) and control group of 100 has 2 drop out (2% of trial arm): difference
in missing data is 3% therefore LOW RISK
· Difference in missing data for mood between the groups not greater than 5%
HIGH RISK
Any one of the following:
· Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data
across intervention groups
· Difference in missing data between the groups greater than 10%
· i.e. intervention group of 120 has 6 drop out (5% of trial arm) and control group of 100 has 26 drop out (26% of trial arm):
difference in missing data is 21% therefore HIGH RISK
· Difference in missing data for mood between the groups greater than 5%
· Overall missing data greater than 10% of the total randomised population
· Overall missing data for mood greater than 5% of the total randomised population
· Stated as ‘intention-to-treat analysis’ but doesn’t use this
· Analysed using ‘per protocol’ analyses
· ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomization
UNCLEAR RISK
Any one of the following:
· Insufficient reporting of attrition/exclusions to permit judgement of ‘Yes’ or ‘No’ (e.g. number randomized not stated, no reasons
for missing data provided)
· Dropouts not mentioned
SELECTIVE OUTCOME REPORTING
LOW RISK
Any of the following:
· The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review
have been reported in the pre-specified way - use trial registration number if available to locate protocol
· The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
· The study protocol is not available but authors state that all outcomes are reported
HIGH RISK
Any one of the following:
· Not all of the study’s pre-specified primary and secondary outcomes have been reported
· Pre-specified in methods section
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(Continued)
· Or pre-specified in protocol
·One or more primary or secondary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales)
that were not pre-specified
·One or more reported primary or secondary outcomes were not pre-specified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect)
· One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis - any
data excluded from the analysis despite the data being available (i.e. so the reviewers decided not to include it in the meta-analysis)
· The study report fails to include results for a key outcome that would be expected to have been reported for such a study
Outcomes refer in all cases to all study outcomes.
UNCLEAR RISK
Insufficient information to permit judgement of ‘Yes’ or ‘No’
· No protocol is available, and no contact can be gained with authors
OTHER BIAS
LOW RISK
The study appears to be free of other sources of bias.
HIGH RISK
· Stopped early due to some data-dependent process (including a formal-stopping rule)
· Significant baseline imbalance for mood outcomes
UNCLEAR RISK
There may be a risk of bias, but there is either:
· Insufficient information to assess whether an important risk of bias exists
· Insufficient rationale or evidence that an identified problem will introduce bias
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 11, 2015
Date Event Description
1 May 2014 New citation required and major changes This protocol replaces the withdrawn protocol Silvers 2009 (withdrawn).
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C O N T R I B U T I O N S O F A U T H O R S
KA wrote the protocol. All authors checked and subsequently revised this draft.
For the review, HS and RP screened all articles identified by searches, and extracted data from all eligible studies. KA also extracted
data from all eligible studies. KA, HS and RP collectively resolved disagreements. HS and RP entered all data into Review Manager 5.
KA checked all entered data, conducted all analyses, and wrote up the review. All authors checked and subsequently revised this draft.
D E C L A R A T I O N S O F I N T E R E S T
KA: None known
HS: None known
RP: None known
AN: None known
RC: None known
S O U R C E S O F S U P P O R T
Internal sources
• Bournemouth University, UK.
Researcher time
• University of Bristol, UK.
Researcher time
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The following differences between protocol and review have arisen, for the reasons provided:
Protocol: “Only studies involving adults (18 years and over) will be included”. Review: One study involving adults (16 years and over)
is included (Gharekhani 2014). Age 16 years is the definition of adult in the country in which this study was undertaken.
Protocol: “Studies will be included regardless of participant medication”. Review: Studies were included regardless of participant
medication and other treatments for depressive symptomology, so we have stated “Studies were included regardless of participant use
of adjunctive therapy”.
Protocol: “Experimental intervention: Studies will be included regardless of source of n-3PUFA provided ..., but records of differences
will be made”. Review: Records of differences based on source of n-3PUFA provided were made and have been investigated in sensitivity
analyses. We conducted sensitivity analyses following the publication of a number of similar comparisons since the conception of this
review, and following reviewers’ comments.
Protocol: “Where studies use multiple time points, data will be tabulated for all outcomes at all time points where assessments have
been made, but only those of longest follow-up will be included in statistical analyses”. Review: Data for all time points have not been
tabulated. This has not been done due to the variety of time points used across studies, and the difficulty and low value of comparing
across varied time points.
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Protocol: “Complementary searches will be conducted .... in BIOSIS Citation Index (1969 to date), and Web of Science (1900 to
date)”. Review: These searches were not completed. We decided that due to the topic of the review, searches in Biosis and Web of
Science would be very unlikely to reveal additional studies.
Protocol: “Wewill assess the risk of bias according to the following domains. 1. Random sequence generation, 2. Allocation concealment,
3. Blinding of participants and personnel, 4. Blinding of outcome assessment, 5. Incomplete outcome data, 6. Selective outcome
reporting, 7. Other bias”. Review: We have made assessments of outcome data (blinding of outcome assessment, and incomplete
outcome data) separately for each primary outcome. This was done because different judgements could be given to different outcome
assessments for some studies, depending on methods of measurement, and it was meaningless to try and combine these.
Protocol: “Data from subgroups of little relevance to the research question, e.g. groups of males and females, will be recorded as
reported, and subsequently combined for analysis”. Review: Data have not been presented separately for subgroups of little relevance
to the research question, because we found none.
Protocol: “Adverse effects and failure to complete data will not be statistically summarised”. Review: We have statistically summarised
data on adverse effects and failure to complete, where data were available. We did this becuase of the amount of data available and the
value of these statistical summaries.
Protocol: Subgroup analyses will be conducted “using only studies in which participants are clearly identified as having comorbid
conditions, and using only studies in which participants are clearly identified as being without comorbid conditions. Studies where
participants with and without comorbid conditions were mixed, and studies that do not clearly identify whether participants have
comorbid conditions or not, will not be included in this analysis”. Review:We have conducted subgroup analyses based on comorbidities
using all studies. We did this to allow investigation of effects of comorbidities in the whole data set.
Protocol: Subgroup analyses will be conducted “using only studies in which participants are clearly identified as receiving adjunct
therapy, and using only studies in which participants are clearly identified as not receiving adjunct therapy. Studies where participants
with adjunct therapies are mixed, and studies that do not clearly identify whether participants are receiving or not receiving adjunct
therapies will not be included in this analysis”. Review: We have conducted subgroup analyses based on adjunctive therapy using all
studies. We did this to allow investigation of effects of adjunctive therapy in the whole data set. For these analyses, We have defined
adjunctive therapy as including psychotherapy as well as antidepressant medication, and we have limited it to adjunctive therapies for
depression.
Protocol: Sensitivity analyses on risk of bias will be conducted where “low risk of bias will be defined as in the Cochrane Handbook
(Higgins 2011)”. Review: we have further defined low risk of bias as “using (i) selection bias, measured using allocation concealment;
(ii) performance bias, using blinding of participants and personnel; (iii) attrition bias, using incomplete outcome data. We conducted
three separate analyses, one for each type of bias”.
We conducted sensitivity analyses that we had not proposed in the protocol. These analyses investigated possible methodological sources
of heterogeneity that became apparent during the review or the write-up processes, or both. These sensitivity analyses are provided in
the review as “additional sensitivity analyses”, to distinguish them from our preplanned sensitivity analyses. We applied the sensitivity
analyses using a fixed-effect model to all outcomes for completeness, but restricted all other sensitivity analyses to testing only our
primary outcomes.
Planned methods not used in the review
Protocol: Unit of analysis issues: Cross-over RCTs: We will include only the first study phase of cross-over RCTs in analyses. We think
cross-over RCTs are unlikely to be used in this field. Cluster-RCTs: We will include cluster-RCTs in primary analyses, where cluster will
act as the unit of investigation. We think cluster-RCTs are unlikely to be used in this field. Review: We have not used these methods
because we did not find any cross-over or cluster-RCTs during our searches. The statements in the protocol will be applied where
appropriate in future updates of the review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [adverse effects; ∗therapeutic use]; Depressive Disorder, Major [∗drug therapy]; Fatty Acids, Omega-3 [adverse
effects; ∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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